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ABSTRACT 
Macromolecular interactions are essential for virtually all cellular functions including signal 
transduction processes, metabolic processes, regulation of gene expression and immune responses. 
This dissertation focuses on the characterization of two important macromolecular interactions 
involved in the relationship between Equine Infectious Anemia Virus (EIAV) and its host cell in 
horse: i) the interaction between the EIAV Rev protein and its binding site, the Rev-responsive 
element (RRE) and ii) interactions between equine MHC class I molecules and epitope peptides 
derived from EIAV proteins. 
EIAV, one of the most divergent members of the lentivirus family, has a single-stranded 
RNA genome and carries several regulatory and structural proteins within its viral particle. Rev is an 
essential EIAV regulatory encoded protein that interacts with the viral RRE, a specific binding site in 
the viral mRNA. Using a combination of experimental and computational methods, the interactions 
between EIAV Rev and RRE were characterized in detail. EIAV Rev was shown to have a bipartite 
RNA binding domain containing two arginine rich motifs (ARMs). The RRE secondary structure 
was determined and specific structural motifs that act as cis-regulatory elements for EIAV Rev-RRE 
interaction were identified. Interestingly, a structural motif located in the high affinity Rev binding 
site is well conserved in several diverse lentiviral genomes, including HIV-1.  
Macromolecular interactions involved in the immune response of the horse to EIAV infection 
were investigated by analyzing complexes between MHC class I proteins and epitope peptides 
derived from EIAV Rev, Env and Gag proteins. Computational modeling results provided a 
mechanistic explanation for the experimental finding that a single amino acid change in the peptide 
binding domain of the equine MHC class I molecule differentially affects the recognition of specific 
epitopes by EIAV-specific CTL. Together, the findings in this dissertation provide novel insights into 
the strategy used by EIAV to replicate itself, and provide new details about how the host cell 
responds to and defends against EIAV upon the infection. Moreover, they have contributed to our 
understanding of the macromolecular recognition events that regulate these processes. 
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CHAPTER 1. GENERAL INTRODUCTION 
 
This dissertation describes and characterizes the molecular details of interactions 
between regulatory proteins and their binding partners, including other proteins, RNA, and 
small peptides. In this study, a lentivirus, Equine Infectious Anemia Virus (EIAV) is used as 
a model system to analyze the interactions systematically. We focused on the interactions 
between the viral regulatory protein, Rev, and its binding target in viral mRNA, the Rev-
Responsive Element (RRE) to characterize EIAV protein-RNA interactions essential for 
replication of the virus. We also observed and characterized protein-peptide interactions 
important in the immune response of the equine host by modeling of the equine MHC class I 
protein and its interactions with peptide epitopes derived from EIAV proteins, using docking 
approaches.  
INTRODUCTION 
Proteins are the most critical molecules in macromolecular interactions, playing 
essential roles in virtually all cellular functions. The regulation of DNA replication, 
transcription and translation, signal transduction pathways, metabolic processes, and immune 
responses are performed and controlled largely by protein-protein, protein-nucleic acid, and 
protein-small ligand interactions. Currently, macromolecular interactions are a central theme 
of structural and functional genomics, and genome-wide protein interaction networks are 
being generated and analyzed in model organisms by taking advantage of high-throughput 
experimental approaches (30). For example, in Drosophila melanogaster, the networks of 
interactions between proteins that control cell function are beginning to be revealed using 
two-hybrid-based protein-interaction maps (23). However, detailed mechanisms of 
macromolecular interactions, especially in protein-RNA and protein-small ligand complexes 
are still poorly understood, in part because of insufficient data. 
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Viruses are excellent model systems for studying macromolecular interactions. A 
virus contains only a small DNA or RNA genome, packaged together with a few enzymatic 
and/or structural proteins within a viral particle. To replicate themselves in the host, viruses 
use all kinds of macromolecular interactions, such as:  protein-DNA (for replication of viral 
genomic DNA), protein-RNA (for reverse transcription and transport of mRNAs), and 
protein-small ligand (for escape from host immune system). Even though viruses have their 
own restricted resources, they are clever enough to direct these macromolecular interactions 
using their own proteins and various "borrowed" components of the host's machineries. 
Therefore, analyzing macromolecular interactions in viral model systems can give us 
understanding of some of the most effective ways for regulating macromolecular recognition 
processes. In this study, we have focused on one family of Retroviruses, the lentiviruses, to 
investigate two types of macromolecular interactions: i) protein-RNA interactions critical for 
replication of the virus in host cells, and ii) protein-peptide interactions involved in the host 
immune response to viral infection. 
 
Equine Infectious Anemia Virus 
Lentiviruses are a family of single-stranded, positive-strand RNA viruses that use an 
RNA-dependent DNA polymerase, called a reverse-transcriptase, encoded in viral genome 
(16). In a lentiviral infection, the virus attaches to the cell membrane of host cell and the core 
of virus is injected into the cytoplasm of infected cell. In the early stages of infection, the 
single-stranded RNA genome is reverse transcribed into DNA by the reverse transcriptase. 
The transcribed double-stranded DNA can be shuttled into the nucleus where it is integrated 
into the host genome and is maintained as a provirus. At some point, proviral genes are 
transcribed by the host's transcriptional machinery. Because lentiviruses have relatively small 
genomes, they utilize complex mechanisms to regulate viral replication and gene expression 
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at the transcription and post-transcriptional levels. One important mechanism is alternative 
splicing of viral transcripts, which generates several different spliced transcripts from the 
same region of the genome to express genes for later stages of viral replication (13). For 
example, in the case of HIV-1, there are more than 20 different spliced mRNAs for different 
viral gene products.  
The Equine Infectious Anemia Virus (EIAV) is one of the most divergent members of 
the lentiviridae (17). EIAV has a complex genomic organization, and shares several common 
lentiviral genes essential for the viral life cycle. Unlike HIV-1, however, EIAV infection 
sometimes stimulates a rapid and variable disease course in the host, rather than a slow 
chronic and inevitably fatal disease. Figure 1.1 shows the organization of EIAV genome and 
spliced transcripts produced from it. The Gag gene encodes the inner structural proteins of 
the virion, which include the capsid, nucleocapsid and matrix proteins. The products of the 
Env gene are the envelope glycoproteins (surface and transmembrane glycoproteins) 
involved in virus-host cell fusion and entry of the virus. Also, there are genes involved in 
regulating viral replication, including the important and functionally conserved regulatory 
gene products, Tat and Rev. Tat is an RNA binding protein that interacts with a viral RNA 
structure called the TAR element. By binding to a stem-loop motif of the TAR element, Tat 
functions as a transcriptional activator, which increases the efficiency of transcription (10). 
The second critical regulatory protein, Rev, plays a role in regulating the expression of 
unspliced and incompletely spliced viral mRNAs (48). Rev protein in the cytoplasm enters 
the nucleus, binds to the specific viral mRNA element called the Rev-responsive Element 
(RRE), multimerizes, and directs the export of incompletely spliced mRNA to the cytoplasm, 
using CRM1 nuclear export pathway of the host cell. A detailed description of Rev and its 
functions will be provided below. In the late stage of viral infection, structural proteins and 
the progeny viral RNA genomes are targeted to the cell membrane, assembled as viral 
particles and finally released from the host cell.  
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Figure 1.1. EIAV genome organization and transcript splicing patterns. Schematic of the EIAV genome and 
open reading frames (ORFs) within mRNA transcripts.  (a) mRNA transcript "a" encodes both the Tat (T) and 
Rev (r, rev) proteins. (b) In the presence of Rev protein, EIAV exon 3 is skipped and the Tat (T) protein is 
produced from mRNA "b". (c) mRNA "c" encodes Ttm, a protein of unknown function. (d, e) Structural and 
enzymatic proteins are translated from mRNAs "d" and "e". Unspliced mRNA "e" corresponds to progeny RNA 
that is packaged to produce infectious virus. 
 
The EIAV Rev protein and Rev-responsive element (RRE) 
Rev is a regulatory protein essential for lentiviral replication. Many lentiviruses, 
including EIAV, BIV, FIV, visna virus, SIV, and CAEV, use a Rev-dependent RNA export 
pathway to achieve differential expression of incompletely spliced viral mRNAs, which 
encode structural and enzymatic proteins as well as the progeny viral RNA. Rev serves as the 
gear shift from the early expression of regulatory genes like Tat and Rev, to the late 
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expression of structural genes such as Gag and Env. Rev's function in the regulation 
lentiviral replication have been best studied in HIV-1(28).  Briefly, after entering the nu
the HIV-1 Rev protein binds to a specific cis-acting element, the Rev responsive element 
(RRE) within the viral pre-mRNA (12, 53), multimerizes (46, 54) and then facilitates nucl
export of the incompletely spliced viral mRNA via the CRM1 nuclear export pathway (18, 
19) (Fig 1.2). Rev has discrete functional domains essential for the shuttling process, RNA 
binding, and multimerization. In the case of HIV-1 Rev, the N-terminal nuclear localization
signal (NLS), which directly interacts with importin-β, is required for the nuclear 
transportation of Rev (25, 28, 44). The NLS includes an arginine-rich motif (ARM
important for binding to the HIV-1 RRE. An NMR structure of a Rev-RRE protein-RNA 
complex (a 23 aa Rev peptide bound to a 39 nt RRE fragment) was determined by Battiste
and Williamson (2); in this complex, the Rev peptide formed an alpha-helix. Also, several 
studies showed that the N-terminal region of HIV-1 Rev, including the NLS/RNA binding 
domain (RBD), forms a helix-loop-helix structure (8, 52). Biochemical and biophysical 
experiments have suggested that Rev multimerization occurs on an extended RRE region
Rev concentration increases (14, 29, 37). After multimerization of Rev in Rev-RRE 
complexes, the nuclear export signal (NES) in the C-terminal of Rev interacts with h
proteins, such as CRM1 or exportin 1. The NES motifs among different lentiviruses are 
conserved, in terms of their leucine-rich sequences, and it has been shown that the NES i
functionally interchangeable between several lentiviral Rev proteins (19). 
 
of 
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ear 
 
), which is 
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Figure 1.2. Schematic representation of Rev function.  Rev enters the nucleus, facilitated by the 
interaction between its nuclear localization domain (NLS) and the host import machinery, including the 
importin-β protein.  The RNA binding domain (RBD) of Rev binds to structured RRE sequences in unspliced or 
multiply spliced mRNAs. Rev then multimerizes on the mRNA and Rev-RRE (mRNA) complexes are exported 
from nucleus, through interactions between the nuclear export signal (NES) in Rev and components of the host 
nuclear export machinery, such as CRM1. 
 
Rev proteins in all lentiviruses carry out similar functions, but the sequence 
similarities among them are quite low. In particular, Equine Infectious Anemia Virus (EIAV) 
Rev is genetically even more distant from HIV than other non-primate lentiviruses (17). As a 
result, at the primary sequence level, the organization of functional domains within the Rev 
proteins of HIV and EIAV Rev is very different (Fig 1.3). EIAV Rev has 165 amino acid 
residues compared to 116 amino acid residues in HIV-1 Rev. There are two exons in EIAV 
Rev and the first exon of Rev, which is the same ORF with env gene, has no known function 
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Rev in Rev export. The NES domain of EIAV Rev is located in the N-terminus, rather than 
C-terminus, as it is in HIV-1 Rev (26). A short arginine-rich stretch in the C-terminal region 
serves as a NLS in EIAV Rev, but HIV-1 Rev has a 17-residue arginine-rich motif (ARM) 
that functions as both an NLS and as a high affinity RNA binding domain. Although no 
typical ARM like that in HIV-1 Rev is found  in EIAV Rev, previous studies have identified 
two specific motifs, RRDR (aa 76-89) and ERLE (aa 93-96), which affect functional activity 
of EIAV Rev in in vivo assays (26). Especially, the latter motif, ERLE has been also been 
shown, by alanine substitution mutations, to abrogate the RNA binding activity of Rev (11), 
and it has been assumed that the middle region of EIAV Rev was likely to be the RNA 
binding domain. But no extensive direct investigations of the RNA binding activity or 
specific RNA binding motifs in EIAV Rev had been reported when we initiated our study. In 
Figure 1.3A, the two putative RNA binding motifs within the potential RNA binding domain 
(RBD) discussed above, as well as the arginine-rich motif within the NLS of EIAV Rev 
(shown to be involved in RNA binding by our experiments, described in Chapter 2) as shown 
in red, for comparison with the well-characterized ARM within the RBD of HIV-1 Rev, 
which is also shown in red in Figure 1.3B.    
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Figure 1.3. The domain organization of EIAV and HIV-1 Rev. (A) Domain organization of  the EIAV 
Rev protein.  NES = Nuclear export signal, located in the N-terminus of Rev exon 2.  RBD = Putative RNA 
binding domain, including two putative RNA binding motifs (RRDRW and QERLE).  NLS = Nuclear 
localization signal, located in the C-terminus of Rev, and including a KRRRK motif  (B) Domain organization 
of the HIV-1 Rev protein. Note that the RBD and NLS are located in the N-terminal half of HIV-1 Rev.  The 
NES is located in the C-terminal half of  HIV-1 Rev. The ARM is shown in red. 
 
The interaction between Rev protein and the RRE is a critical step in the export of 
incompletely spliced or unspliced lentiviral mRNA from the nucleus to the cytoplasm of 
infected cells.  This step is key in regulation of lentiviral gene expression and genomic 
replication. In HIV-1, the RRE region within the viral mRNA is known to form specific 
RNA secondary structures required for recognition by the HIV-1 Rev protein. The HIV-1 
RRE, and especially the secondary structure of the RRE, has been investigated extensively, 
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using biochemical and biophysical assays (15, 32, 37, 53). The HIV-1 RRE is highly 
structured, and contains stem-loop structures important for high affinity binding to the HIV-1 
Rev protein and for interacting with cellular proteins. Mann et al. (37), showed that an 
extended region of the HIV-1 RRE is important for Rev multimerization. The RRE region in 
many lentiviruses, including HIV-1, HIV-2, SIV, VV, and CAEV, has been mapped to the 
junction between SU and TM genes, which corresponds to a protease cleavage site within the 
env gene (15, 33, 49, 51, 53). In case of FIV, the RRE is located in the 3’ end of env gene 
(47). On the other hand, the essential RRE (ERRE) has been approximately mapped within 
the 3' end of the genome (38) in EIAV. Using functional assays, Belshan et al. (4), 
demonstrated that two separable elements of the RRE can efficiently mediate Rev-dependent 
pre-mRNA export in EIAV. Even though ERRE-1 (555 nt) is shorter than ERRE-2 (1698 nt), 
it supports a higher level of functional activity in vivo (~60% vs ~20%) (4). ERRE-1 includes 
an Exonic Splicing Enhancer (ESE) region, which contains several purine-rich tracts, two of 
which, Pu-A and Pu-B, have been shown to be important both for alternative splicing of 
EIAV mRNAs and for Rev binding (5, 11, 24, 36). ERRE-1 thus plays an important role in 
the complex interactions between viral pre-mRNAs, the viral Rev protein, and host cellular 
splicing factors, such as SF2/ASF, which also binds to ERRE-1 (3, 11, 24, 36). Prior to our 
work, however, detailed structural information regarding the EIAV RRE was not available, 
nor had interactions between the EIAV Rev protein and the EIAV RRE been investigated. 
 
The Virus-specific CTL (Cytotoxic T Lymphocytes) Response 
There are two kinds of immune responses to virus infection (16). One is the response 
of the innate immune system, which includes the activities of cytokines (such as interferon), 
complement (a complex collection of serum proteins), natural killer cells (cytolytic 
lymphocytes) and local sentinel cells (such as dendratic cells and macrophases). The innate 
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immune system has quick responses, is relatively non-specific and has no immunological 
"memory". The innate immune system is important not only because it is a first barrier 
against viral infection, but also because it plays a role in activating the adaptive immune 
responses.   
The adaptive immune responses represent the second type of immune response to 
viral infection, and are complicated and sophisticated responses. There are two major aspects 
of the adaptive immune response: the humoral response and the cell-meditated response. 
Unlike the innate immune system, the adaptive immune system has highly antigen-specific 
recognition. In the humoral response, antibodies bind to virions in vessels and at mucosal 
surfaces to prevent an increase in viral infection. On the other hand, in the cell-mediated 
response, T cells recognize infected cells and synthesize cytokines, ultimately resulting in 
infected cells being killed by CTLs (cytotoxic T-lymphocytes). There are two kinds of 
effector T cells:  T helper cells (Th cells) and cytotoxic T cells (cytotoxic T lymphocytes, or 
CTLs). Th cells presenting CD4 (cluster of differentiation marker-4), are able to interact with 
B cells and antigen-presenting cells, which display MHC class II proteins. The main roles of 
Th cells are the activation of B cell precursors, by direct interaction, and activation of CTL 
precursors, by secretion of cytokines such as interleukins and interferon-gamma. CTLs 
recognize the infected cell, which presents MHC class I proteins on its cell surface (16). 
MHC class I proteins are composed of two different subunits: a long alpha-chain (heavy 
chain) and a short β2-microglobulin (β2m, light chain). In the infected cell, the viral protein is 
proteolysed in the proteasome and short processed peptides bind to MHC class I proteins in 
the lumen of the endoplasmic reticulum (ER). Based on the known 3-dimensional  (3D) 
structure of the MHC class I molecule, it has been shown that a peptide binds to the cleft 
between two helix domains (α-1 and α -2), and rests on a β strand domain chain (β-1)  (7, 
20). Because of polymorphic features in peptide binding domains (binding groove), the 
ability of MHC class I molecules to bind and display peptides on the cell surface varies from 
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individual to individual. The MHC I complex (MHC class I protein bound to viral peptide) 
on the surfaces of infected cells is recognized by the T cell receptor (TCR) of CTLs. The 
interaction between the MHC I complex and the TCR triggers the activation of CTLs and 
finally CTLs kill the infected cell. The detailed pathway of MHC class I antigen presentation 
is well reviewed elsewhere (27, 45). Figure 1.4 shows some of the processes involved in the 
virus-specific CTL response described above. 
 
Figure 1.4. Schematic mechanism of virus-specific CTL response.  (1) Viral-derived protein is 
proteolysed in the proteasome complex. (2) Processed peptide is transported into the endoplasmic reticulum 
(ER) by TAP protein. (3) In ER, a peptide binds to an MHC class I  protein. (4) The MHC I-peptide complex is 
transported to the membrane surface through the Golgi apparatus.  (5) The MHC I-peptide complex on the 
surface of membrane is recognized by a T-cell receptor on a Cytotoxic T lymphocyte (CTL). (Figure adapted 
from Nolan, D. et al., 2006 (45)) 
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During lentiviral infection, the Env, Gag and Rev proteins are important targets for 
CTLs and the CTL response to epitope peptides derived from viral proteins is important for 
control of viral load and associated clinical disease. Several studies clearly show that HIV-1 
Env, Gag and Rev-specific CTLs are tightly connected with the progression of AIDS in HIV-
1 infected humans (1, 6, 9, 22). As they are in HIV-1 infection, Env, Gag and Rev proteins 
are critical targets for CTL responses in EIAV infected horses, and specific CTLs for Env 
and Gag peptides are observed in the progression of Equine Infectious Anemia (EIA) (41, 
42). An important aspect of the virus-specific CTL response, is how the MHC class I 
molecule recognizes and interacts with viral epitope peptides, and subsequently activates 
CTL recognition processes. Although all MHC class I molecules belong to same structural 
supertype and have similar binding affinities for epitope peptides, polymorphism in the 
binding groove of MHC class I molecules affects the recognition of MHC class I-peptide 
complexes by CTLs (50). In human cases, many studies have investigated the correlation 
between specific MHC I alleles and the progress of disease (21, 31, 43). In horses, there are 
fewer known MHC I alleles, compared with humans. Recently, one of the classical MHC I 
molecules, designated 7-6, associated with the equine leukocyte Ag (ELA)-A1 haplotype has 
been identified (39).It has been shown that 7-6 presents both Env and Gag epitopes. 
Interestingly, Rev epitopes are also associated with the ELA-A1 haplotype, but the molecule 
presenting the Rev epitope has not been identified (39, 42). In addition, the lack of a 3D 
structure for the equine MHC class I molecule makes it difficult to understand the detailed 
mechanisms by which equine MHC class I molecules interact with epitopes from EIAV 
proteins, and how equine CTLs recognize equine MHC class I–peptide complexes. Therefore, 
we undertook a study of the structural features of equine MHC class I molecules, in complex 
with specific epitopes derived from EIAV proteins, using experimental and comparative 
computational approaches. Our long term goal in this work is not only to understand the 
detailed interactions that mediate recognition events among equine MHC class I molecules, 
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epitope peptides and CTLs in horses, but also the relationship between disease progression 
and the molecular mechanisms. 
 
OVERALL GOALS 
The overall goal of this research is to characterize regulatory interactions between 
proteins and RNA or small peptides. To achieve this goal, we proposed to accomplish the 
following: 
 
1. Map and characterize the RNA binding domains and motifs in the Equine 
Infectious Anemia Virus Rev protein, focusing on those that interact with the 
Rev-responsive element (RRE) (Chapter 2) 
2. Analyze the RNA secondary structure of the EIAV RRE and characterize the 
sequences and/or structures within it that are recognized and bound by the 
EIAV Rev protein (Chapter 3) 
3. Generate computational models for equine MHC class I molecules in 
complexes with epitope peptides derived from EIAV proteins (Env, Gag and 
Rev), to investigate how MHC class I molecules differentially recognize the 
different viral epitope peptides (Chapter 4) 
 
Also we proposed to explore other aspects of macromolecular structure and interactions 
in studies described in the Appendices: 
 
4. Predict the structures of the N-terminal domain of the human and yeast 
telomerase reverse transcriptase enzymes, using a combination of homology 
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modeling and threading approaches;  analyze and predict nucleic acid binding 
sites in the same domain, using machine learning approaches (Appendix A) 
6. Analyze potentially regulatory conformational changes that occur in proteins 
upon proline cis/trans isomerization (Appendix B) 
 
DISSERTATION ORGANIZATION 
The dissertation has five chapters and two appendices. Chapter 1 is a general 
introduction to the biology of Equine Infectious Anemia Virus (EIAV), and describes what 
was known about the interactions between EIAV Rev and the RRE when this study was 
initiated. A brief description of the equine immune response to the viral infection is included. 
Chapter 2 is a paper published in the Journal of Virology in 2006 (35), in which mapping 
and characterization of functional domains in EIAV Rev are described. Identification of the 
domains essential for RNA binding activity demonstrated that the RNA binding domain of 
EIAV Rev is bipartite, with two critical arginine-rich RNA binding motifs (ARMs) separated 
by 76 amino acids in the primary sequence of the proteins.  The contributions of other 
authors to this paper are as follows:  In vivo analyses of the roles of specific residues in NLS 
motif were done by Sean C. Murphy and in vivo functional activity assays of Rev point 
mutation mutants (in Fig 2.5B) were performed by Wendy O. Sparks. Plasmid constructs I 
generated in this work were based on Rev-encoding plasmids from Michael Belshan's 
published work (4).  I constructed all Rev deletion mutants, expressed and purified all 
proteins, performed all RNA binding assays, wrote the first draft of the paper and 
participated in revisions and editing. Chapter 3 is a manuscript submitted recently to 
Molecular and Cellular Biology.  It describes the detailed computational and experimental 
analysis of the secondary structure of the EIAV RRE and characterization of its interaction 
with the EIAV Rev protein. This work was done in collaboration with Gloria Culver. I 
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conceived of this study and designed and performed all of the chemical modification and 
footprint analyses, with assistance from members of Culver’s lab, especially Laura Dutca.  I 
performed all the computational analyses and predictions, wrote the first draft of the paper, 
and participated in revisions and editing. Chapter 4 is a paper published in the Journal of 
Immunology in 2006 (40). This study was conceived by Robert H. Mealey, at Washington 
State University. All wet-lab experiments were performed in the Mealey lab, as were 
analyses of experiments shown in Figures. 4.1, 4.2 and 4.3. I performed all computational 
analyses and experiments, including the homology modeling and docking of equine MHC I 
molecules and epitope peptides. Chapter 5 is a summary in which general conclusions of this 
dissertation study and future directions, based on my recommendations, are presented.  
In the Appendices, several studies related to the main goal in this dissertation are 
introduced and described. Appendix A is a paper recently accepted for publication in the 
Pacific Symposium on Biocomputing,  PSB08 (34). It describes structural modeling and 
functional residue prediction (DNA and RNA interfacial residues) for human and yeast 
telomerase reverse transcriptase (TERT) enzymes. The modeling N-terminal domains of 
human and yeast TERT proteins was performed Michael Hamilton and me. Prediction of 
DNA interacting residues was done by Cornelia Caragea in the lab of Vasant Honavar. 
Prediction of RNA interacting residues using RNABindR and comparisons between available 
experimental data and predictions on telomerases were carried out by Colin Gleeson, in the 
Dobbs lab. Appendix B is a study of the relationship between sequence, structure and 
function in folded proteins with prolines that undergo cis/trans isomerization. When 
complete, we plan to submit a manuscript decribing this look to Journal of Molecular 
Biology. All computational experiments, including the classification experiments using 
machine learning algorithms, and the large-scale identification and analysis of prolyl 
isomerization, were performed by me. 
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CHAPTER 2. CHARACTERIZATION OF FUNCTIONAL 
DOMAINS OF EQUINE INFECTIOUS ANEMIA VIRUS REV 
SUGGESTS A BIPARTITE RNA-BINDING DOMAIN 
 
A paper published in Journal of Virology 
 
Jae-Hyung Lee, Sean C. Murphy, Michael Belshan, Wendy O. Sparks, Yvonne 
Wannemuehler, Sijun Liu, Thomas J. Hope, Drena Dobbs, and Susan Carpenter 
 
ABSTRACT 
Equine infectious anemia virus (EIAV) Rev is an essential regulatory protein that 
facilitates expression of viral mRNAs encoding structural proteins and genomic RNA and 
regulates alternative splicing of the bicistronic tat/rev mRNA. EIAV Rev is characterized by 
a high rate of genetic variation in vivo, and changes in Rev genotype and phenotype have 
been shown to coincide with changes in clinical disease. To better understand how genetic 
variation alters Rev phenotype, we undertook deletion and mutational analyses to map 
functional domains and to identify specific motifs that are essential for EIAV Rev activity. 
All functional domains are contained within the second exon of EIAV Rev. The overall 
organization of domains within Rev exon 2 includes a nuclear export signal, a large central 
region required for RNA binding, a nonessential region, and a C-terminal region required for 
both nuclear localization and RNA binding. Subcellular localization of green fluorescent 
protein-Rev mutants indicated that basic residues within the KRRRK motif in the C-terminal 
region of Rev are necessary for targeting of Rev to the nucleus. Two separate regions of Rev 
were necessary for RNA binding: a central region encompassing residues 57 to 130 and a C-
terminal region spanning residues 144 to 165. Within these regions were two distinct, short 
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arginine-rich motifs essential for RNA binding, including an RRDRW motif in the central 
region and the KRRRK motif near the C terminus. These findings suggest that EIAV Rev 
utilizes a bipartite RNA-binding domain. 
  
INTRODUCTION 
Equine infectious anemia virus (EIAV) infection of horses can result in a rapid, 
variable, and dynamic disease course. Moreover, horses that survive the early clinical 
episodes of disease are generally able to control virus replication and remain clinically 
normal, inapparent carriers of EIAV. The unique features of clinical disease, and the ability 
of some infected horses to eventually control virus replication, provide an excellent system 
for longitudinal analyses of virus and host factors important in lentivirus persistence and 
pathogenesis. Genetic diversity is a hallmark of lentiviruses and is considered an important 
mechanism of virus persistence and pathogenesis. Previous studies have identified a high rate 
of genetic variation in EIAV in the region overlapped by the transmembrane protein gp45 
(TM) and the major exon of Rev (2, 30). Genetic variation in rev/tm can significantly alter 
Rev activity (7), and in vivo studies suggest that changes in Rev phenotype correlate with 
changes in the clinical stage of disease (4, 6). In particular, Rev is significantly less active 
during the inapparent compared to the chronic stage of disease, suggesting that the Rev 
phenotype contributes to selection of virus variants in vivo. Insight into the genetic changes 
and factors that contribute to Rev selection in vivo requires identification of the functional 
domains and motifs that mediate EIAV Rev activity. 
The Rev/Rex proteins of complex retroviruses differentially regulate expression of 
incompletely spliced mRNAs encoding virion structural and enzymatic proteins and progeny 
RNA molecules (reviewed in reference 17). The prototypical member of this family, human 
immunodeficiency type 1 (HIV-1) Rev, binds to the viral pre-mRNA at a specific sequence 
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called the Rev-responsive element (RRE) (15, 48), multimerizes (37, 47), and facilitates 
export of incompletely spliced RNAs from the nucleus via a nucleoporin pathway distinct 
from that used by most cellular mRNAs (18, 19). Mutational analyses indicate that the 
activities of HIV-1 Rev are mediated by discrete functional domains, including an N-terminal 
arginine-rich RNA-binding motif (ARM), which also functions as a nuclear localization 
signal (NLS) (24, 32), and a C-terminal leucine-rich nuclear export signal (NES) (18, 19). 
EIAV Rev is a 165-amino-acid protein translated from exons 3 and 4 of a multiply spliced, 4-
exon, bicistronic mRNA that also encodes the trans-activating protein Tat (Fig. 2.1A) (12). 
EIAV Rev is functionally homologous to HIV-1 Rev (20, 33) but is less well characterized. 
The N-terminal leucine-rich NES, which maps to amino acids 31 to 55 (Fig. 2.1B) (20, 23, 
33), is similar to other leucine-rich viral and cellular export proteins that interact with the 
nuclear exporter CRM1; however, EIAV Rev is atypical in the spacing of the leucine 
residues within the NES (23, 38). The C-terminal basic region has been found to be 
important for nuclear localization, while the central region of the protein has been implicated 
in RNA binding (14, 23). 
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Figure 2.1. Organization and splicing patterns of EIAV and the EIAV Rev amino acid sequence. (A) 
Schematic of the EIAV genome showing open reading frames (ORF) and predominant mRNAs (a to e) isolated 
from virus-infected tissue culture cells (27). Regulatory proteins Tat (T) and Rev (r, rev) are translated from the 
four-exon mRNA (a). In the presence of Rev, EIAV exon 3 is skipped, resulting in a three-exon multiply 
spliced mRNA that encodes only Tat (b). Structural proteins and progeny RNA molecules are translated from 
singly spliced (d) and unspliced mRNAs (e). Ttm, a protein of unknown function (5), is encoded by a two-exon 
mRNA (c). (B) The amino acid sequence of the wild-type EIAV Rev H21 (7) is shown and numbered 1 to 165. 
The nuclear export signal (aa 31 to 55) is boxed. 
 
In addition to promoting nuclear export of incompletely spliced RNA, EIAV Rev 
regulates alternative splicing of the viral RNA. In the presence of Rev, the multiply spliced 
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mRNA, which lacks exon 3 (Fig. 2.1A), is produced (34). Exon 3 contains the translational 
start site for Rev, and alternative splicing was originally proposed as a novel mechanism for 
autoregulation of Rev expression (21, 23). Exon 3 is flanked by a suboptimal splice acceptor 
and contains a purine-rich exonic splicing enhancer (ESE) that interacts with the SR protein 
SF2/ASF (21). The ESE also functions as an EIAV RRE (6), and we have suggested that 
EIAV Rev mediates alternative splicing of exon 3 through protein-RNA interactions required 
for efficient export of incompletely spliced viral RNAs. While the exact mechanism of 
alternative splicing is not known, current models (6, 14) agree that alternative splicing 
requires both nuclear localization and RNA binding and perhaps an as yet unidentified 
domain(s) of Rev that interacts directly with SF2/ASF and/or other cellular splicing factors. 
To date, the specific amino acids that mediate EIAV Rev nuclear import, RNA binding, and 
alternative splicing have not been identified. Using a series of deletions and mutations in 
EIAV Rev cDNA, we mapped functional domains of EIAV Rev and identified specific 
motifs required for nuclear localization and RNA binding. Two noncontiguous, short ARMs 
were required for RNA binding, suggesting that EIAV Rev contains a bipartite RNA-binding 
domain. 
 
MATERIALS AND METHODS 
Construction of Rev mutants  
EIAV Rev cDNA deletion mutants were generated in the previously described 
plasmid pRevWT (7). Rev mutants containing internal deletions were constructed by PCR-
ligation-PCR mutagenesis as described by Ali and Steinkasserer (3). Briefly, upstream and 
downstream blunt-ended cDNA fragments of each mutant were amplified from pRevWT 
using the primers designed from the EIAV Wyoming cell culture-adapted isolate (GenBank 
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accession no. M16575) (27). Specific primer sequences used for cloning are available upon 
request. Fragments were gel purified, and downstream fragments were phosphorylated and 
ligated to the corresponding upstream fragment. Ligation products were amplified by PCR 
using wild-type 5′ (CAGCATGGCAGAATCGAAGG) and wild-type 3′ 
(CGAGAGTTCCTTCTTGGGA) primers. Following the second PCR, the cDNAs were TA 
cloned into pCR3.1 (Invitrogen, Carlsbad, CA) and transformed into Escherichia coli DH5-
{alpha}, and transformants were screened by colony blot hybridization. The C-terminal 
deletion mutants were PCR amplified using the 5′ wild-type flanking primer and unique 3′ 
primers that generated premature stop codons. PCR was performed using standard methods, 
and cDNAs were TA cloned into pCR3.1 as described above. Site-specific mutations were 
introduced by PCR-based mutagenesis. All constructs were confirmed by sequencing, and 
protein expression was verified by Western blotting using EIAV convalescent horse sera (10). 
 
Rev fusion proteins 
To construct green fluorescent protein (GFP) fusion proteins, Rev sequences were 
PCR amplified from wild-type and deletion constructs with primers that introduced 5′ EcoRI 
and 3′ BamHI restriction sites. PCR products were digested with EcoRI and BamHI and 
cloned into the GFP expression vector pEGFP-C2 (Clontech, Palo Alto, CA). The C-terminal 
region of Rev (specifying amino acids 145 to 165) was synthesized as complementary 
oligonucleotides that created 5′ EcoRI and 3′ BamHI overhangs after annealing. Wild-type 
and mutant oligonucleotides were synthesized, annealed, digested with EcoRI and BamHI, 
and cloned into similarly restricted pGFP-RDM12. All plasmids were sequenced to verify 
that each mutant Rev was translated from a single open reading frame. 
A series of maltose-binding protein (MBP)-Rev fusion proteins were used for RNA-
binding studies. ERev fragments amplified from EIAV R1A (6) or Rev cDNA plasmids were 
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cloned in pHMTc (43), which is based on the pMal-c2x expression vector (New England 
Biolabs, Beverly, MA). For most MBP-ERev constructs, Rev cDNA templates were 
amplified from EIAV variant R1A; MRD8 contains the Rev deletion mutant RDM11, which 
is based on pRevWT (see above). MBP-ERev constructs containing point mutations were 
cloned using amplified mutated PCR fragments based on R1A Rev cDNA template. All 
plasmid constructs were confirmed by DNA sequence analysis. 
 
CAT assays 
Rev nuclear export activity was quantified in transient transfection assays using a 
pDM138-based EIAV Rev reporter construct, pERRE-All, as previously described (7). 293T 
cells were seeded in triplicate at 1 x 105 to 5 x 105 cells/well in 6-well tissue culture dishes 
and maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% 
fetal calf serum (FCS) and penicillin-streptomycin (P-S) at 37°C and 8% CO2. One day after 
seeding, cells were transfected with 1.0 µg Rev cDNA or empty vector, 0.2 µg pERRE-All 
reporter plasmid DNA, 0.2 µg beta-galactosidase reporter plasmid DNA, and sufficient 
pUC19 to bring each well to 2.0 µg total transfected DNA. Medium was changed the next 
day, and cells were harvested at 48 h posttransfection, lysed by freezing-thawing, and 
normalized for transfection efficiency by measuring beta-galactosidase activity as described 
previously (7). Cell lysates were assayed for ß-galactosidase activity and normalized reaction 
volumes were assayed for chloramphenicol acetyltransferase (CAT) enzyme activity or for 
CAT protein using thin-layer chromatography or a commercial CAT enzyme-linked 
immunosorbent assay kit (Roche Molecular Biochemicals, Indianapolis, IN), respectively (7, 
8). All assays were performed in triplicate, and results represent at least six independent 
transfections. Statistical analysis was performed using analysis of variance and Student's t 
test assuming unequal variance among groups. 
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Trans-complementation assays  
Cf2Th (ATCC no. CRL-1430) clonal cell lines containing Rev (+) or Rev (–) EIAV 
proviral DNA were used to characterize nuclear export activity (7). Cf2Th/112 cells contain a 
Rev-competent proviral clone and produce supernatant reverse transcriptase (RT) activity, 
viral structural proteins, and all classes of viral mRNAs. Cf2Th/51 cells contain Rev-
defective proviral DNA, express only fully spliced mRNA, and lack detectable levels of viral 
structural proteins or RT activity. Trans-complementation of Cf2Th/51 cells with Rev cDNA 
results in viral protein expression and RT activity (7). Cells were seeded at 5 x 105 cells/well 
in 6-well tissue culture plates and maintained in DMEM supplemented with 10% FCS and P-
S at 37°C and 8% CO2. The next day, cells were transfected with 2 µg of wild-type Rev 
cDNA, Rev mutant cDNA, or empty vector DNA using the liposome-mediated transfection 
reagent Lipofectamine (Invitrogen). At 3 days posttransfection, supernatant was collected 
and assayed for RT activity as previously described (11). 
 
Nuclear localization assays and microscopy  
Cf2Th cells were plated at 2 x 104 cells/cm2 in 6- or 24-well plates or 8-well glass 
chamber slides (Nunc, Rochester, NY). Twenty-four hours after plating, cells were 
transiently transfected with 0.25 µg GFP or GFP-Rev plasmid DNA per 2 x 104 cells using 
the liposome-mediated transfection reagent TransIT-LT1 according to manufacturer 
instructions (Mirus, Madison, WI). In certain experiments, replicate cultures were treated at 
20 h posttransfection with 5 nM leptomycin B (LMB) in dimethyl sulfoxide. At 24 h after 
transfection, cells were fixed in 3.7% formaldehyde in 10 mM phosphate-buffered saline 
(PBS) for 30 min at 25°C and washed twice with complete DMEM supplemented with 10% 
FCS and P-S. Nuclei of fixed cells were stained with 0.5 µg/ml Hoechst 33258 dye (Sigma, 
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St. Louis, MO) in 0.5% NP-40 and 10 mM PBS for 15 min at 25°C. Cells were subsequently 
washed twice in complete DMEM and once in 10 mM PBS. All transfections were 
performed in triplicate. 
Fixed cells in 6- and 24-well plates were examined with an inverted Nikon Diaphot 
fluorescence microscope with a 40x objective and a 100-W high-pressure mercury lamp; 
epifluorescence filters were used to visualize Hoechst-stained nuclei and GFP. For confocal 
microscopy, chambers were removed from slides and a coverslip was sealed over fixed cells; 
slides were examined with a Leica TCS NT laser confocal microscope using a 63x oil-
immersion objective; digital filters with 400- to 480-nm and 500- to 560-nm excitation 
wavelengths were necessary to visualize Hoechst-stained DNA and GFP, respectively. 
Brightness and contrast of images obtained by confocal microscopy were adjusted with 
Adobe Photoshop 4.0. 
 
RNA-binding assays  
MBP-Rev fusion proteins were expressed in Rosetta-Gami DE3 (pLacI) (Novagen, 
Madison, WI). Harvested cells were lysed by freezing-thawing, and His-tagged fusion 
proteins were purified under native conditions using Ni2+-charged resin (Invitrogen). The 
purity of fusion proteins was confirmed by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) followed by Coomassie staining or Western blotting using 
EIAV convalescent-phase sera or polyclonal antibodies directed against the His Tag (MBL 
International, Woburn, MA). Purified MBP-Rev proteins were dialyzed and stored in 50 mM 
Tris-HCl (pH 8.0), 50 mM NaCl at 4°C. The EIAV Rev-responsive element (RRE) 
(nucleotides 5443 to 5565) was amplified by PCR from pERRE-All (8) using a 5′ primer 
containing a T7 promoter site. The PCR product was purified using QIAquick PCR 
purification columns (QIAGEN, Valencia, CA), and RNA was generated by in vitro 
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transcription (T7-MEGAshortscript; Ambion, Austin, TX) in the presence of [α-32P]UTP. 
Transcribed radiolabeled RNA was purified on a G50 column (Roche, Indianapolis, IN), 
denatured at 80°C for 5 min in 20 mM Tris-HCl, pH 7.5, 100 mM NaCl, annealed by slow 
cooling, and stored at –80°C. 
For RNA-binding reactions, 2 to 4 µg purified MBP-Rev fusion protein was 
incubated with 104 cpm of 32P-labeled EIAV RRE RNA in binding buffer (10 mM HEPES-
KOH, pH 7.5, 100 mM KCl, 1 mM MgCl2, 0.5 mM EDTA, 1 mM dithiothreitol, 50 µg/ml E. 
coli tRNA, and 10% glycerol) for 20 min at room temperature. After incubation, reaction 
samples were irradiated with 3 x 105 µJ at 254 nm for 7 min. Samples were treated with 0.1 
mg/ml RNase A at 37°C for 20 min; the reaction was terminated by boiling 5 min in an equal 
volume of SDS and separated in SDS-12% PAGE in Tris-glycine buffer. Gels were fixed in 
50% methanol-10% acetic acid, dried, and exposed to PhosphorImager screens overnight. 
UV cross-linked complexes were quantified using a PersonalFX scanner and Quantity One 
software (Bio-Rad, Hercules, CA). 
 
RESULTS 
Functional analyses of Rev deletion mutants.  
Lentiviral Rev proteins utilize discrete functional domains to control expression of 
viral mRNAs and structural proteins. To aid in identification of EIAV Rev functional 
domains, we constructed a nested set of Rev deletion mutants (RDM) (Fig. 2.2A) and tested 
them for nuclear export activity in transient transfection assays using the CAT reporter 
construct, pERRE-All (7). Nuclear export activity was highly sensitive to deletions in the 
Rev protein (Fig. 2.2B, panel 1). Mutants RDM4, RDM6-RDM10, and RDM12 showed no 
CAT activity, whereas activity was significantly reduced in RDM5. Only one mutant, 
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RDM11, showed levels of CAT activity comparable to wild-type Rev. To ensure that these 
results were not an artifact of the CAT reporter construct, all mutants were also tested by 
trans-complementation of a Rev-defective clonal cell line, Cf2Th/51 (Fig. 2.2B, panel 2). 
Overall, there was good agreement between the two assays: transfection with mutants 
RDM4-RDM10 and RDM12 showed no RT activity, while cells transfected with mutant 
RDM11 had activity similar to that of wild-type Rev. Western blot analysis using anti-EIAV 
polyclonal horse sera was done to confirm that all mutants expressed Rev. Some variation in 
protein expression was observed; however, the levels of expression did not correlate with 
levels of Rev activity. Mutants RDM4, RDM5, RDM6, RDM11, and RDM12 expressed at 
levels equal to or higher than Rev-WT, while RDM7, RDM8, and RDM10 expression levels 
were somewhat lower than Rev-WT. Only RDM9 showed markedly reduced levels of 
protein expression compared to other mutants. With the exception of RDM9, therefore, the 
loss of nuclear export activity was likely due to deletion of discrete functional domains 
and/or the loss of tertiary structure(s) required for activity. 
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Figure 2.2. Functional analyses of Rev deletion mutants. (A) Terminal and internal deletions in Rev 
cDNA were generated from pRevWT by PCR-ligation-PCR as described in the text. The region of amino acids 
deleted in each cDNA is indicated. (B) Activity of Rev deletion mutants was assayed in transient expression 
assays. Results are reported as activity relative to pRevWT. Cells transfected with the pCR3.1 vector DNA were 
used as the negative control (Neg.) in all assays. Error bars denote the standard error of the mean. Graph 1 
shows nuclear export activity measured using a CAT reporter assay (7). Lysates were normalized by ß-
galactosidase activity, and CAT activity was measured as the percentage of acetylation. Individual experiments 
included triplicate wells, and the data shown represent the means of at least three separate experiments. Graph 2 
shows supernatant reverse transcriptase (RT) activity following trans-complementation of a Rev-defective 
clonal cell line, Cf2Th/51, with Rev deletion mutants. Wt, wild type. 
 
The KRRRK motif in the C terminus of Rev is required for nuclear localization.  
The highly basic C terminus of EIAV Rev contains residues essential for nuclear 
entry (23); however, the precise NLS has not been identified. To more specifically identify 
the amino acids necessary for nuclear localization, each of the Rev deletion mutants shown in 
Fig. 2.2A were used to construct GFP-Rev fusion proteins. Plasmid DNA was transiently 
transfected into Cf2Th cells, and subcellular localization of fusion proteins was assessed by 
fluorescence and confocal microscopy. Only two of the nine GFP-Rev deletion mutants 
exhibited subcellular localization patterns different from that of wild-type Rev (data not 
shown). GFP-RDM4, which contains a deletion in the NES, was found only in the nucleus, 
and GFP-RDM12, which lacks the 21 C-terminal residues of Rev, was found exclusively in 
the cytoplasm. The C terminus contains a strongly basic KRRRK motif that is similar to 
other basic NLSs (22, 25, 46) and was previously suggested to be a component of the EIAV 
Rev NLS (23). To identify critical residues within the C-terminal region, we introduced 
additional deletions or alanine substitutions across the last seven residues of GFP-Rev (Fig. 
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2.3A). Mutants were transfected into Cf2Th cells and assayed for subcellular localization in 
the presence and absence of leptomycin B (LMB) (Fig. 2.3B). Rev is a nucleocytoplasmic 
shuttling protein, and LMB was used to block export of fusion proteins once they had 
translocated to the nucleus. Deletion of six (GFP-RDM13) or two (GFP-RDM14) amino 
acids from the C terminus of EIAV Rev abrogated nuclear localization. Alanine substitution 
within the KRRRK motif indicated that mutation of the middle arginine (C3 = KRARK) or 
the terminal lysine (C6 = KRRRA) did not alter nuclear import; however, Rev-GFP proteins 
with alanine substitutions of any two adjacent basic residues within amino acids 159 to 163 
(C1 = AARRK, C2 = KAARK, C4 = KRAAK, C5 = KRRAA) remained in the cytoplasm. 
Therefore, nuclear localization was dependent on the presence of a cluster of basic amino 
acids within the KRRRK motif in the C-terminal region. 
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Figure 2.3. The KRRRK motif in the C terminus of Rev is required for nuclear localization. (A) 
Amino acid sequence of the C terminus of wild-type Rev (aa 144 to 165) and the location of deletions or alanine 
substitutions introduced into wild-type GFP-Rev mutants. (B) Subcellular location of GFP-Rev deletion 
mutants (GFP-RDM13 and GFP-RDM14) and GFP-Rev containing alanine substitutions in the C terminus. 
Cf2Th cells were transfected with the specified Rev-GFP cDNAs in the presence or absence of 5 nM 
leptomycin B (LMB). Images of fixed and stained Cf2Th cells were obtained by confocal laser microscopy. 
Brightness and contrast were adjusted with Adobe Photoshop 4.0. 
 
Mapping the RNA-binding domain of EIAV Rev.  
In HIV-1 Rev, the RNA-binding domain overlaps the NLS (24). In EIAV Rev, 
however, the NLS is located in the C-terminal basic region, while the RNA-binding domain 
is thought to reside within the central region of EIAV Rev (23). To better define the RNA-
binding domain of EIAV Rev, we assessed RNA binding activity of a series of truncated 
MBP-Rev deletion (MRD) mutants in UV cross-linking assays (Fig. 2.4A). The purity and 
integrity of the MBP-Rev fusion proteins were confirmed by SDS-PAGE (Fig. 2.4B). RNA-
protein complexes were observed in reactions containing either MBP-Rev or MRD1 and the 
sense strand of the RRE but not in reactions containing the antisense RRE RNA (Fig. 2.4C). 
RNA-protein complexes included a clearly defined, faster migrating band and diffuse slower 
migrating products. No RNA-protein complexes were observed with either bovine serum 
albumin or MBP, demonstrating the specificity of Rev-RNA binding (Fig. 2.4C). 
Our analysis of the Rev-MBP deletion mutants showed that MRD1 and MRD3 each 
formed an RNA-protein complex, indicating that neither exon 1 (amino acids [aa] 1 to 30) 
nor the N-terminal leucine-rich NES (aa 31 to 56) was required for RNA binding. Constructs 
lacking either the last 20 or 40 C-terminal residues (MRD2, MRD4, and MRD5) did not form 
a complex with the EIAV RRE (Fig. 2.4D). However, no RRE binding was detected using 
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fusion proteins containing only C-terminal residues (MRD6 and MRD7). Therefore, residues 
within the C-terminal domain were necessary, but not sufficient, for RNA binding. To aid in 
identifying the boundaries of the Rev RNA binding domain, we constructed MRD8, a mutant 
with an internal deletion of aa 131 to 143. This is the same region deleted in RDM11 (Fig. 
2.2), a deletion mutant with wild-type levels of nuclear export activity. MRD8 bound the 
RRE RNA at levels comparable to wild-type Rev and MRD1 (Fig. 2.4E). There appeared to 
be a relative increase in the slower migrating RNA-protein complexes (compare Fig. 2.4E 
with C and D); however, this may be due to variability between experiments rather than 
differences in Rev binding. The RNA-binding activity of MRD8, together with the lack of 
RNA binding in MRD5, MRD6, and MRD7, indicate that two, noncontiguous regions of 
EIAV are required for RNA-binding activity. One region encompasses aa 57 to 130, and the 
second region is located in the C terminus of Rev, encompassing aa 144 to 165. 
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 Figure 2.4. Identification of sequences critical for RNA-binding activity of EIAV Rev. (A) MBP-Rev 
deletion mutants (MRD) containing 5′ or 3′ deletions used to map regions of Rev required for RNA binding. 
The Rev amino acids retained in each construct are indicated. (B) Expression and purity of MRD mutants were 
assessed by Coomassie staining of SDS-PAGE gels. The molecular size of each deletion mutant was confirmed 
using molecular size (MW) markers. (C) RNA-binding activity of MBP-Rev fusion proteins was determined by 
UV cross-linking and SDS-PAGE. Rev fusion proteins were incubated with radiolabeled EIAV RRE 
(nucleotides 5443 to 5565), cross-linked with UV irradiation, and treated with RNase. RNA-protein complexes 
were separated by SDS-PAGE and quantified using a PersonalFX scanner and Quantity One software (Bio-Rad). 
Negative controls included bovine serum albumin (BSA), MBP, and antisense RRE. (D and E) RRE-binding 
activity of Rev deletion mutants as described for panel C. 
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Two noncontiguous ARMs are required for RNA binding and nuclear export 
activity.  
Arginine-rich motifs are among the most common and well-characterized RNA-
binding motifs (9) and are essential for RNA-binding activities of HIV Rev and Tat (24, 29, 
41, 45). In HIV-1 Rev, a single 12-aa-long ARM located within the N-terminal domain 
functions in both RNA binding and nuclear localization (24). EIAV Rev contains two short 
Arg-rich motifs: RRDRW (aa 76 to 80) within the central region and KRRRK (aa 159 to 
163) in the C-terminal region. Another motif within the central domain, ERLE (aa 93 to 96), 
was proposed as an RNA-binding motif based on studies showing that replacement of the 
motif with alanines abolished nuclear export and alternative splicing activity (23) and 
abrogated RNA binding in gel mobility shift assays (14). All three motifs are located within 
the regions we identified as essential for RNA-binding activity of EIAV Rev (Fig. 2.4). To 
directly test their contribution to RRE binding, we introduced alanine substitutions into each 
motif in the background of MBP Rev construct MRD1. The amount of RNA-protein 
complexes was greatly reduced with either MRD1-AADAA, where all of the residues except 
the Asp in the RRDRW motif were replaced by Ala, or MRD1-KAAAK, in which all Arg 
residues in the KRRRK motif were replaced by Ala (Fig. 2.5A). However, near wild-type 
levels of RNA-protein complexes were observed with MRD1-AALA, where the charged 
residues (Arg and Glu) in the ERLE motif were replaced by Ala. Thus, Arg residues in both 
the RRDRW and the KRRRK motif are essential for RNA binding. The finding that two 
separate, noncontiguous Arg-rich motifs are required for RNA binding indicates that EIAV 
Rev contains a bipartite RNA-binding domain, one portion of which overlaps the nuclear 
localization signal. This RNA-binding arrangement of EIAV Rev differs markedly from that 
of HIV-1 Rev. 
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Figure 2.5. RRE-binding activity and functional analyses of Rev mutants. (A) Identification of specific 
motifs essential for RRE-binding activity of EIAV Rev. Point mutations introduced into the RRDRW, ERLE, 
and KRRRK motifs include alanine substitution of charged and/or Arg residues (AADAA, AALA, and 
KAAAK) and substitution of Asp for Leu in the ERLE motif (L95D). Binding activity was assessed as 
described in the legend to Fig. 2.4C. (B) Activity of Rev point mutation mutants (AADAA, AALA, KAAAK, 
and L95D) and deletion mutant (RDM13) were assayed as described in the legend to Fig. 2.2B. Neg., negative 
control. Wt, wild type. 
 
Although others have reported a loss of RNA-binding activity due to alanine 
substitutions for the ERLE motif in the central domain of EIAV Rev (14), we observed no 
decrease in RNA binding when Ala was substituted for only the charged residues in the 
ERLE motif (MRD1-AALA). This suggested that the Leu residue at position 95 was critical 
for the RNA-binding activity. The predicted secondary structure of EIAV Rev, based on 
consensus results using five different prediction programs (16, 28, 29, 39, 42), places the 
ERLE motif in the middle of an {alpha}-helix, and it was previously suggested that the Ala 
substitutions may disrupt the {alpha}-helical structure (14). To explore this, we substituted 
an Asp for the Leu residue at position 95 (L95D). The Asp can act not only as a helix breaker 
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but also can disrupt hydrophobic interactions between helices. The L95D mutation resulted 
in an 80% reduction of the maximum binding of Rev to RRE (Fig. 2.5A). Therefore, the 
ERLE may play a role in stabilizing the protein structure required for RNA-binding activity. 
To extend our analyses of the RRDRW and ERLE motifs, we introduced the Ala or 
Asp substitutions in R1A cDNA and analyzed the effect of mutations on Rev nuclear export 
activity in transient transfection assays (Fig. 2.5B). All of the RRDRW and ERLE mutants 
had significantly reduced Rev nuclear export activity. In addition, deletion of the KRRRK 
motif (RDM13), which is required for both RNA binding and nuclear export, eliminated Rev 
nuclear export activity in cell-based transfection assays. The results of these functional 
studies support our RNA-binding studies and establish a critical role for these motifs in Rev 
nuclear export activity. Interestingly, the AALA mutant was able to bind to viral RNA but 
was defective for nuclear export activity. Although its exact role is not known, this confirms 
previous findings that ERLE is critical for Rev activity (14, 23). More detailed analyses of 
Rev-RRE interactions will further enhance the results of our in vitro RNA-binding assays. 
 
DISCUSSION 
The Rev/Rex proteins of complex retroviruses are essential regulatory proteins that 
mediate nuclear export of incompletely spliced viral mRNAs via discrete functional domains 
that interact with cellular proteins and viral RNA. This family of proteins contains an 
interchangeable nuclear export signal that interacts with the cellular protein Crm1 and an 
ARM that binds specifically to homologous viral mRNA. Compared to most lentiviral Rev 
proteins, EIAV Rev is atypical with respect to the organization of functional domains (20, 
23), the spacing of critical residues in the NES (23, 33), the use of a purine-rich, exonic 
splicing element as an RRE (8, 34), and the regulation of alternative splicing of the 
bicistronic tat/rev mRNA (34). In addition, EIAV Rev is highly variable in vivo, and we have 
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shown that changes in Rev phenotype correlate with changes in clinical stages of EIAV 
infection (4, 6, 7). To better understand the significance of Rev variation in vivo, we 
undertook more detailed analyses of the functional domains of EIAV Rev. Previous studies 
identified point mutations in EIAV Rev that reduced nuclear export (7, 20, 23, 33, 35), 
alternative splicing (7, 23), RNA binding (14), and nuclear localization activities (23). Here, 
we extend those studies to map functional domains and identify specific motifs that are 
essential for EIAV Rev activity. All domains essential for Rev activity are contained within 
the second exon of EIAV Rev (20, 23). The overall functional organization of EIAV Rev 
exon 2 includes the N-terminal nuclear export signal, a large central region that contains 
amino acids required for RNA binding, a nonessential region, and a C-terminal region 
required for both nuclear localization and RNA binding. Two short, noncontiguous ARMs 
are necessary for RNA binding: a central RRDRW motif and a C-terminal KRRRK motif 
that is also essential for nuclear localization. The bipartite ARM is unique among lentivirus 
Rev proteins and provides another example of how EIAV uses an unusual protein 
arrangement to carry out a common lentiviral function. 
In HIV-1 Rev, the prototypical lentiviral Rev, a 17-aa ARM is located in the N-
terminal half of the protein and serves as both a sequence-specific RNA-binding domain and 
the NLS (32, 37, 40). No typical ARM is found within EIAV Rev, and prior studies have not 
directly examined the RNA-binding domain of EIAV Rev. However, previous studies have 
identified several mutants defective in either nuclear localization or RNA binding (14, 23). 
Mutants containing alanine substitutions of 157DSKR160 (M15) or 161RR162 (M1) were 
defective in nuclear entry and showed reduced alternative splicing activity (23). Alanine 
substitutions of 76RRDR79 (M11) and 93ERLE96 (M27) resulted in loss of nuclear export 
activity (23), and the latter was defective in RNA binding and alternative splicing (14). Based 
on these results, it appeared that there was no overlap between the NLS and RNA-binding 
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domain and that the EIAV Rev RNA-binding domain was distinct from the ARMs 
characteristic of other complex retroviruses. 
The present study is the first to directly characterize the RNA-binding activity of 
EIAV Rev and provides further insight into the specific motifs essential for EIAV Rev 
activity. The EIAV Rev NLS is relatively compact and requires the KRRRK motif contained 
within the C terminus of Rev. Mutants that retained four or five basic residues at amino acids 
159 to 163 were able to translocate to the cell nucleus (C3 and C6), while mutants with less 
than four basic residues in this motif remained in the cytoplasm (C1, C2, C4, and C5). The 
KRRRK motif is similar to the arginine-rich NLSs of HIV-1 Rev and HTLV-1 Rex (32, 36, 
40) and is nearly identical to the KRRR nuclear localization motifs found in the Drosophila 
melanogaster gcm gene product (1) and the RNA-binding human DEDD caspase protein (44). 
The ERLE and RRDR motifs identified in previous mutants M11 and M27 (23) were both 
found to be important in the RNA-binding activity of EIAV Rev, but they act through 
different mechanisms. Mutations of the charged residues in the ERLE motif had no effect on 
RNA binding, whereas the L95D mutation reduced binding by more than 80%. Therefore, 
the ERLE motif may play a role in stabilizing the protein structure required for binding of 
Rev to the viral RNA. In contrast, the arginine residues in both the RRDRW and KRRRK 
motifs were required for RNA binding, suggesting these short ARMs directly contact the 
RRE. Based on the results of our deletion analyses, other residues in the central domain 
likely contribute to RNA binding through direct contact with RNA and/or stabilization of 
protein structure. 
Arginine rich motifs are short, arginine-containing regions of 10 to 20 amino acids 
that mediate RNA binding of a number of viral and ribosomal proteins (9). The arginine 
residues are thought to play two general roles in RNA binding: first, as a probe to search for 
a high-affinity binding site, and second, to form a network of specific hydrogen bonds with 
the RNA backbone and specific bases (9). In the present study, we found that RNA binding 
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of EIAV Rev required two short ARMs separated by 79 amino acids in the primary protein 
sequence. One motif is located in the central region, and the second overlaps with the NLS in 
the C terminus. The results of UV cross-linking experiments showed that the C-terminal 20 
amino acids of EIAV Rev are required, but not sufficient, for binding to the RRE. 
Importantly, site-specific mutation of arginine residues in either the central ARM or the C-
terminal ARM abolished RRE binding. These results strongly suggest that the two ARMs 
interact with the EIAV RRE in concert and thus comprise a bipartite RNA-binding domain. 
Coordinated action of two, noncontiguous ARMs was also found to be necessary for binding 
of hepatitis delta antigen to viral RNA (13). It is not clear how two ARMs interact to bind 
viral RNA. The two domains may be in close proximity within the three-dimensional 
structure of the folded protein, where they could form a single RNA-binding domain 
containing at least seven arginine residues. Alternately, the two ARMs could interact with 
different regions of the viral RNA. Further analyses of EIAV Rev-RRE interactions will 
provide insight into this potentially novel class of RNA-binding motifs. 
In addition to promoting export of incompletely spliced viral RNA, EIAV Rev 
regulates alternative splicing of exon 3 in the bicistronic tat/rev mRNA (34). Exon 3 contains 
a purine-rich region that binds both Rev and the SR protein SF2/ASF and thus functions as 
both the EIAV RRE and an exonic splicing enhancer (7, 21, 31). Alternative splicing, or 
exon 3 skipping, likely results from competition between these two functions at either the 
RNA binding step or at a downstream step involved in spliceosomal assembly or activation 
(7, 14, 21, 31). Previous studies reported a loss in alternative splicing activity in Rev mutants 
containing alanine substitution of the ERLE motif or in both the RRDR and KRRRK motifs 
(14). Mutational analyses of cis-acting sequences required for exon 3 skipping show a close 
correlation between alternative splicing activity and RNA-binding activity (8, 14). Together, 
these data suggest that RNA binding plays an essential role in alternative splicing. Studies to 
date, however, have been unable to identify an alternative splicing domain distinct from other 
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Rev functional domains (23). Therefore, it has been difficult to assess the biological 
significance of alternative splicing in vivo. Exon 3 skipping was originally proposed as a 
novel mechanism for autoregulation of Rev (34); however, mRNAs lacking exon 3 comprise 
only a small percentage of viral mRNA in Rev-expressing cells (31). At present, the primary 
function of EIAV Rev appears similar to other lentiviral Revs in regulating the shift from 
production of multiply spliced to incompletely spliced viral mRNAs. 
There is a relatively high rate of genetic variation in the region of the EIAV genome 
where the second exon of Rev overlaps the cytoplasmic portion of the transmembrane protein 
gp45 (2, 6, 7, 30). The NLS and RNA-binding motifs are highly conserved, while the region 
identified here as nonessential for Rev function is the site of a number of amino acid changes 
that significantly altered Rev phenotypes (6). The nonessential region spans a predicted 
{alpha}-helix, and our results indicate that deletion of this region does not alter the structure 
of the Rev in a way that compromises Rev function. Similarly, the overlapping region of TM 
is found within the cytoplasmic domain, which may also be able to accommodate some 
degree of genetic variation without loss of function. As such, this region of the viral genome 
may be able to tolerate genetic mutations in Rev and/or TM that confer a selective advantage 
in vivo. Future studies may reveal how genetic variation in Rev contributes to viral 
persistence while preserving the function of this critical lentiviral protein. 
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CHAPTER 3. A CONSERVED RNA STRUCTURAL MOTIF IS 
REQUIRED FOR HIGH AFFINITY REV BINDING IN BOTH 
EIAV AND HIV-1 
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ABSTRACT 
 
A cis-acting RNA regulatory element, the Rev-responsive element (RRE), is essential 
for regulation of gene expression and genomic replication in lentiviruses, including human 
immunodeficiency virus (HIV-1) and equine infection anemia virus (EIAV). Despite its 
potential as a clinical target, little is known about the detailed molecular structure and 
mechanisms of RRE function. In this study, we investigate the secondary structure of the 
EIAV RRE and its interaction with the EIAV Rev protein, a critical trans-acting factor that 
effects several key RRE-mediated functions. A combination of computational prediction and 
detailed chemical probing and footprinting experiments were used to determine the RNA 
secondary structure of EIAV RRE-1, a 555 nt region previously shown to function as the 
EIAV RRE in vivo. Chemical probing experiments confirmed the presence of several 
predicted loop and stem-loop structures, which are conserved among 140 EIAV sequence 
variants. Footprinting experiments revealed that Rev binding induces significant structural 
rearrangement in two conserved domains characterized by stable stem-loop structures. Rev 
binding region-1 (RBR-1) corresponds to a genetically-defined Rev binding region that 
overlaps exon 1 of the EIAV Rev gene and contains an Exonic Slicing Enhancer (ESE). 
RBR-2, characterized for the first time in this study, is required for high affinity binding of 
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EIAV Rev to ERRE-1. RBR-2 contains a conserved RNA structural motif that is also found 
within the high affinity Rev binding site in HIV-1 RRE (stem-loop IIB), and within or near 
RRE regions of four additional lentiviruses. Taken together, the experimentally-validated 
RNA secondary structure of the EIAV RRE, and the discovery that high affinity Rev binding 
sites within the RREs of HIV-1 and EIAV share an RNA structural motif also found in at 
least six phylogenetically-diverse lentiviruses, provide the basis for detailed comparative 
analyses that should provide additional insight into the molecular mechanisms of Rev-RRE 
interactions in HIV-1 and other lentiviruses. 
 
INTRODUCTION 
Retroviruses employ a variety of mechanisms to express differentially spliced viral 
mRNAs transcribed from a single promoter. In all retroviruses, the presence of suboptimal 
splice sites allows for expression of several mRNAs from a single pre-RNA. Regulation of 
splice-site selection can be further regulated by cis-acting RNA sequences that either enhance 
or repress recognition of a splice site by the cellular splicing factors. In some retroviruses, 
viral pre-mRNAs contain constitutive transport elements (CTE) that are recognized by 
cellular proteins to facilitate nuclear export of incompletely spliced viral mRNAs.   Other 
retroviruses encode Rev/Rex proteins that act in trans to regulate nuclear export of unspliced 
or incompletely spliced mRNAs required for expression of structural and enzymatic proteins 
as well as progeny viral RNA genomes (10). The Rev/Rex RNA export pathway has been 
best characterized in HIV-1 (24). After entering the nucleus, the HIV-1 Rev protein binds to 
a specific cis-acting element, termed the Rev response element (RRE), within the viral pre-
mRNA (9, 68), multimerizes (50, 69) and then facilitates nuclear export of incompletely 
spliced viral mRNA via the Crm1 nuclear export pathway (17, 18).  Discrete functional 
domains within Rev mediate nuclear localization, RRE binding and multimerization, and 
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nuclear export. The HIV-1 RRE is a highly structured RNA  located at the junction between 
the SU (gp120) and TM (gp41) domains of the env gene (12, 32, 68). Biochemical and 
biophysical experiments have implicated specific stem-loop structures in Rev binding and 
multimerization (2, 30, 38). Because the Rev-dependent export pathway plays an essential 
role in HIV-1 replication, disruption of the Rev-RRE interactions is an attractive target for 
design of effective antiviral therapies. 
All lentiviruses utilize the Rev-dependent, Crm-1-mediated export pathway for 
expression of incompletely spiced mRNAs. There is no conservation among the lentiviral 
RREs at the RNA sequence level; however, the RRE regions of several primate and non-
primate lentiviral genomes map to the SU/TM junction in env gene (12) (32, 55, 64). In 
addition, computational analyses suggest that several of the lentiviral RREs may share RNA 
secondary structural elements (34). Equine infectious anemia virus (EIAV) is one of the most 
divergent members of the subfamily (16). EIAV Rev (E-Rev) is functionally homologous 
with other lentivirus Revs and utilizes the Crm-1 pathway for export of incompletely spliced 
mRNAs; yet EIAV differs from most lentiviruses in structural and functional features of Rev 
and RRE. EIAV therefore offers an opportunity for comparative analysis of the molecular 
interactions important in regulation of lentiviral gene expression.  This approach that may 
identify highly conserved RNA-protein interactions that could be targeted in novel anti-
lentiviral therapies. 
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igure 3.1. Organization of EIAV genome and location of EIAV RRE sequences.  (A) Schematic view 
of the EI
h both 
IAV Rev is a 165 amino acid protein translated from exons 3 and 4 of a multiply 
spliced ig. 
the 
 
F
AV genome showing the locations of open reading frames. (B) Location of RRE regions in the EIAV 
genome. ERRE-All, ERRE-1 and ERRE-2 refer to regions defined by Belshan et al. (4), with numbering 
according to Kawakami et al. (29). (C) The exonic splicing enhancer (ESE) sequence in ERRE-1. Boxed 
sequences represent two purine-rich sequence stretches (PuA and PuB) previously reported to interact wit
EIAV Rev and SF2-ASF (5, 8). 
 
E
, four-exon, bicistronic mRNA that also encodes the trans-activating protein, Tat (F
3.1). The leucine-rich nuclear export signal (NES) in E-Rev is similar to other viral and 
cellular export proteins that interact with the Crm1, but is atypical in the spacing of the 
leucine residues within the NES (18). The E-Rev RNA-binding domain is bipartite, 
comprised of two short arginine-rich motifs (ARMs) separated by 79 amino acids in 
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primary sequence (33). It not clear how the two domains cooperate to form a complex wi
the RRE, but a theoretical structural model of the E-Rev protein places the ARMs in close 
proximity within the three dimensional structure, suggesting they could form a single RNA
binding interface within the Rev-RRE complex (25, 33). In addition to promoting nuclear 
export of incompletely spliced RNA, E-Rev also regulates inclusion of exon 3 in the multip
spliced, bicistronic RNA:  in the presence of Rev, exon 3 is skipped, resulting in a three-
exon, monocistronic mRNA encoding only Tat (5, 21). Exon 3 is flanked by a suboptima
splice acceptor and contains a purine rich, exonic splicing enhancer (ESE) required for exo
three inclusion (35). ESEs typically are purine rich sequences embedded within alternatively 
spliced exons that bind cellular SR proteins and recruit essential splicing factors to 
suboptimal splice sites, resulting in exon inclusion of alternatively spliced exons. It 
thought that Rev-mediated skipping of exon 3 is a consequence of either Rev-SR prote
Rev-RNA interactions that disrupt ESE-SR protein interactions (5, 8, 19, 35). 
The EIAV RRE (ERRE) differs from other lentiviral RREs with respec
th 
 
ly 
l 
n 
is 
in, or 
t to location 
and fun
e 
 57 nt 
s 
nd its interactions 
with th
ction. The ERRE is located in a 555 nt region near the 5′ end of env, which spans 
exon 3 of the bicistronic Tat-Rev mRNA (4, 5, 19, 39). A 57 nt sequence encompassing th
ESE within exon 3 was shown to bind GST-Rev and to act as a functional RRE in a 
heterologous nuclear export assay system (5); however, nuclear export activity of the
“minimal ERRE” was reduced as compared to the full-length ERRE (4). Mutational analyse
of ERRE demonstrated that the purine rich sequences within exon 3 function as both an ESE 
and an RRE (4, 8, 35). The ERRE thus plays an important role in the complex interactions 
between viral pre-mRNAs, the viral Rev protein, and cellular splicing factors to mediate 
alternative splicing and regulation of viral gene expression (3, 8, 19, 35). 
In this paper, we investigate the RNA structure of the EIAV RRE a
e Rev protein. We propose an RNA secondary structure model for the essential RRE 
in EIAV, based on a combination of secondary structure prediction and chemical probing 
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experiments. We present the first detailed in vitro footprinting analysis of EIAV Rev-RRE
complexes, and identify two distinct domains within the essential RRE that undergo 
significant structural transitions upon Rev binding. Computational analyses revealed 
secondary structural motif within the high affinity Rev-binding sites of both HIV-1 and 
EIAV that is present within the mapped RREs of four additional lentiviruses. The 
identification of a conserved recognition element for lentiviral Rev-RRE interactio
groundwork for more detailed comparative analyses of lentiviral Rev-RRE interactions.  
 
 
an RNA 
ns lays the 
MATERIALS AND METHODS 
Preparation of ERRE-1 RNA and purified EIAV Rev protein 
dard” wildtype 
EIAV s E-
 
ed 
 
d 
Chemical probing of RRE RNA secondary structure and footprinting Rev-RRE 
complexes 
Prior to chemical probing or footprinting experiments, ERRE-1 in RNA storage 
buffer (10mM Tris-HCl, pH 7.5) was pre-incubated at 42℃ for 15 min. To generate 
The EIAV ERRE-1 (corresponding nts 5280 to 5843 of our “stan
train, MA-1, GenBank accession no. M58039) was amplified by PCR from pERR
All (4, 5, 29) using a 5′ primer containing a T7 promoter site. The PCR product was purified
using QIAquick PCR purification columns (QIAGEN, Valencia, CA), and RNA was 
generated by in vitro transcription (T7-MEGAscript; Ambion, Austin, TX). Transcrib
RNA was purified using MEGAClear kits (Ambion, Austin, TX), denatured at 90°C for 2
min and annealed by slow cooling. Ethanol precipitation was performed to remove salts an
concentrate ERRE-1 RNA. Concentrated RNA was stored at -80℃. EIAV Rev protein was 
expressed as an MBP-ERev fusion protein and purified as described previously (33). 
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unmodified and modified unbound ERRE-1 samples for RNA secondary structure probing 
experiments, two aliquots (each containing 35 pmol) of ERRE-1 were added to RNA binding 
buffer (  To 
, St. 
al 
ature. 
ing, 
5 µℓ 
 
To identify positions of chemically modified nucleotides in ERRE-1, primer 
extension analysis was used using 5 different oligonucleotide primers (Table 3.1), essentially 
as previously described (47, 48). 
10 mM HEPES-KOH, pH 7.5, 100 mM KCl, 1 mM MgCl2, and 0.5 mM EDTA).
generate ERev-ERRE-1 protein-RNA complexes for footprinting experiments, samples 
containing one to thirty-fold molar excess of purified MBP-ERev fusion protein were 
incubated with pre-folded ERRE-1 RNA (35pmol) in binding buffer in a total volume of 87.5 
µℓ for 20 min on ice. Samples containing folded ERRE-1 RNA alone or RNA-protein 
complexes were incubated with 10.5 µℓ 880 mM dimethylsulfate (DMS) (Sigma-Aldrich
Louis, MO) or 7 µℓ 720 mM kethoxal (ICN, Costa Mesa, CA) or 16 µℓ hydroxyl radic
probing mixture (4 µℓ of 50mM Fe(NH4)2(SO4)2·6H2O, 4 µℓ of 100mM EDTA, 4 µℓ of 
250mM ascorbic acid, and 4 µℓ of 2.5% hydrogen peroxide) for 10 min at room temper
DMS modification reactions were stopped by addition of 59.3 µℓ of DMS stop buffer (1M 
Tris-HCl pH 7.5, 0.1M EDTA pH 8.0, and 1M 2-mercaptoethanol). For the kethoxal prob
8.2 µℓ of 0.5 M potassium borate was added for stabilizing kethoxal. Hydroxyl radical 
probing reactions were quenched by the addition of 92.8 µℓ of 1M thiourea. After ethanol 
precipitation of RNA or RNA-protein complexes, 3 phenol and 2 chloroform extractions 
were performed to purify RNA from RNA-protein complexes. RNA was concentrated and 
washed using 100% and 70% ethanol precipitations. Finally, RNA was resuspended in 3
of water (for DMS and hydroxyl radical modifications) or 35 µℓ of 40mM potassium borate
for kethoxal modification. Additional details are provided in (47). 
 
Primer extension analysis of chemically-modified EIAV RRE sequences 
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Nitrocellulose filter b
Nitrocellulose filter binding assays were carried out using purified P-labelled RNAs 
corresponding to ERRE-1 (555 nt; 5280 to 5834) or subfragment of ERRE-1 (123 nt; 5443 to 
5465) using standard procedures. Binding affinities were calculated using Dynafit software 
The EIAV genomic RNA sequences used in the present study were originally 
collected for analyzing sequence variants in the EIAV Env SU protein by Mealey, et al. (46) 
and deposited in the NCBI GenBank in two segments (5′ and 3′). From a total of 284 EIAV 
re collected. 
After re uences 
inding assays 
32
(31).   
 
Sequences of gp90 (SU) variants and information content analysis  
sequences used in Mealey, et al., those that overlapped the ERRE-1 region we
moval of sequences with deletions or premature stop codons, a total of 258 seq
(126 corresponding to the 5′ fragment and 132 corresponding to the 3′ fragment of SU), 
corresponding to 139 complete Env gene variant sequences, remained. The concept and 
methods for analyzing of information content are described elsewhere (7, 51, 59). Briefly, 
collections of the 5′ or 3′ fragment sequences were aligned using CLUSTALW 
(http://www.ebi.ac.uk/clustalw/) and information content was calculated according to the
following equation:  
 
where I
 
ation content for the nucleotide position i in the alignment, the index j 
sums over all possible nucleotides (A, T, G, and C), qij represents the observed frequency of 
I = q∑ log
i is the inform
i ij
j
2
qij
pj
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nucleotide j at position i and pj quency value, which is 0.25. The 
calculated information content at each nucleotide position was plotted using Microsoft Excel. 
Different methods for RNA secondary structure prediction have been reviewed 
recently (40, 44). In this work, Mfold (70) was used to predict the lowest free energy 
secondary structure of ERRE-1, (http://frontend.bioinfo.rpi.edu/applications/mfold/cgi-
 represents the expected fre
 
RNA secondary structure prediction  
bin/rna-form1.cgi) using only the standard EIAV sequence as input (i.e., with no 
sequen
h.org
experimental constraints). To model the secondary structure of ERRE-1, using a single 
ce of ERRE-1 and experimental constraints derived from the results of chemical 
probing experiments, four different methods, Mfold, Sfold (13) (http://sfold.wadswort ), 
RNAfold (23) (http://www.tbi.univie.ac.at/~ivo/RNA/), and RNAStructure 
(41)(http://rna.urmc.rochester.edu/rnastructure.html) were used. Experimental con
data were preprocessed to generate appropriately formatted input files for each of the fo
programs. A fifth method, RNAalifold, generates an optimal RNA secondary structure b
on calculation of the minimum free energy structure, and a partition function and base-
pairing probability matrix derived from an multiple sequence alignment (22)
(
straints 
ur 
ased 
 
http://www.tbi.univie.ac.at/~ivo/RNA/). Input for RNAalifold consisted of an alignment o
140 ERRE-1 variant sequences generated using CLUSTALW (63) 
(
f 
http://www.ebi.ac.uk/clustalw/). The resulting alignment and experimental constraint input 
was used to determine an optimal RNA secondary structure for ERRE-1. RNA seconda
structures were drawn using PSEUDOVIEWER2 (20) 
(
ry 
http://wilab.inha.ac.kr/pseudoviewer2/). 
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Identification of a conserved RNA structural motif within lentiviral genomes 
RNAstructure Dynalign software (43) (http://rna
) was used to test whether sequences corre
.urmc.rochester.edu/rnastructure.html 
sponding to the high affinity Rev binding sites of 
EIAV and HIV-1 have the capacity to form similar RNA secondary structures. Sequences of 
R-
2 region (nt 371-470) were compared, resulting in two very similar ensembles of predicted 
secondary structures. RNA motif models based on common features of the HIV-1 and EIAV 
RRE structures were generated using RNAMotif (37) 
(http://www.scripps.edu/mb/case/casegr-sh-3.5.html) and used to scan the complete genomic 
sequences of ten different lentiviruses (GenBank accession no. M15654;HIV-1, NC_001450; 
EIAV, NC_001722; HIV-2, NC_001549; SIV, NC_001452; VV, NC_001463; CAEV, 
NC_001511; OLV, NC_001482; FIV, NC_001413; BIV, NC_001654; JDV) and rabbit 
endogenous lentivirus type K (RELIK) (28). 
 
Probing the RNA secondary structure of ERRE-1 
the EIAV genomic RNA essential for Rev 
responsiveness, we focused on a 555 nucleotide region (nt 5280-5834), referred to as ERRE-
1 (Fig. 3.1B) (4). Initial mapping of cis-acting RRE regions in the EIAV genome had 
, that provide partial RRE 
function (39), and subsequent studies demonstrated that several distinct regions of the EIAV 
genome can contribute to RRE function (4, 19). The 555 nt ERRE-1 region was shown to 
function as a "minimal" RRE, retaining 60% of wildtype function in vivo, by Belshan, et al. 
(4). ERRE-1 encompasses exon 3 of the bicistronic that encodes both Env and Rev. It also 
contains an ESE (Fig. 3.1C) for Rev-mediated alternative mRNA splicing (5, 19), and is 
100 nt regions encompassing the HIV-1 stem-loop IIB region (nt 8-107) and the EIAV RB
RESULT 
To identify structural features of 
identified two elements, one near each end of the Env gene
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required for Rev-mediated nuclear export of partially spliced mRNAs (4, 5). Both EIAV Rev 
and the cellular protein, SF2/ASF, a member of the SR family of splicing factors, have bee
shown to interact with the ESE within ERRE-1 (5, 8, 33). Thus, the ERRE-1 sequence was 
chosen for RNA secondary structure analysis and as substrate for ERev-RRE footprinting 
experiments. 
The secondary structure of ERRE-1 was analyzed using a combination of 
computational and experimental approaches. First, the lowest free energy structure of ERRE-
1 was predicted by computational method (Fig. 3.2A). The structure was generated by Mfold
(70) with default parameters. Also we experimentally interrogated the structure by analyzin
the accessibili
n 
 
g 
ty of ribonucleotides in the folded RNA to single-strand specific chemical 
probes (14). (kethoxal and DMS), thus identifying regions not involved in base-pairing 
Chemically-modified nucleotides in ERRE-1 were identified by primer extension analysis 
using 5 different primers (Table 3.1). Experimental data from chemical probing experiments 
were integrated into computational predictions of secondary structure of the ERRE-1 using 
several different algorithms designed to incorporate experimental constraints from chemical 
probing assays.  
Primers Nucleotide sequence 
Primer 90 TTTTTCTGACTGTTGGG 
Primer 185 TCTTGGTCTCTTGCTTC 
Primer 291 CCAAAGTATTCCTCCAG 
Primer 389 CCCCAGCATTCTATAGC 
Primer 485 GCTTCTAATAATGTAGC 
Primer 555 TCCCCAATATTCCGCTGTGT 
Table 3.1. A primer list for the primer extension analysis for ERRE-1 
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Figure 3.2. RNA secondary structural models for ERRE-1 (A) The lowest free energy secondary 
structure of ERRE-1, predicted by Mfold without incorporatating experimental constraints (70). (B) Lowest free 
energy R A secondary structure models of ERRE-1, generated by for different algorithms, all using chemical 
probing sults as experimental constraint input: Mfold, Sfold (13), RNAStructure (41), and RNAfold (23). SL-
X, -Y an for 
 four models differ in detail, they are in similar in the overall topology: all four 
models share a set of 3 stem-loop structures (SL-X, -Y, and -Z) and in every case, the ESE is 
N
re
d -Z, stem-loop structures common to all four models, are highlighted (see Materials and Methods 
details).  
 
In Figure 3.2B, four different secondary structure models were generated by Mfold (70), 
Sfold (13), RNAstructure (42) and RNAfold (23), with experimental constraints. Although 
the latter
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located within a large loop (heavy line in Fig. 3.2B). Notably, with the exception of SL-X, 
l 
able 
onsensus RNA secondary structure based on thermodynamic 
conside
ard 
y 
none of these shared features is also found in the structure generated without experimenta
constraints (Fig. 3.2A). 
To further refine and validate the RRE secondary structure models, we used avail
sequence information from EIAV variants to perform covariation analyses, using RNAalifold 
software (22). RNAalifold can incorporate covariation information from a collection of 
aligned RNA sequences, in addition to experimental constraint data, as input. Thus, the 
algorithm determines a c
rations and the evaluates the compatibility of observed sequence covariations with 
that secondary structure. Experimental constraints are used in the final step to identify an 
optimized RNA secondary structure. A total of 140 different EIAV sequences (the stand
or "wildtype" sequence from strain MA-1 strain and 139 SU variant sequences (46) that 
overlap ERRE-1) were used to generate a multiple sequence alignment for computing 
ribonucleotide covariation frequencies within ERRE-1. The secondary structure generated b
RNAalifold is shown in Figure 3.3.  
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igure 3.3.  Chemical probing results mapped onto the RNA secondary structure of ERRE-1. 
RNAalif
formation 
cles), 
 
 
F
od (22) was used to generate an optimized RNA secondary structure of ERRE-1, based on a 
combination of thermodynamic considerations, experimental constraints, and sequence co-variation in
derived from multiple sequence alignment of a collection of 140 ERRE-1 sequence variants. Arrowheads 
denote ribonucleotides modified by chemical probing reagents: kethoxal (red squares) and DMS (green cir
with the relative extent of modification represented by either two (strong) or one (weak) symbol. SL-X, -Y and -
Z are stem-loop structures also shown in Figure 3.2. 
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Arrows indicate ribonucleotides for which chemical probing experiments indicated 
e 
 
e 
55 
 
.90 
 
EIAV Rev "footprints" two regions within ERRE-1 
SE within ERRE-1 as a 
primary ing 
, 
ev. 
 
accessibility to modification by kethoxal (red rectangles) or DMS (green circles). Th
number of rectangles or circles corresponds to the intensity of the cleavage band at that
position, with more symbols indicating a higher probability of "single-strandedness." Th
overall topology of this secondary structure of ERRE-1 is very similar to the secondary 
structures presented in Figure 3.2. In the optimized model shown in Figure 3.3, 373 of 5
ribonucleotides in ERRE-1 participate in the base-pairing and 182 are located in single-
stranded regions. The estimated free energy for this structure, based on a combination of
thermodynamic considerations, chemical probing results and co-variation analyses, is -77
kcal/mol. Notably, the ESE and the previously identified EIAV Rev binding region (5, 8, 33),
are both located within the single-stranded loop B. Several structural features, including loop 
B, and stem-loop regions SL-X and SL-Y, are the same all five models shown in Figure 3.2B 
and Figure 3.3. The inclusion of covariation information results in one significant difference: 
in SL-Z, the base-paired region between nt 425-428 and nt 470-473 (Fig. 3.2) is converted to 
a single-stranded region in the optimized RNA secondary structure model, creating a new 
loop (loop D, Fig. 3.3). 
 
Previous experiments had implicated the purine-rich E
 binding site for EIAV Rev protein (5, 8). To obtain detailed information regard
the interaction of EIAV Rev with ERRE-1 sequences and structural motifs, we performed 
RNA "footprinting" experiments, using chemical probing and primer extension analysis (11
47). Three different chemical reagents were used to compare the accessibilities of 
ribonucleotides in ERRE-1 to modification in the presence or absence of bound E-R
Hydroxyl radicals were used to monitor cleavages in the sugar-phosphate backbone, and
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kethoxal (which modifies N1 and N2 of guanines) and DMS (which methylates N1 of 
adenines and N3 of cytosines) were employed as base-specific probes. The folded ERR
RNA alone or Rev-ERRE-1 complexes were subjected to modification by each chemical 
reagent. Primer extension by reverse transcriptase was used to identify the chemically-
modified ribonucleotides in the ERRE-1 sequence. In ladders of 
E-1 
 of 
3′) 
e 3.4, and representative 
footprin re 
 
l and 
e 
ical 
32P-labelled primer 
extension products visualized by denaturing polyacrylamide gel electrophoresis, sites
modification correspond to a "stop" or enhanced band located one position downstream (
of the band corresponding to the modified ribonucleotide site.  
A summary of the footprinting results is shown in Figur
ting gels are shown in Figures 3.5 and 3.6. Two distinct regions within ERRE-1 a
"footprinted" by Rev (highlighted in yellow, Figure 3.4). Rev binding region-1 (RBR-1) is 
~90 nt long (nt 170-260) and encompasses the ESE, including both purine-rich regions PuA
and PuB (5, 8). A second domain, RBR-2, is ~110 nucleotides long (nt 360-470), and 
represents a newly-identified Rev interaction domain. Positions with enhanced kethoxa
DMS reactivity (circled residues) in ERev-ERRE-1 complexes, compared with the unbound 
RNA, are located primarily in single-stranded regions of the ERRE-1 secondary structure. 
Most regions protected from hydroxyl radical cleavage are also in single-stranded loops Th
experiments illustrated in Figures 3.5 and 3.6, together with many similar experiments using 
different primers (Table 3.1) to probe the entire ERRE-1 sequence were used to generate 
Figure 3.4, which summarizes the reproducible patterns of significant differences in chem
reactivity of the ERRE upon Rev binding. 
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Figure 3.4. Two distinct regions of ERRE-1 undergo structural transitions in the presence of bound 
EIAV R al 
ith 
otifs 
ev protein. Consensus chemical modification patterns, based on at least 3 experiments in which sever
different primers were used to probe the complete ERRE-1 RNA, are mapped onto the RNA secondary 
structure model shown in Figure 3.3. Ribonucleotides that consistently display enhanced modification w
either kethoxal or DMS upon Rev binding are circled: bold circle (strong) and thin circle (mild). Regions 
protected from hydroxyl radical cleavage in the presence of Rev are denoted by a thick line. Purine-rich m
are highlighted in green. 
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RBR-1: Rev binding induces structural changes both within the ESE in ERRE-1 
and in adjacent single-stranded regions  
inal region of ERRE-1, several purine-
rich regions and GAR (g
Within RBR-1, corresponding to the 5′ term
uanine-adenine-purine) motifs have been identified as binding sites 
for the host splicing factor, SF2/ASF (19, 67). The purine-rich regions PuA and PuB, in 
particular, have been shown to bind both EIAV Rev and SF2/ASF in electrophoretic mobility 
shift assays (5, 8, 19, 33). To obtain more detailed footprinting information for this region, 
we systematically analyzed changes in the relative extent of ribonucleotide modification 
using titration experiments, in which ERev-ERRE-1 complexes were formed with increasing 
amounts of purified EIAV Rev protein (Fig. 3.5A, B).  
Within loop B, numerous changes in ribonucleotide accessibilities were detected with 
increased amounts of EIAV Rev bound, especially in the PuA and PuB regions (Fig. 3.5). In 
the PuA, enhanced reactivity was seen for 4 out of 9 nucleotides and in PuB, all 20 purine 
residues showed enhanced reactivity, with both kethoxal and DMS (Fig. 3.5). Two regions of 
Rev-mediated protection from hydroxyl radical cleavage, which are not as strong as ones in 
the loop C and D, (see below) were also observed in loop B, one located in the sequence 
between PuA and PuB and another immediately downstream from PuB (nt 245-255, Fig 3.4). 
In addition to the two purine-rich motifs within the ESE, a third purine-rich motif, located in 
loop A, was strongly affected by Rev binding. Enhanced reactivity was seen for 7 out of 15 
nucleotides within this motif and for 4 additional purine residues near the stem at the base of 
loop A (Fig. 3.5) 
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extensio ysis of chemical probing experiments  using kethoxal (a) and DMS (b). Similar experiments were 
performe es 
-1 
e. 
Figure 3.5. Representative footprinting results for RBR-1 (A) Representative gels from primer 
n anal
d using the hydroxyl radical cleavage reagent, Fe-EDTA (data not shown). Circled ribonucleotid
denote positions with enhanced reactivity in the presence of bound EIAV Rev protein ("footprints"). Lanes A & 
G, Dideoxy sequencing markers; lane K, control, unmodified ERRE-1, in the absence of Rev; lane M, ERRE
modified in the absence of Rev; (lanes ◢) ERRE-1 modified in the presence of increasing amounts of Rev 
protein (1~30 fold molar excess).  (B) Consensus chemical modification patterns in RBR-1, based on several 
experiments similar to those illustrated in part (A), are mapped onto the corresponding portion of the RNA 
secondary structure of ERRE-1 (from Fig. 3.3). Ribonucleotides that consistently display enhanced 
modification with either kethoxal or DMS upon Rev binding are circled: bold circle (strong) and thin circle 
(mild). Regions protected from hydroxyl radical cleavage in the presence of Rev are denoted by a thick lin
Purine-rich motifs are highlighted in green. 
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Although the region corresponding to loop A, formed by nt 172 to 202, has not 
previously been implicated in EIAV Rev binding, our footprinting analyses revealed 
signific e 
 that 
RBR-2: A newly identified structured region in ERRE-1 also undergoes 
conformational changes upon Rev binding 
cross the 
RBR-2, a region that has not been 
previou
cted 
 
ced 
antly enhanced reactivities of ribonucleotides in this loop. Therefore, we conclud
that within RBR-1, a purine-rich motif in loop A, in addition to a region within loop B
encompasses the previously identified purine-rich PuA and PuB motifs in the ESE, 
undergoes significant structural rearrangement upon Rev binding. 
 
By monitoring nucleotide accessibility changes in response to Rev binding a
entire ERRE-1 sequence, we were able to identify 
sly implicated in Rev binding, located approximately 100 nt 3′ to RBR-1. Hydroxyl 
radical probing identified several regions within loops C and D that are strongly prote
from hydroxyl radical cleavage upon EAIV Rev binding (Fig. 3.6). Enhanced DMS and 
kethoxal reactivities were also observed for several positions within loops C and D. Within
RBR-2, most ribonucleotides involved EIAV Rev binding are located within these large 
single-stranded regions. However, one stem-loop region, SL-Z, is strongly footprinted by 
Rev. SL-Z contains two protected stretches (nts 439-451 and 459-468) and several enhan
nucleotide reactivities (e.g., nts 451 and 459) (Fig. 3.6).  
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Figure 3.6. Representative Rev footprinting results in RBR-2 (A) Representative gels from primer 
extension analysis of chemical probing experiments  using hydroxyl radical cleavage reagent, Fe-EDTA (•OH) 
(a) and D des 
e. 
MS (b). Similar experiments were performed using kethoxal (data not shown). Circled ribonucleoti
denote positions with enhanced reactivity in the presence of bound EIAV Rev protein ("footprints"). Lanes A & 
G, Dideoxy sequencing markers; lane K, control, unmodified ERRE-1, in the absence of Rev; lane M, ERRE-1 
modified in the absence of Rev; (lanes ◢) ERRE-1 modified in the presence of increasing amounts of Rev 
protein (1~30 molar excess). (B) Consensus chemical modification patterns in RBR-2, based on several 
experiments similar to those illustrated in part (A), are mapped onto the corresponding portion of the RNA 
secondary structure of ERRE-1 (from Fig. 3.3). Ribonucleotides that consistently display enhanced 
modification with either kethoxal or DMS upon Rev binding are circled: bold circle (strong) and thin circle 
(mild). Regions protected from hydroxyl radical cleavage in the presence of Rev are denoted by a thick lin
Purine-rich motifs are highlighted in green. 
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The discovery of interactions between EIAV Rev and RBR-2 is consistent with 
previous reports that the complete 555 nt ERRE-1 has more functional activity in vivo than 
several esize 
r 
s 
is 
The RNA sequence of ERRE-1 is conserved in variant EIAV sequences 
An analysis of 178 HIV-1 variant sequences revealed that RNA sequences 
 for 
mainten ich the 
E 
s. 
eic acid 
 
 shorter ERRE-derived constructs that encompass the ESE region (5). We hypoth
that Rev-binding sites within RBR-2 are, in fact, the functional elements "missing" in shorte
constructs that retain less activity than the complete ERRE-1 in vivo. Nitrocellulose filter 
binding experiments support this interpretation: the binding affinity of purified ERev for 
ERRE-1 (555 nt) is ~20nM, whereas a 123 nt fragment of ERRE-1 (nts 164-286) that lack
RBR-2 has much lower affinity, ~5µM, in vitro (data not shown), suggesting that RBR-2 
required for high affinity binding of EIAV Rev to ERRE-1. 
 
corresponding to the RRE are highly conserved as a result of evolutionary pressure
ance of both: i) the protein sequence encoded by the gp160 gene (within wh
HIV-1 RRE is embedded), and ii) the RNA sequence and secondary structure of the RR
(51). To investigate the potential conservation of the ERRE-1 sequences at the RNA 
sequence level, we evaluated the information content in a group of variant EIAV sequence
Information content analysis is widely used to quantify sequence conservation in nucl
or protein sequences, (e.g., (51, 57, 58, 62)). Sequences of the EIAV gp90 gene, collected for
analysis of envelope SU protein variants by Mealey, et al. (46) were aligned and information 
content was calculated as described in Materials and Methods. The plot in Figure 3.7 shows 
the distribution of information content values for ribonucleotide positions in the gp90 gene. 
The highest possible value for information content is 2, corresponding to cases in which all 
ribonucleotides at a particular position in the alignment are identical. Lines representing the 
previously described hypervariable regions in gp90 (46), the EIAV Rev exon 1 (61) coding 
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region and the Rev-footprinted regions determined in this study are shown. This analysis 
shows that, except for one segment corresponding to a known hypervariable region of gp90,
the entire ERRE-1 region is highly conserved relative to the rest of gp90 gene. Further, the
two major Rev-footprinted regions (RBR-1 and RBR-2) are located within this conserved 
region. Taken together, these results suggest that the conservation of ERRE-1 sequences 
results from evolutionary pressure for conservation of not only the protein sequence encode
by the gp90 gene, but also the RNA sequence and, potentially, RNA secondary structural 
features of ERRE-1 required for Rev binding.   
 
Figure 3.7. Conservation of RNA sequences in t
 
 
d 
he gp90 (SU) gene of EIAV. Conservation of RNA 
sequences in EIAV Env gene (gp90) was assessed by evaluating information content at each nucleotide position 
in a CLU
, 
STAL-W generated multiple sequence alignment of 140 gp90 sequence variants (see Materials and 
Methods for details). Information content (I) is plotted against nucleotide position, numbered from the first 
ribonucleotide in ERRE-1. The gp90 gene begins at position 35. The maximum information content value is 2
which corresponds to 100% conservation at a particular position in this alignment. The locations of gp90 
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hypervariable regions, identified in a previous analysis of SU variants (46), are indicated by blue lines above the 
graph. Colored horizontal lines indicate the locations of (pink), EIAV Rev binding regions 1 and 2 (RBR-
RBR-2) (red), and EIAV Rev exon 1 (green).   
 
1 & 
The high affinity Rev-binding sites of EIAV-1 and EIAV form a conserved RNA 
structural motif found in the RRE regions of diverse lentiviruses 
ether RBR-1 and 
RBR-2  
st, the 
v 
ompted us to generate a computational RNA 
structur
as 
n 
pped 
To explore the possibility that RNA secondary structural elements required for Rev 
binding in EIAV might also be found in other lentiviruses, we first asked wh
, identified in this study, have any predicted RNA structural features in common with
one another or with the previously identified high affinity Rev binding site in HIV-1 RRE 
(stem-loop IIB) (9, 65). Pairwise RNA sequence and secondary structure alignments 
performed using RNAstructure Dynalign software (43) failed to identify significant RNA 
structural similarities in EIAV RBR-1 and RBR-2 (data not shown). In striking contra
stem-loop IIB region of HIV-1 and RBR-2 of EIAV, which encompasses a high affinity Re
binding site in EIAV, have potential to form a very similar ensemble of secondary structures 
(two examples are shown in Fig. 3.8A).   
The unexpected RNA structural similarities detected through pairwise analysis of the 
HIV-1 and EIAV Rev-binding domains pr
al motif model based on shared features of the two regions, using RNAMotif (37) 
(http://www.scripps.edu/mb/case/casegr-sh-3.5.html). The resulting RNA motif model w
used to scan complete genomic sequences of ten different lentiviruses (see Materials and 
Methods). Figure 3.8B illustrates nine of the conserved RNA motifs identified in this 
analysis. In all except three cases (Visna virus, CAEV and BIV), the RNA motif lies withi
the Env gene. Both EIAV and HIV-1 have two copies of the RNA motif within the ma
RRE. In four other cases, a single copy of the motif occurs either within or near (< 250 nt 
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from) the proposed boundaries of RRE regions mapped in previous studies. The striking 
conservation of this RNA structural motif, together with its occurrence in or near within th
known RRE regions of eight different lentiviruses and rabbit endogenous lentivirus type K
(RELIK), suggests that it plays an important role in Rev-RRE recognition, not only in HIV-1
and EIAV, but potentially in all lentiviruses. 
 
e 
 
 
DISCUSSION 
The Rev-responsive element (RRE) is an essential cis-acting RNA element 
recognized by the multifunctional Rev ntiviruses, including HIV-1 and 
EIAV.  and 
ed 
se 
Organization of Functional Domains in the EIAV Rev Protein 
Previous work has shown that the organization of functional domains within the 
ificantly (18, 21, 
33), de  
-
ar 
/Rex proteins of le
Rev-RRE interactions are involved in the regulation of viral gene expression
genomic replication, playing a critical role in the export of incompletely spliced or unsplic
lentiviral mRNAs from the nucleus to the cytoplasm of infected host cells (24, 53). Becau
of their central role in viral replication, a better understanding of the molecular mechanisms 
that regulate Rev binding to RREs could give rise to new therapeutic approaches for treating 
for lentiviral diseases.  
 
sequences of the EIAV Rev protein and its HIV-1 counterpart differ sign
spite the fact that activation domain is functionally interchangeable between EIAV
and HIV-1 (18). In EIAV Rev, exon 1 appears to be non-essential, and exon 2 contains all 
functional domains identified to date: an N-terminal nuclear export signal (NES), a large 
central region that contains an arginine-rich motif (ARM) required for RNA binding, a non
essential region, and C-terminal region that contains overlapping motifs required for nucle
localization (NLS) and RNA binding (ARM) (18, 21, 33). In HIV-1 Rev, a single RNA 
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binding domain is located in the N-terminal half of the protein (53), whereas in EIAV Rev, 
the RNA binding domain is bipartite, composed of two ARMs separated by 79 amino ac
in the linear amino acid sequence (33). One objective of the current study was to investigate
whether these differences in the RNA binding domains of the two Rev proteins reflect 
differences in RNA sequences or structural features they recognize within the RREs of HIV-
1 and EIAV. 
 
ids 
 
Mapping Rev Responsive Elements in Lentiviral Genomes 
In most lentiviruses, including HIV-1, HIV-2, SIV, VV, and CAEV, the RRE is 
en SU and TM proteins 
(12, 32 n 
 
ithin 
unsucc
pped RREs 
 
 
ted 
 
located near the HIV-1 protease cleavage site in the Env gene, betwe
, 55, 64, 68). In case of FIV, the RRE is located near the 3′ end of Env gene and i
HTLV-1, the RRE in located within the 3′ LTR (10, 52, 56). In contrast, in EIAV, two RREs 
were roughly mapped in the Env gene (19, 39), and quantitative assays for Rev nuclear 
export activity showed that a 555 nt segment, ERRE-1, can provide RRE function in vivo (4). 
Several groups have attempted to identify stable secondary structural elements w
the EIAV RRE using computational approaches. Martarano et al., (39) searched 
essfully for stable secondary structures analogous to the RREs within the 3′ halves of 
Env genes in other retroviruses. In that study, analyses of two experimentally ma
(one near each end of the Env gene) failed to identify similarities in the sequence or predicted
structures of the two putative RREs (39). More extensive computational analyses aimed at 
identifying highly structured regions (HSRs) in the EIAV Env gene were carried out by 
Lesnik et al., (34), who identified two HSRs that appeared to coincide with RREs proposed
by  Gontarek, et al. (19). The two HSRs identified in EIAV had relatively unstable predic
structures (-0.28 and -0.26 kcal/mol nt) compared with those found in other retroviral RREs,
such as those of HIV-1 and SIV (-0.42 and -0.46 kcal/mol nt) (34). One of the HSRs 
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identified in the Lesnik study appears to roughly co-localize with RBR-1 and the ESE, 
although its predicted structure and precise location differ. 
 
 81
Figure 3.8. An RNA structural motif identified in the high affinity Rev-binding sites of HIV-1 and 
EIAV is conserved within or near the RRE regions or Env gene of diverse lentiviruses. (A) Two representative 
structures (#1 and #11) among 20 identified ensemble structures, were represented. 100 nt HIV-1 and EIAV 
binding region was extracted and structurally aligned (see Materials and Methods) using Dynalign software 
(43).  (B) A conserved RNA structural motif was identified in the genomic RNA sequences of eight different 
lentiviruses, HIV-2, SIV (simian immunodeficiency virus), RELIK (rabbit endogenous lentivirus type K), FIV 
(feline immunodeficiency virus), OLV (ovine lentivirus), JDV (jembrana disease virus), BIV (bovine 
immunodeficiency virus), CAEV (caprine arthritis-encephalitis virus), and Visna (visna virus). An identified 
RNA structural motif (structure #11) based on shared RNA secondary structural features of high affinity Rev 
binding sites of from EIAV and HIV-1, was used to scan the complete genomic RNA sequences of eight 
different lentiviruses. 
 
An Experimentally Validated RNA Structure for the EIAV RRE 
This study represents the first high-resolution analysis of EIAV RRE secondary 
structure and Rev-RRE interactions. Using a combination of computational and experimental 
approaches, we generated an optimized RNA secondary structure model for the EIAV 
ERRE-1. In the context of this structure, individual ribonucleotides and secondary structural 
elements that are protected from chemical cleavage or undergo structural transitions upon 
Rev binding were identified using detailed RNA footprinting experiments.  
One striking characteristic of our proposed ERRE-1 structure is the relative paucity of 
stable stem structures and abundance of single-stranded loops, several of which are unusually 
large compared with loops in known RNA structures. The calculated free energy of the 
optimized ERRE-1 secondary structure, based on a combination of thermodynamic 
calculations, chemical probing data and ribonucleotide co-variation frequencies using 
RNAalifold is -77.9 kcal/mol (Figure 3.3), a value similar to that obtained using 
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RNAStructure -71.3 kcal/mol (Fig. 3.2D). These values are significantly higher than free 
energies of alternative secondary structures predicted using computational methods that do 
not incorporate experimental constraints or available phylogenetic information, e.g., -126.05 
kcal/mol, using Mfold (Fig. 3.2A). Incorporating experimental constraints has been shown to 
result in significant improvement in the fidelity of RNA structure predictions using 
RNAStructure software, for a variety of RNAs (41, 42). Thus, we believe the structural 
model for ERRE-1 shown in Figure 3.2A, based solely on thermodynamic calculations, is 
less likely to be physiologically relevant than structures presented in Figures 3.2B and Figure 
3.3, which may reflect features of the ensemble of ERRE-1 structures that exist in vivo.  
 
Two Distinct Rev Binding Domains within the RRE of EIAV 
The ERRE-1 footprinting experiments provided a detailed view of the interaction 
between EIAV Rev and RBR-1, which contains the ESE region previously implicated in Rev 
binding. Within loop B, changes in chemical reactivities of every purine residue in PuA and 
several As in PuB were detected, consistent with previous studies reporting decreased Rev 
binding when mutations converting several GAA motifs into GCAs were introduced within 
PuB (5). Similarly, EIAV Rev binding activity was virtually abolished when a GAA 
sequence was changed to GAU in PuB (8). Both previous studies reported that mutations in 
PuA had little effect on the binding affinity of EIAV Rev, again consistent with the 
footprinting results reported here: only a few changes in ribonucleotide accessibilities in this 
region were detected upon Rev binding. In contrast, Rev binding resulted in significant 
changes in ribonucleotide accessibilities in a third purine-rich motif, located within loop A 
(Fig. 3.3), including enhanced chemical reactivities at several purines within the loop. Thus, 
in RBR-1, structural changes that occur upon Rev binding include enhanced nucleotide 
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reactivities within loop A, in addition to the previously mapped Rev-binding region in loop 
B. 
RBR-2, a novel Rev-binding region within ERRE-1, was identified as second Rev-
mediated footprint, encompassing relatively long tracts of residues protected from hydroxyl 
radical cleavage and several individual ribonucleotides with enhanced reactivity to kethoxal 
and DMS. Quantitative in vitro binding assays showed that RBR-2 is required for high 
affinity binding of EIAV Rev: ERRE-1 fragments containing both RBR-1 and RBR-2 have 
much higher affinity for EIAV Rev than those containing only RBR-1.  
For RBR-2, all computational methods produced the same RNA secondary structure. 
The Rev-induced footprint in SL-Z (nt 439-462) in RBR-2 is especially interesting because 
the topology of this stem-loop structure is very similar to that of stem-loop IIB in HIV-I, 
which corresponds to the primary high-affinity Rev binding site in the HIV-1 RRE (9, 65). 
Although the sequences of the two structures differ, they share a strong protection pattern on 
opposite strands in the stem, characteristic of a "5′ stagger" of 7 nucleotides. A 5′ stagger in 
the footprinting protection pattern on complementary strands of an RNA duplex suggests 
interaction of the bound protein within the major groove of the RNA (as in the interaction 
between ribosomal protein S7 and the 3′ domain of 16S rRNA in E. coli. (54)). This 
similarity supports the hypothesis that EIAV Rev binds within major groove of the RNA 
stem-loop structure, SL-Z, in RBR-2 (Fig. 3.5C), in a manner analogous to that observed for 
HIV-1 peptides bound to RNA oligonucleotides corresponding to stem-loop IIB (2).  
In HIV-1, an extended RRE sequence that includes structured regions surrounding the 
stem-loop IIB binding site has been shown to enhance Rev binding and promote its 
multimerization on HIV-1 RNAs (27, 38). We have observed multimerization of EIAV Rev 
on fragments of ERRE-1 using in vitro binding assays such as EMSA and UV-crosslinking 
(Lee pub & unpublished data), but we are not aware of any direct evidence for a functional 
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role of EIAV Rev multimerization in vivo. Further investigation will be required to elucidate 
the functional relationships among RBR-1, RBR-2 and the full length EIAV RRE.  
 
RNA Structural Motifs in Lentiviral RREs may also Regulate Alternative mRNA 
Splicing  
In the EIAV secondary structure proposed in this study, there are two stem-loop 
structures near the splicing donor and acceptor sites of EIAV Rev exon 1. The 3′ splicing 
acceptor site of Rev exon 1 is located within SL-X and the 5′ splicing donor site is near SL-
Y. Both of these stem-loop structures were predicted by every secondary structure prediction 
method used in this study (Figs. 3.2, 3.3 and data not shown). In addition, both stem-loop 
structures are well conserved in EIAV variant sequences. Two compensatory mutations 
observed in SL-X maintain the stem structure: i) 146U-154G to 146C-156G and ii) 148U-
152A to 148U-152G. In SL-Y, 3 compensatory mutations: i) 272U-281G to 272C-281G, ii) 
270U-283A to 270U-283G, and iii)267U-285A to 267U-285G are observed in the stem.  
The importance of specific RNA secondary structures in regulating of pre-mRNA 
splicing events is well established (6) and there are several cases in which stem-loop 
structures near splicing donor and acceptor sites are known to play a role in alternative 
splicing (15, 36, 45, 60). In HIV-1 pre-mRNA, stem-loop structures have been identified near  
splicing acceptor sites and are proposed mediate splicing events (26). Stem-loop structure 2 
(SLS2), encompassing the 3′ splice acceptor site (A3) for the HIV-1 Tat exon is well 
conserved in HIV-1 variants and in related SIVcpz strains. One cis-regulatory element 
required for splicing, a polypyrimidine track (PPT) is located in the SLS2 stem. By designing 
specific mutations that either changed the base-pairing potential of this region or altered its 
pyrimidine composition, or both, Jacquenet et al, demonstrated that both the sequence of the 
PPT and the thermodynamic stability of the helical stem in SLS2 affect splicing efficiency 
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(26). Similarly, both the configuration and nucleotide composition of a cis-acting intronic 
stem-loop motif near the 5′ splice were shown to be important for regulating alternative 
splicing of the HIV-1 Tat exon (45).  
In EIAV, the SL-X loop of ERRE-1 includes two cis-regulatory elements for splicing, 
an AG consensus sequence and weak polypyrimidine track (PPT), similar to that in the A3 
splicing site in HIV-1 tat exon (26). Interestingly, in the absence of the ESE sequence in exon 
1, virtually all multiply-spliced EIAV mRNAs do not include exon 1 (35). We hypothesize, 
therefore, that the masking of 3′ splicing sites due to formation of stem-loop structures 
identified here, in conjunction with the weak PPT, could prevent the spliceosome from 
recognizing the 3′ splicing site in the absence of splicing factors like SF2/ASF, an idea that 
has been suggested previously (19). Further analysis will be required to elucidate the 
complex interactions among cis-acting RNA regulatory elements and trans-acting proteins 
within ERRE-1 in directing alternative splicing of exon 1 in EIAV. 
As in other lentiviruses, the EIAV RRE overlaps the Env gene (gp90). ERRE-1 
differs from other lentiviral RREs, however, in that it also overlaps exon 1 of the Rev gene. 
As discussed above, alternative splicing events in EIAV appear to be regulated both by the 
EIAV Rev protein and by cellular splicing factors such as SF2/ASF (5, 8, 19, 35, 39). In 
particular, Rev-RRE interactions likely affect the ratio of partially-spliced to fully-spliced 
cytoplasmic EIAV mRNAs. Partially-spliced viral mRNAs are essential for the late stages of 
EIAV replication and production of only fully-sliced mRNAs, generated by the host's cellular 
splicing machinery, can prevent viral replication (3, 8, 19, 35). Direct competition between 
EIAV Rev and SF2/ASF for binding the RRE has been suggested as one potential 
mechanism for regulating the course of EIAV infection (5, 19, 35), an idea supported by 
footprinting results showing that SF2/ASF and EIAV Rev bind overlapping elements within 
ERRE-1 (Park et al., unpublished data).  
 
 86
A Conserved RNA Structural Motif for Rev Recognition in both EIAV and HIV-
1 
To examine the relationship between conservation of the ERRE-1 sequence and 
potential conservation of its RNA secondary structure, we assessed ribonucleotide 
conservation of the RRE sequence using classical information theory. Measurement of the 
information content of nucleotide or protein sequences has been widely used to evaluate the 
conservation of certain motifs, such as transcription factor binding sites in DNA, splice sites 
in pre-mRNAs, and functional motifs in proteins (1, 49, 66). Our analysis of 258 EIAV 
sequence variants showed that ERRE-1 region is highly conserved compared with other 
regions within the gp90 gene. In EIAV, the gp90 gene overlaps both ERRE-1 and the non-
essential exon 1 of the Rev gene, making it difficult to clearly delineate the relationship 
between specific sequence variants and the functions of the overlapping genes. However, 
constant and hypervariable regions of the gp90 gene were previously identified using this 
approach (46) and even within the context of the conserved region of gp90, the 555 nt 
ERRE-1 is more highly conserved at the ribonucleotide sequence level than expected for a 
non-functional region (Figure 3.7). Finally, it is intriguing that two protein encoding regions 
(a gp90 constant region and exon 1 of Rev), as well as three cis-acting RNA elements 
recognized by regulatory proteins (an ESE, RBR-1 and RBR-2), are all located within the 
most highly conserved region of the ERRE-1 sequence, suggesting that it has experienced 
selective pressure at both the amino acid and ribonucleotide sequence levels.   
To investigate whether the RBR-2 domain might have RNA structural features in 
common with the high affinity Rev binding stem-loop IIB region of HIV-1, we performed 
pairwise comparisons using Dynalign software (43). We found that the two RRE regions can 
form very similar ensembles of secondary structures (Fig. 3.8A and data not shown). Because 
these predictions were generated using fragments of the two RRE sequences, we tested 
whether such similar structures could be detected in the context of the complete genomic 
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RNA sequences of the two lentiviruses. Using a computational RNA motif model based on 
common structural elements identified in the HIV-1 and EIAV Rev binding sites, a shared 
RNA motif was detected within the RREs of HIV-1 and EIAV. Strikingly, the same motif 
was found within or very near the proposed RREs in six out of ten lentiviruses examined, 
suggesting that it could play a role in Rev-RRE recognition in diverse lentiviruses (Fig. 3.8). 
This hypothesis is supported by an unexpected similarity in the binding mode of HIV-1 and 
EIAV Rev to this conserved RNA motif. Results of our detailed footprinting experiments 
suggest that EIAV Rev binds in the major groove of the double-stranded RNA stem 
corresponding to the high affinity Rev binding site in ERRE-1, as is the case for HIV-1 Rev 
binding to stem-loop IIB in the HIV-1 RRE. Recently, the first endogenous lentivurses were 
discovered and characterized by Katzourakik et al. (28). Although the viruses are more than 7 
million years old, the viruses still have many lentiviral features like genomic structures and 
regulation proteins like tat and rev.  Interestingly, when we did the same search using RELIK 
entire sequence, we found the common secondary structural motif in RELIK Env gene region 
(Fig 3.8B). 
EIAV is genetically the simplest of the exogenous lentiviruses, has the fewest number 
of genes, and lacks a vif protein. Phlyogenetic analyses suggest that the ancient endogenous 
rabbit lentivirus clusters more closely with EIAV than with the other exogenous lentivirus 
(28). EIAV therefore offers an opportunity for comparative analysis of the molecular 
interactions important in regulation of lentiviral gene expression that may identify highly 
conserved interactions that could be targeted in novel anti-lentiviral therapies. 
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ABSTRACT 
Although CTL are critical for control of lentiviruses, including equine infectious 
anemia virus, relatively little is known regarding the MHC class I molecules that present 
important epitopes to equine infectious anemia virus-specific CTL. The equine class I 
molecule 7-6 is associated with the equine leukocyte Ag (ELA)-A1 haplotype and presents 
the Env-RW12 and Gag-GW12 CTL epitopes. Some ELA-A1 target cells present both 
epitopes, whereas others are not recognized by Gag-GW12-specific CTL, suggesting that the 
ELA-A1 haplotype comprises functionally distinct alleles. The Rev-QW11 CTL epitope is 
also ELA-A1-restricted, but the molecule that presents Rev-QW11 is unknown. To determine 
whether functionally distinct class I molecules present ELA-A1-restricted CTL epitopes, we 
sequenced and expressed MHC class I genes from three ELA-A1 horses. Two horses had the 
7-6 allele, which when expressed, presented Env-RW12, Gag-GW12, and Rev-QW11 to 
CTL. The other horse had a distinct allele, designated 141, encoding a molecule that differed 
from 7-6 by a single amino acid within the α-2 domain. This substitution did not affect 
recognition of Env-RW12, but resulted in more efficient recognition of Rev-QW11. 
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Significantly, CTL recognition of Gag-GW12 was abrogated, despite Gag-GW12 binding to 
141. Molecular modeling suggested that conformational changes in the 141/Gag-GW12 
complex led to a loss of TCR recognition. These results confirmed that the ELA-A1 
haplotype is comprised of functionally distinct alleles, and demonstrated for the first time 
that naturally occurring MHC class I molecules that vary by only a single amino acid can 
result in significantly different patterns of epitope recognition by lentivirus-specific CTL. 
 
INTRODUCTION 
Infections by lentiviruses induce virus-specific CTL responses that are critical for 
control of viral load and clinical disease. Specifically, Env, Gag, and Rev proteins are 
important targets for CTL in HIV-1-infected individuals (1, 2, 3, 4). Sustained HIV-1 Gag-
specific CTL responses are associated with very low numbers of infected CD4+ T cells and 
stable CD4+ T cell counts in long-term nonprogressors, whereas loss of Gag-specific CTL is 
associated with clinical progression to AIDS (5). Moreover, HIV-1 Gag-specific CTL 
responses and frequency are inversely correlated with viral load (6, 7, 8), and high 
frequencies of Gag-specific CTL are significantly associated with slower disease progression 
(9). In addition, high levels of HIV-1 Env- and Gag-specific memory CTL are strongly 
associated with low viral load and lack of disease in long-term nonprogressors (10), and CTL 
responses directed against the early expressed viral regulatory protein Rev inversely correlate 
with rapid HIV-1 disease progression (11, 12). 
Equine infectious anemia virus (EIAV) is a macrophage-tropic lentivirus that causes 
persistent infections in horses worldwide. In contrast to HIV-1 infection however, most 
EIAV-infected horses eventually control plasma viremia and clinical disease and remain life-
long inapparently infected carriers (13, 14, 15). The initial as well as the long-term control of 
viremia and clinical disease is the result of adaptive immune responses, including 
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neutralizing Ab and importantly, CTL (16, 17, 18, 19, 20, 21, 22). Due to these robust viral-
specific immune responses that contain viral replication, EIAV infection in horses is a unique 
and useful model system for the study of lentiviral immune control. 
As in HIV-1, Env, Gag, and Rev proteins are important CTL targets in EIAV-infected 
horses. EIAV Env- and Gag-specific CTL are detected during acute and inapparent infection 
(17, 23, 24), with Gag-specific CTL responses occurring in the majority of horses tested (25, 
26). Although EIAV Env-specific CTL can be immunodominant and may be important in 
early viral control, viral escape can limit the effectiveness of CTL directed against variable 
Env epitopes, and Gag-specific CTL frequency can correlate with the ability to control viral 
load and clinical disease (27, 28). Epitope clusters occur within EIAV Gag proteins that are 
recognized by CTL (including high-avidity CTL) in horses with disparate MHC class I 
(MHC I) haplotypes and are likely important in control of clinical disease (29, 30). 
Additionally, moderate and high-avidity Rev-specific CTL are associated with control of 
viremia and disease in EIAV-infected nonprogressor horses (27). Significantly, no viral 
escape from high-avidity Rev-specific CTL has been observed. The Rev epitope recognized 
by these CTL is highly conserved among other strains of EIAV, and independent studies by 
other investigators show that this sequence does not change during long-term EIAV infection 
(31, 32). 
Given that CTL epitopes in Env, Gag, and Rev are critical for lentiviral immune 
control, factors that affect the presentation and recognition of these peptides by CTL in a 
population of infected individuals are important considerations for vaccine development. One 
of the most important factors is MHC I polymorphism, because CTL recognize peptide 
epitopes only in the context of allelic forms of MHC I molecules. The CTL TCR binds to a 
cell surface MHC I complex consisting of the MHC I molecule, a peptide processed from a 
viral protein, and β2-microglobulin (β2m) (33). The HLA classical MHC I genes are the 
products of three loci, and as of July 2006, there were 478 HLA-A, 805 HLA-B, and 256 
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HLA-C named alleles (http://www.ebi.ac.uk/imgt/hla/intro.html) (34). MHC I polymorphism 
occurs primarily in the residues that form the peptide-binding domain, therefore influencing 
the types of peptides that are selectively bound. Similarities in peptide-binding specificity 
between human MHC I molecules have been identified based on the structure of peptide-
binding pockets, peptide-binding assays, and analysis of motifs, and sets of molecules with 
similar specificities are called supertypes (35, 36, 37, 38). Despite the fact that different 
MHC I molecules can belong to a supertype and have similar peptide-binding specificities, 
differences in only a few residues among class I molecules can significantly affect the 
recognition of the MHC I-peptide complex by CTL. Saturation mutagenesis of a murine 
MHC I molecule has shown that a single amino acid substitution in the α-1 domain can result 
in more effective killing of lymphocytic choriomeningitis virus-infected target cells by 
lymphocytic choriomeningitis virus-specific CTL (39). Importantly, the HLA-B*35 subtypes 
HLA-B*3503 and HLA-B*3502 (B*35-Px genotype) correlate more strongly with rapid 
progression to AIDS than does the HLA-B*3501 subtype (B*35-PY genotype), which varies 
from HLA-B*3503 and HLA-B*3502 by only one and two amino acids, respectively, in the 
peptide-binding domain (40). It is presumed that this effect is due to differential presentation 
of epitopes to HIV-1-specific CTL, and it has been demonstrated that a higher frequency of 
Gag-specific CTL correlate with lower viral loads in individuals with the B*35-PY genotype, 
whereas no significant relationship exists between CTL activity and viral load in the B*35-
Px group (41). 
Compared with humans, less is known regarding the numbers and locus assignments 
of equine MHC I alleles. Serology has been the most widely used MHC I typing method in 
horses, with 17 equine leukocyte Ag (ELA)-A haplotypes defined (42, 43, 44, 45). More 
recently, classical MHC I alleles have been identified and sequenced, but it has not been 
possible to assign alleles to loci (46, 47, 48, 49, 50, 51, 52). Recent work indicates that up to 
three or four (or more) classical MHC I loci exist, and it is likely that the number of loci is 
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variable and dependent on haplotype (48, 52). Regardless, we have identified the classical 
equine MHC I molecule 7-6, which is associated with the serologically defined ELA-A1 
haplotype (51). The 7-6 molecule presents Env and Gag epitopes (Env-RW12 and Gag-
GW12) to distinct populations of EIAV-specific CTL (27, 51). Target cells from some ELA-
A1 horses present both epitopes, whereas target cells from other ELA-A1 horses present only 
Env-RW12 (51), suggesting that subtypes that comprise functionally distinct alleles exist 
within the ELA-A1 haplotype. In addition, a CTL epitope in EIAV Rev (Rev-QW11) is also 
restricted by the ELA-A1 haplotype (27), but the molecule that presents Rev-QW11 has not 
been identified. The purpose of the present study was to determine whether different horses 
sharing the ELA-A1 haplotype used functionally distinct MHC I molecules to present ELA-
A1-restricted CTL epitopes. To test this hypothesis, we sequenced and expressed MHC I 
genes from three different horses with the ELA-A1 haplotype and determined how these 
different molecules affected the recognition of important Env, Gag, and Rev epitopes by 
EIAV-specific CTL. 
 
 
MATERIALS AND METHODS 
Horses 
Arabian horses A2140, A2150, and A2152 were used in this study. A2152 is a 
noninfected 7-year-old breeding stallion in which the 7-6 MHC I allele was initially 
identified (51). A2140 and A2150 are 8- and 7-year-old mares, respectively, that have been 
infected with EIAVWSU5 for 7 and 6 years, respectively (27). The ELA-A haplotypes were 
determined serologically by lymphocyte microcytotoxicity (42, 53, 54) using reagents 
provided by Dr. E. Bailey (University of Kentucky, Lexington, KY). All experiments 
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involving horses were approved by the Washington State University Institutional Animal 
Care and Use Committee. 
 
Identification of equine MHC I alleles 
The full-length 141 gene (GenBank accession no. AY374512) from A2150 was 
cloned and sequenced as previously described (51). Briefly, PBMC were isolated and 
cultured for 48 h in RPMI 1640 medium with 10% FBS, 2 mM L-glutamine, and 10 µg/ml 
gentamicin. Con A (40 µg/ml) was added to up-regulate MHC I expression. mRNA isolated 
from these cells was used for first-strand synthesis, which was primed with 1 µg of 
oligo(dT)12–18 and 50 ng of random hexamers. This reaction was incubated at an initial 
temperature of 37°C for 15 min, followed by an additional hour at 49°C. The second-strand 
reaction was incubated at 16°C for 2 h using Escherichia coli DNA ligase, polymerase, and 
RNase H. cDNA was blunt-ended with T4 DNA polymerase, EcoRI adapters were added 
with T4 ligase, and the adapters were phosphorylated with T4 polynucleotide kinase. The 
cDNA was then size fractionated, and cDNA between 2 and 3 kb was ligated into EcoRI-
digested and dephosphorylated pcDNA3 vector (Invitrogen Life Technologies). E. coli 
electrocompetent cells (Invitrogen Life Technologies) were transformed with this ligation 
mixture resulting in a cDNA library. Clones were selected from the library by colony-lift 
hybridization with a 32P-labeled HindIII-XbaI fragment from horse MHC I gene 8/9 
(provided by Dr. D. Antczak, Cornell University, Ithaca, NY) (46). Positive colonies were 
isolated, and those with inserts of the correct size were sequenced. Sequencing was 
performed at the Laboratory for Biotechnology and Bioanalysis (Washington State 
University) using dye-labeled dideoxynucleotide-cycle sequencing with an ABI 377 
automated sequencer. 
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The presence of the 7-6 allele (GenBank accession no. AY225155) was confirmed in 
A2140 using a RT-PCR as previously described (48) with modifications. Briefly, total RNA 
was isolated from 2 x 107 equine kidney (EK) cells with an RNeasy mini kit (Qiagen). Ten 
microliters of RNA and a SuperScript One-Step RT-PCR kit (Invitrogen Life Technologies) 
was then used with 1 µM each of forward (5'-ATG ATG CCC CCA ACC TTC-3') and 
reverse (5'-TGA ACA AAT CTT GCA TCA CTT G-3') primers. The reaction conditions 
were 45°C for 50 min, followed by 94°C for 2 min, then 35 cycles of 94°C for 30 s, 53°C for 
30 s, and 72°C for 1 min. The 1116-bp product was gel isolated and extracted (Qiagen), then 
used for TOPO TA cloning into the pCR4-TOPO vector for sequencing (Invitrogen Life 
Technologies). Isolated colony minipreps were digested and electrophoresed to screen for 
inserts and those with inserts of correct size were sequenced by the Laboratory for 
Biotechnology and Bioanalysis using dye-labeled dideoxynucleotide-cycle sequencing with 
an ABI 377 automated sequencer. 
Although we independently named the alleles in this study, official Immuno 
Polymorphism Database nomenclature (http://www.ebi.ac.uk/ipd/) will soon be available for 
equine MHC alleles (55). 
 
Expression of equine MHC I alleles 
Two retroviral vectors were constructed as described (51) using the plasmid pLXSN 
(provided by Dr. A. Dusty Miller, Fred Hutchinson Cancer Research Center, Seattle, WA). 
The MHC I genes 7-6 and 141 were PCR amplified and ligated into the cloning site of 
pLXSN downstream of the Moloney murine sarcoma virus long terminal repeat and upstream 
of the neomycin phosphotransferase gene, which was under the control of the SV40 early 
promoter (56). The sequences of the inserts and flanking plasmid DNA were determined. To 
generate vector-producing cell lines, published procedures were used (51, 57). Briefly, an 
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amphotropic packaging cell line, PA317 (CRL-9078; American Type Culture Collection) 
was transfected with each plasmid. Supernatant from PA317 cells was used to transduce 
amphotropic PG13 packaging cells (CRL-10686; American Type Culture Collection), which 
were then selected using 750 µg/ml G-418 sulfate (Invitrogen Life Technologies). Vectors 
were harvested from the selected PG13 cells and used to transduce CTL target cells. EK cells 
and human mutant B lymphoblastoid 721.221 cells (58) were transduced with the retroviral 
vectors expressing 7-6 and 141, pulsed with peptides, and used as CTL targets (51). The 
721.221 cells (obtained from Dr. A. Sette, La Jolla Institute for Allergy and Immunology, 
San Diego, CA) express human β2m, but not HLA-A, -B, or -C class I molecules (58). 
 
PBMC stimulations and CTL assays 
PBMC stimulations and CTL assays were performed as described (17, 27, 28, 51) 
with modifications. Briefly, PBMC were isolated from A2140 and A2150 and stimulated 
with peptide-pulsed autologous monocytes. EK target cells from A2140 and A2150 and 
mixed-breed pony H585 were established from kidney tissue obtained by biopsy (17). For 
stimulation with peptides, 2 µM Env-RW12, Gag-GW12, or Rev-QW11 was added to PBMC 
in 10% FBS. Peptide and PBMC were incubated for 2 h at 37°C with occasional mixing 
before centrifugation at 250 x g for 10 min. PBMC were resuspended to 2 x 106/ml in RPMI 
1640 medium with 10% FBS, 20 mM HEPES, 10 µg/ml gentamicin, and 10 µM 2-ME. One 
milliliter was added to each well of a 24-well plate and incubated for 1 wk at 37°C before use 
in CTL assays. CTL activity was measured using a 51Cr release assay with a 17-h incubation 
period using EK target cells (17, 27, 28). In addition, human B lymphoblastoid 721.221 
target cells transduced with retroviral vectors expressing equine MHC I genes 7-6 or 141 as 
described above were used in assays with a 5-h incubation period (51). The shorter 
incubation period was used because 721.221 target cells are less hardy than EK target cells 
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and they develop spontaneous lysis sooner (51). Target cells were pulsed with various 
amounts of peptide Env-RW12, Gag-GW12, and Rev-QW11 as indicated in the figures. The 
formula, percent-specific lysis = [(E – S)/(M – S)] x 100, was used, where E is the mean of 
three test wells, S is the mean spontaneous release from three target cell wells without 
effector cells, and M is the mean maximal release from three target cell wells with 2% Triton 
X-100 in distilled water. The E:T ratio was 20:1 or 50:1 as indicated in the figures, and each 
well contained ~30,000 target cells. The 50:1 E:T ratio was used to confirm 20:1 E:T ratio 
results. Comparisons were only made between assays that used the same E:T ratio. Previous 
work indicates that these E:T ratios yield consistent results corresponding to the log portion 
of the killing curve, and that the 50:1 E:T ratio results in the highest percent-specific lysis (17, 
19, 24, 25, 26, 27, 28, 29, 30, 51, 57, 59, 60, 61, 62). Assays with similar constant E:T ratios 
have been used by others (63). Only assays with a spontaneous target cell lysis of <30% were 
used. The SE of percent-specific lysis was calculated using a formula that accounts for the 
variability of E, S, and M (64). Significant lysis was defined as the percent-specific lysis of 
peptide-pulsed target cells that was >10% and also >3 SE above the nonpulsed target cells or 
above target cells transduced with control vectors and pulsed with the relevant peptide. For 
comparisons of CTL recognition efficiency, the peptide concentration that resulted in 50% 
maximal target cell-specific lysis (EC50) was used. The EC50 was calculated after 
transforming the percent-specific lysis data to percent-maximal lysis (with the lowest 
percent-specific lysis value set to 0% and the highest percent-specific lysis value set to 
100%) and fitting the curve with nonlinear regression using GraphPad Prism version 3.03 
(GraphPad). This is an established method to measure and compare CTL recognition 
efficiency and avidity (27, 30, 65, 66). All CTL assays were performed at least twice, and the 
results were consistent in each case. 
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Live cell peptide-binding assay 
Peptide binding to equine MHC I molecules 7-6 and 141 was measured as previously 
described (51), with slight modifications, using the chloramine-T method (67, 68). Briefly, 
721.221 cells transduced with MHC I gene 7-6, 141, or with a retroviral vector that did not 
express an equine gene, were preincubated with human β2m. The cells were washed and 
resuspended in RPMI 1640 containing β2m, EDTA, PMSF, and Nα-p- tosyl-L-lysine 
chloromethyl ketone. One hundred microliters containing 2 x 106 cells plus 1 µl containing 
1.5 x 105 cpm of 125I -labeled Env-RW12 was incubated for 4 h at 22°C in wells of a 96-well 
U-bottom plate. Cells were then washed three times with serum-free medium, centrifuged 
through calf serum to remove any remaining unbound radiolabeled peptide, and then washed 
a final time. The radioactivity of the cell pellet was counted with a gamma scintillation 
counter (Packard Instrument). Competitive inhibition assays were performed twice in 
triplicate by adding 10 µl containing sufficient unlabeled peptide competitors to result in 
final concentrations of 1–1000 nM to the initial mixture of cells before addition of 
radiolabeled Env-RW12 peptide. Competing peptides were unlabeled Env-RW12, Gag-
GW12, Rev-QW11, and control peptide 1b4a (VRVEDVTNTAEY), which does not inhibit 
the binding of Env-RW12 to 7-6 (51). For each competing peptide, the concentration 
resulting in 50% inhibition of radiolabeled Env-RW12 binding (IC50) was calculated by 
fitting the curve with nonlinear regression using GraphPad Prism version 3.03. All peptides 
used in binding assays had 95% purity and were synthesized by Sigma-Genosys. 
 
Molecular modeling 
Because crystal structures of equine MHC I molecules are not available, three-
dimensional computer models of 7-6 and 141 were generated based on known structures of 
human MHC I molecules using MODELLER 8v2 (http://www.salilab.org/modeler) (69). 
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Templates for modeling were chosen based on PSI-BLAST searches of the Brookhaven 
Protein Data Bank database. The 1XR9A structure was used for 7-6 and the 1ZSDA structure 
(70) was used for 141. The models were verified using VERIFY3D 
(http://nihserver.mbi.ucla.edu/Verify_3D) (71). Models of the Env-RW12, Gag-GW12, and 
Rev-QW11 peptides were also generated. To predict the side chain conformations for each 
peptide, SCWRL3.0 (http://dunbrack.fccc.edu/SCWRL3.php) (72) was used. Viral peptides 
bound to human MHC I molecules served as templates and were chosen from the 
Brookhaven Protein Data Bank database (1ZHKC for Env-RW12 and Gag-GW12, and 
1ZSDC for Rev-QW11). The 1ZSDC structure is an 11-mer peptide (70), like Rev-QW11. 
Because no structures of 12-mer peptides bound to MHC I molecules were available, the first 
residue (L) of 1ZHKC, a 13-mer peptide (73), was eliminated before use as the backbone 
template for Env-RW12 and Gag-GW12. To model the binding of the three peptides to 7-6 
and 141, the docking program FTDock2.0 (http://www.bmm.icnet.uk/docking) (74, 75, 76) 
was used, and the docking score (RPScore) for each complex was determined (76). The 
interacting residues for each complex were identified, and the interactions by category 
(hydrophobic, salt bridges, repulsive charged, hydrogen bonds, and aromatic stacking) 
between atoms of contact residues were determined using the STING Millennium Suite 
program (http://trantor.bioc.columbia.edu/SMS/index_m.html) (77, 78). Finally, the models 
were visualized using the PyMOL Molecular Graphics System (DeLano Scientific, 
http://www.pymol.org). 
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RESULTS 
Target cells from A2140 and A2152 pulsed with Env-RW12, Gag-GW12, and 
Rev-QW11 were recognized differently by CTL than target cells from A2150 
Horses A2140, A2152, and A2150 all had the ELA-A1 haplotype as determined 
serologically, inheriting ELA-A1 from unrelated dams 172, 162, and 169, respectively (Table 
4.1). 
 
Horse ELA-A 
Haplotype 
Dam Dam ELA-A 
Haplotypea
Sire Sire ELA-A 
Haplotype 
A2140 A1/w11 172 A1 Sire B A4/w11 
A2152 A1/A4 162 A1 Sire B A4/w11 
A2150 A1/w11 169 A1/A4 Sire B A4/w11 
Table 4.1. Pedigree of ELA-A1 horses 
a ELA-A haplotypes were determined serologically by lymphocyte microcytotoxicity. It was not 
known whether horses with one haplotype were homozygous or heterozygous with a haplotype not recognized 
by available antisera. 
 
Our previous work indicates that EK target cells from A2140 and A2152 present both 
the Env-RW12 (RVEDVTNTAEYW) and Gag-GW12 (GSQKLTTGNCNW) epitopes to 
Env-RW12- and Gag-GW12-specific A2140 CTL (27, 51). Although EK target cells from 
A2150 present Env-RW12 to Env-RW12-specific A2140 CTL, they do not present Gag-
GW12 to Gag-GW12-specific A2140 CTL (51). Because the 7-6 MHC I molecule identified 
in A2152 presents both Env-RW12 and Gag-GW12 (51), it was likely that a different MHC I 
molecule presented Env-RW12 but not Gag-GW12 in A2150. 
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The Rev-QW11 (QAEVLQERLEW) epitope is recognized by CTL from A2150 (27). 
Although EK target cells from all three horses were capable of presenting Rev-QW11 to 
Rev-QW11-specific A2150 CTL, these CTL recognized A2150 EK targets more efficiently 
than A2140 and A2152 targets (Fig. 4.1a). This observation suggested that the MHC I 
molecule presenting Rev-QW11 in A2150 was different from the one presenting Rev-QW11 
in A2140 and A2152. 
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Figure 4.1. Differential CTL recognition efficiencies and sequences of MHC I alleles. (a) CTL 
recognized Rev-QW11-pulsed A2150 EK target cells more efficiently than A2152 and A2140 EK target cells. 
A2150 CTL were stimulated with Rev-QW11 peptide and percent-specific lysis was determined on A2150, 
A2152, and A2140 EK targets pulsed with increasing concentrations of Rev-QW11 peptide. E:T cell ratio was 
20:1. EC50, Peptide concentration resulting in 50% maximal-specific lysis. Actual minimum and maximum 
percent-specific lysis for A2150, A2152, and A2140 targets was 7.1 and 49.3, 4.9 and 32.5, and 2.7 and 34.7, 
respectively. (b) Equine MHC I molecules 7-6 and 141 differed in only one amino acid in the α-2 domain. 
Amino acid sequences of 7-6 and 141 are shown with domains (46, 49) indicated. The E->V substitution at 
position 152 is shown in bold. (c) CTL recognized Env-RW12 more efficiently than Gag-GW12 when 
presented by equine MHC I molecule 7-6. A2140 CTL were stimulated with Env-RW12 or Gag-GW12 peptides 
and percent-specific lysis was determined on 7-6-transduced 721.221 cells pulsed with increasing 
concentrations of Env-RW12 or Gag-GW12 peptides. E:T cell ratios were 20:1. Actual minimum and maximum 
percent-specific lysis for Env-RW12 and Gag-GW12 targets was 0 and 43.8, and 2.1 and 21.9, respectively. 
 
Identification of MHC class I alleles in A2140 and A2150 
Because the 7-6 molecule that presents Env-RW12 and Gag-GW12 occurs in A2152 
(51), and because Env-RW12- and Gag-GW12-specific CTL display similar recognition of 
A2152 and A2140 EK target cells (51), it was hypothesized that A2140 also possessed the 7-
6 allele. Therefore, RT-PCR was used to amplify MHC I genes from A2140 PBMC. Cloning 
and sequencing confirmed the presence of the 7-6 allele in A2140. Of the 21 isolates 
processed, 5 were copies of a pseudogene, 3 were other pseudogenes, 6 were copies of a 
classical gene, and 7 were other classical genes, which included 7-6 (data not shown). 
Because previous work indicates that A2150 EK target cells are recognized 
differently by Env-RW12- and Gag-GW12-specific CTL (51), and because Rev-QW11-
specific CTL recognized A2150 EK target cells more efficiently than A2140 and A2152 
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targets, it was hypothesized that a MHC I molecule distinct from 7-6 presented these epitopes 
in horse A2150. A previous study identified partial sequences for three MHC I alleles in 
A2150, one of which, designated 141, shared the 7-6 sequence except for a single amino acid 
difference encoded at position 152 (E→V) in the α-2 domain (48). Due to its sequence 
similarity to 7-6, it was of interest to determine whether 141 had similar functional 
characteristics. To obtain the full-length 141 gene for expression, a cDNA library from 
A2150 was screened for MHC I genes and 141 was subsequently identified by sequencing 
(Fig. 4.1b). 
Previous work indicated that the 141 allele is not present in A2152 and that the 7-6 
allele is not present in A2150 (48). In addition, allele 141 was not identified among 
sequenced MHC I clones in A2140 (data not shown). Therefore, the 141 class I molecule was 
a likely candidate for presenting Env-RW12 and Rev-QW11 but not Gag-GW12 in horse 
A2150. 
 
CTL recognized Env-RW12 more efficiently than Gag-GW12 when presented by 
the 7-6 molecule, and also recognized Rev-QW11 presented by 7-6 
PBMC from A2140 were stimulated separately with Env-RW12 and Gag-GW12 
peptides, then assayed for CTL activity on 7-6-transduced human 721.221 target cells that 
were pulsed with increasing concentrations of Env-RW12 and Gag-GW12 peptides, 
respectively. Human mutant B lymphoblastoid 721.221 cells express human β2m, but not 
HLA-A, -B, or -C class I molecules (58). Env-RW12 was recognized by CTL more 
efficiently than Gag-GW12, with 50% maximal lysis (EC50) of 2.8 nM for Env-RW12 vs 220 
nM for Gag-GW12 (Fig. 4.1c). 
Initial assays indicated that recognition of 7-6-transduced 721.221 cells pulsed with 
Rev-QW11 by A2150 Rev-QW11-specific CTL was equivocal (Fig. 4.2a). Because it was 
 111
possible that the absence of equine β2m on 721.221 cells contributed to poor recognition of 
Rev-QW11 by CTL, ELA-A mismatched EK cells from pony H585 (ELA-A6) were 
transduced with 7-6, pulsed with Rev-QW11, and used as targets. Results indicated that in 
addition to Env-RW12 and Gag-GW12, 7-6 also presented Rev-QW11 (Fig. 4.2b). 
  
 
Figure 4.2. Presentation of CTL epitopes by equine MHC I molecules 7-6 and 141. (a) and (b), MHC I 
molecule 7-6 presented Env-RW12, Gag-GW12, and Rev-QW11 to CTL. A2140 Env-RW12-, A2140 Gag-
GW12-, and A2150 Rev-QW11-stimulated CTL on 7-6-transduced 721.221 cells (a) pulsed with 104 nM of the 
corresponding peptide and on 7-6-transduced H585 EK cells (b) pulsed with 104 nM of the corresponding 
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peptide. (c) and (d), CTL recognized Env-RW12 and Rev-QW11 when presented by equine MHC I molecule 
141, but did not recognize Gag-GW12-pulsed targets expressing 141. A2140 Env-RW12-, A2140 Gag-GW12-, 
and A2150 Rev-QW11-stimulated CTL on 141-transduced 721.221 cells (c) pulsed with 104 nM of the 
corresponding peptide and on 141-transduced H585 EK cells (d) pulsed with 104 nM of the corresponding 
peptide. a–d, vLXSN, empty vector. Error bars are SE for the assay shown, derived as described in Materials 
and Methods. E:T ratio is 50:1. 
 
The 141 molecule presented Env-RW12 and Rev-QW11 to CTL, but CTL failed 
to recognize Gag-GW12 on 141-expressing target cells 
A retroviral vector containing the 141 gene was constructed and used to transduce 
721.221 cells and H585 EK cells. Rev-QW11-specific CTL from A2150 recognized both 141 
-transduced 721.221 and 141-transduced H585 EK target cells pulsed with the Rev-
QW11 peptide (Fig. 4.2, c and d). Similarly, Env-RW12-specific CTL from A2140 
recognized both 141-transduced 721.221 and 141-transduced H585 EK target cells pulsed 
with Env-RW12 (Fig. 4.2, c and d). In contrast, Gag-GW12-specific CTL from A2140 failed 
to recognize both 141-transduced 721.221 and 141-transduced H585 EK target cells pulsed 
with Gag-GW12 (Fig. 4.2, c and d). 
CTL recognized Env-RW12 with similar efficiency when presented by the 7-6 
and 141 molecules, whereas CTL recognized Rev-QW11 more efficiently when 
presented by 141 
PBMC from horse A2140 were stimulated with Env-RW12, then assayed for CTL 
activity on 7-6- and 141-transduced 721.221 target cells that were pulsed with increasing 
concentrations of Env-RW12. The efficiency of Env-RW12 recognition on 7-6-transduced 
targets (EC50: 15 nM) was similar to that on 141-transduced targets (EC50: 8.8 nM) (Fig. 
4.3a). 
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Because 7-6-transduced 721.221 cells presented Rev-QW11 poorly, MHC I-
mismatched H585 EK target cells were used to compare the efficiency of Rev-QW11 
recognition when presented by the 7-6 and 141 molecules. Following Rev-QW11 stimulation, 
A2150 CTL recognized Rev-QW11-pulsed 141-transduced H585 EK targets more efficiently 
(EC50: 0.68 nM) than Rev-QW11-pulsed 7-6-transduced H585 EK targets (EC50: 40 nM) (Fig. 
4.3b). These results were consistent with those obtained using A2140, A2152, and A2150 EK 
targets cells (Fig. 4.1a), and confirmed that in addition to abrogating the recognition of Gag-
GW12, the single 152E→V amino acid substitution in class I molecule 141 increased the 
recognition efficiency of Rev-QW11 by CTL. 
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Figure 4.3. Env-RW12- and Rev-QW11-specific CTL recognition efficiencies and competitive 
peptide-binding inhibition. (a) CTL recognized Env-RW12 with similar efficiency when presented by equine 
MHC I molecules 7-6 and 141. A2140 CTL were stimulated with Env-RW12 peptide and percent-specific lysis 
was determined on 7-6- and 141-transduced 721.221 cells pulsed with increasing concentrations of Env-RW12 
peptide. E:T cell ratios were 20:1. EC50, peptide concentration resulted in 50% maximal-specific lysis. Actual 
minimum and maximum percent-specific lysis for 7-6 and 141 targets was 0 and 63.5, and 0 and 49.1, 
respectively. (b) CTL recognized Rev-QW11 more efficiently when presented by equine MHC I molecule 141 
than when presented by 7-6. A2150 CTL were stimulated with Rev-QW11 peptide and percent-specific lysis 
was determined on 7-6- and 141-transduced H585 EK cells pulsed with increasing concentrations of Rev-QW11 
peptide. E:T cell ratios were 20:1. Actual minimum and maximum percent-specific lysis for 7-6 and 141 targets 
was 4.0 and 38.1, and 7.8 and 53.4, respectively. c and d, Unlabeled Env-RW12, Gag-GW12, and Rev-QW11 
inhibited 125I-labeled Env-RW12 binding to live 721.221 cells expressing MHC I molecule 7-6 (c), and live 
721.221 cells expressing MHC I molecule 141 (d). IC50, peptide concentration resulted in 50% inhibition of 
radiolabeled Env-RW12 binding. 
 
Env-RW12 and Gag-GW12 bound to 7-6 and 141 with higher affinity than Rev-
QW11 
Live-cell Env-RW12 peptide-binding inhibition experiments were performed to 
determine the relative binding affinities of the three peptides to 7-6 and 141. The Env-RW12 
peptide was chosen for 125I labeling because CTL recognized Env-RW12 on 7-6- and 141-
expressing targets with similar efficiency (Fig. 4.3a), suggesting that Env-RW12 bound 7-6 
and 141 with similar affinity. Moreover, Env-RW12 was the only peptide with a tyrosine 
residue, necessary for the chloramine-T method used for 125I labeling (68). The relative 
binding affinities of each peptide were then determined by using unlabeled peptides in 
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competitive binding inhibition assays. Binding of 125I -labeled Env-RW12 to 7-6 was more 
efficiently inhibited by unlabeled Env-RW12 (IC50: 54 nM) than by Gag-GW12 (IC50: 71 
nM) or Rev-QW11 (IC50: 525 nM) (Fig. 4.3c). For 7-6 binding, the IC50 of the negative 
control peptide 1b4a was >1000 nM (percent inhibition caused by 1000 nM was 27%; data 
not shown). These results were in agreement with the CTL recognition data.  
Binding of 125I -labeled Env-RW12 to 141 was efficiently inhibited by unlabeled Env-
RW12 (IC50: 41 nM) (Fig. 4.3d), consistent with the observation for 7-6. Surprisingly, 
binding of Env-RW12 to 141 was also inhibited by Gag-GW12 (IC50: 120 nM). Thus, the 
lack of Gag-GW12-specific CTL recognition of 141-expressing target cells was not due to 
the inability of Gag-GW12 to bind 141. However, the IC50 values indicated that Gag-GW12 
bound 141 with lower affinity than 7-6 (120 nM vs 71 nM). Also unexpectedly, Rev-QW11 
bound to 141 with lower affinity (IC50: 251 nM) than Gag-GW12. Consistent with the CTL 
results however, Rev-QW11 bound to 141 with higher affinity than it did to 7-6 (251 nM vs 
525 nM). For 141 binding, the IC50 of the negative control peptide 1b4a was >1000 nM 
(percent inhibition caused by 1000 nM was 33%; data not shown). Taken together, these 
experiments suggested that differences in MHC/peptide-binding affinity were not sufficient 
to explain the differential CTL recognition of Gag-GW12 and Rev-QW11 on 7-6- and 141-
expressing target cells. 
 
Computer modeling and docking of peptides with the 7-6 and 141 molecules 
Because crystal structures are not available, three-dimensional molecular modeling 
was performed to determine the possible structural and functional effects of the 152E→V 
substitution. Computer models were generated for 7-6 and 141 and the Env-RW12, Gag-
GW12, and Rev-QW11 peptides. A docking algorithm was then used to dock each of the 
three peptides with 7-6 and 141, and docking scores for each complex were calculated. 
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Modeling each of the MHC-peptide complexes indicated that amino acid position 152 
occurred in the α-2 helix of 7-6 and 141, within the wall of the peptide-binding cleft, and it 
appeared that the conformations of the bound peptides were affected differently (Fig. 4.4). 
Modeling suggested that the peptides bound 7-6 and 141 in a bulged conformation, with the 
first and last residues of each peptide anchored in the binding clefts (Fig. 4.5). The 
conformation of Env-RW12 was similar when bound to 7-6 and 141 (Fig. 4.5a), whereas 
Rev-QW11 was slightly more bulged when bound to 7-6, presumably because of the W11 
residue binding less deeply in the peptide-binding cleft of 7-6 (Fig. 4.5b). Interestingly, the 
bound conformation of Gag-GW12 was shifted and more sharply bulged in the 141 complex, 
apparently because the G1 residue of Gag-GW12 bound less deeply in the cleft of 141 as 
compared with 7-6 (Fig. 4.5c). Based on an analysis of pair potentials at the interface (76), 
the docking algorithm predicted the 7-6/Env-RW12 complex as the most favorable (highest 
RPScore docking score), followed by the 141/Rev-QW11 and 141/Env-RW12 complexes 
(Table 4.2). The 7-6/Gag-GW12 and 7-6/Rev-QW11 complexes were less favorable and the 
141/Gag-GW12 complex was the least favorable, although the docking score differences 
between these latter three complexes were not profound (Table 4.2). Based on the 
MHC/peptide-docking models, the 7-6/Env-RW12 complex had a greater number of 
hydrophobic, salt bridge, hydrogen bond, and aromatic stacking interactions than did the 
141/Env-RW12 complex (Table 4.2 and Fig. 4.6). For the 7-6/Rev-QW11 and 141/Rev-
QW11 complexes, there were more hydrophobic, hydrogen bond, and aromatic stacking 
interactions for 7-6/Rev-QW11, but 141/Rev-QW11 had a greater number of salt bridges 
(Table 4.2 and Fig. 4.6). Importantly, the 7-6/Rev-QW11 complex had two destabilizing 
repulsive charged interactions that were absent in the 141/Rev-QW11 complex. For the 7-
6/Gag-GW12 and 141/Gag-GW12 complexes, the two salt bridges in 7-6/Gag-GW12 were 
absent in 141/Gag-GW12, and 141/Gag-GW12 had one less hydrogen bond (Table 4.2 and 
Fig. 4.6). The salt bridges present in 7-6/Gag-GW12 but absent in 141/Gag-GW12 occurred 
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between the 69E residue of 7-6 and the K4 residue of Gag-GW12 (Fig. 4.6, c and d, and Fig. 
4.7, a and b). In addition, the G1 residue of Gag-GW12 had more interactions with residues 
of 7-6 (7Y: two hydrophobic, one hydrogen bond; 99Y: two hydrophobic; 159Y: three 
hydrophobic, two hydrogen bonds) than it did with residues of 141 (159Y: three hydrophobic) 
(Fig. 4.6, c and d, and Fig. 4.7, c and d). Based on the numbers of interactions between 
contact residues in the docking models for each of the six MHC/peptide complexes, the first 
two residues and W12 were probable anchor residues for Env-RW12 and Gag-GW12, 
whereas the first three residues and W11 were probable anchor residues for Rev-QW11 (Fig. 
4.6). In general, the molecular modeling results supported the experimental data and 
suggested specific mechanisms for the observed differences in peptide binding and CTL 
recognition. 
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Figure 4.4. Molecular modeling of the Env-RW12, Rev-QW11, and Gag-GW12 peptides bound to 
MHC I molecules 7-6 and 141. Top views of Env-RW12 bound to 7-6 (a) and 141 (b), Rev-QW11 bound to 7-6 
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(c) and 141 (d), and Gag-GW12 bound to 7-6 (e) and 141 (f). The binding clefts of 7-6 and 141 are shown in 
green, the peptides in red, and the 152E (V) residue in blue. The first residue of the bound peptides is oriented 
down. 
 
Figure 4.5. Molecular modeling suggested that the Env-RW12, Rev-QW11, and Gag-GW12 peptides 
bound to MHC I molecules 7-6 and 141 in bulged conformations, and that Env-RW12 (a) and Rev-QW11 (b) 
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maintained similar conformations when bound to 7-6 and 141, whereas the conformation of Gag-GW12 (c) 
changed when bound to 141. For each peptide, the conformation when bound to 7-6 is shown in red, and the 
conformation when bound to 141 is shown in blue. The first residue of the bound peptides is oriented to the 
right. 
 
 7-6 141 
Docking scorea   
Env-RW12 6.35 4.66 
Gag-GW12 2.96 2.25 
Rev-QW11 2.84 4.89 
Interaction category   
Hydrophobic   
Env-RW12 55 33 
Gag-GW12 26 26 
Rev-QW11 24 20 
Salt bridges (attractive charged)   
Env-RW12 10 5 
Gag-GW12 2 0 
Rev-QW11 8 11 
Repulsive charged   
Env-RW12 3 3 
Gag-GW12 0 0 
Rev-QW11 2 0 
Hydrogen bonds 1  
Env-RW12 2 1 
Gag-GW12 7 6 
Rev-QW11 6 5 
Aromatic stacking   
Env-RW12 6 5 
Gag-GW12 2 2 
Rev-QW11 2 1 
Table 4.2. Docking scores and numbers of interactions (by category) among atoms of contact residues 
for the Env-RW12, Gag-GW12, and Rev-QW11 peptides complexed with the 7-6 and 141 MHC class I 
molecules 
a The RPScores were calculated for each complex using the FTDock2.0 program (69). 
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b The number of interactions by category between atoms of contact residues for each complex was 
determined using the STING Millenium Suite program (71, 72). 
Figure 4.6. Numbers of interactions by category between each residue of Env-RW12 and its contact 
residues in the 7-6 (a) and 141 (b) complex, each residue of Gag-GW12 and its contact residues in the 7-6 (c) 
and 141 (d) complex, and each residue of Rev-QW11 and its contact residues in the 7-6 (e) and 141 complex (f). 
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Figure 4.7. Interactions between contact residues of Gag-GW12 and the 7-6 and 141 MHC I 
molecules. (a) Two salt bridges (bright green dotted lines) between 69E (bright green) of 7-6 and the K4 residue 
(white) of Gag-GW12 (red ribbon). 69E protrudes from the α-1 helix (turquoise coiled ribbon) of 7-6. The other 
green and blue ribbons represent the floor of the peptide-binding cleft. (b) A single hydrophobic interaction 
(purple dotted line) between 69E (purple) of 141 and the K4 residue (white) of Gag-GW12 (red ribbon). Other 
designations are the same as in Fig. 4.1a. (c) Seven hydrophobic interactions (purple dotted lines) and three 
hydrogen bonds (tan dotted lines) among 7Y (tan), 99Y (purple), and 159Y (tan) of 7-6 and the G1 residue 
(white) of Gag-GW12 (red ribbon). 7Y and 99Y protrude from the floor of the peptide-binding cleft (blue and 
green ribbons), and 159Y protrudes from the α-2 helix (green coiled ribbon) of 7-6. (d) Three hydrophobic 
interactions (purple dotted lines) between 159Y (purple) of 141 and the G1 residue (white) of Gag-GW12 (red 
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ribbon). Other designations are the same as in Fig. 4.1c. Images a–d were generated with the STING 
Millennium Suite (77,78), based on the docking models. 
 
DISCUSSION 
This study provided the first cloning, sequencing, and expressing of functionally 
distinct equine MHC I alleles within an ELA-A haplotype as defined by peptide-specific 
CTL, and demonstrated for the first time that a single residue difference between two 
naturally occurring MHC I molecules affected the recognition of Gag and Rev epitopes by 
lentiviral-specific CTL. This was accomplished using standard 51Cr release assays to assess 
the ability of EIAV Env-, Gag-, and Rev-specific CTL to recognize the corresponding 
peptides on human 721.221 and heterologous EK target cells transduced with retroviral 
vectors expressing two distinct MHC I genes derived from three horses with the ELA-A1 
haplotype. When compared with the 7-6 molecule, the single 152E→V substitution in the α-2 
domain of the 141 molecule enhanced CTL recognition of the Rev-QW11 epitope, but 
abolished CTL recognition of the Gag-GW12 epitope. Recognition of the Env-RW12 epitope 
by CTL was not affected. 
The hypothesis that the ELA-A1 haplotype was comprised of functionally distinct 
alleles was based on the initial observations that target cells from ELA-A1 horses A2140 and 
A2152 were recognized by both Env-RW12- and Gag-GW12-specific CTL whereas target 
cells from ELA-A1 horse A2150 were not recognized by Gag-GW12-specific CTL, and that 
Rev-QW11-specific CTL recognized A2150 target cells more efficiently than A2140 and 
A2152 target cells. Although the latter observation was consistent with the conclusion that 
the 7-6 MHC I molecule was used by A2140 and A2152 to present these epitopes while the 
141 molecule was used by A2150, the efficiency of Rev-QW11-specific CTL recognition of 
A2140 and A2152 target cells was not exactly the same. The reason for the slightly greater 
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recognition efficiency of the A2152 targets is not known. However, in addition to inheriting 
ELA-A1 haplotypes from different dams, A2140 and A2150 inherited different ELA 
haplotypes from the sire. It was therefore possible that the heterogeneous complement of 
other class I molecules on the respective target cells affected the expression of 7-6, or 
otherwise decreased peptide binding by 7-6 through competition or other unknown 
mechanisms (79, 80). Nonetheless, later experiments confirmed the hypothesis. 
The loss of Gag-GW12 recognition by CTL was the most striking result of the single 
amino acid difference between the 7-6 and 141 molecules. Live-cell peptide-binding 
inhibition assays indicated that Gag-GW12 was able to bind 141, albeit with 1.7 times lower 
affinity than 7-6. Although this lower binding affinity could have contributed to the inability 
of Gag-GW12-specific CTL to lyse 141-expressing target cells, loss of TCR recognition of 
the 141/Gag-GW12 complex was probably more important. Others have shown that a single 
residue difference between two MHC class I molecules can dictate marked conformational 
differences in the same bound peptide, directly affecting TCR recognition by CTL (81). 
Although crystal structures are necessary for confirmation, molecular modeling suggested 
that the absence of salt bridges, along with the paucity of interactions between the G1 residue 
(a probable anchor residue) of Gag-GW12 and the 141 molecule, resulted in the observed 
lower-affinity binding, lower calculated docking score, and a more sharply protruding Gag-
GW12 bound confirmation as compared with the 7-6/Gag-GW12 complex. These factors 
could have lowered TCR affinity for the 141/Gag-GW12 complex such that 141-restricted 
killing by Gag-GW12-specific CTL no longer occurred. 
For the 7-6 molecule, Env-RW12 bound with only 1.3 times higher affinity than Gag-
GW12, yet Env-RW12 CTL recognized 7-6 targets with 78 times greater efficiency than 
Gag-GW12 CTL. Therefore, the difference in affinity for the 7-6 MHC class I molecule 
between Env-RW12 and Gag-GW12 did not account for the difference in CTL-recognition 
efficiency, again suggesting that TCR affinity for the MHC/peptide complex played a major 
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role in the discrepancy. Earlier work yielded similar results and conclusions (27, 51). 
Although the observed difference in 7-6 binding affinity for Env-RW12 and Gag-GW12 was 
small, molecular modeling provided some possible explanations for the difference. 
Specifically, the 7-6/Gag-GW12 complex had fewer hydrophobic interactions, fewer salt 
bridges, and a lower docking score than the 7-6/Env-RW12 complex. 
Despite the detrimental effects on Gag-GW12-specific CTL recognition, the 152E→V 
change in 141 enhanced recognition of Rev-QW11 by CTL. Although CTL recognized Rev-
QW11 on 7-6-transduced MHC I-mismatched EK cell targets, 7-6-transduced human 
721.221 cells presented Rev-QW11 poorly. This type of differential recognition (equine vs 
human targets) was not observed for the other peptides, suggesting that human β2m did not 
effectively stabilize the 7-6/Rev-QW11 complex. This explanation is supported by the 
observation that human and murine β2m have different murine MHC I-stabilizing effects (82). 
It is not known why the presentation of the other peptides was not negatively affected by 
human β2m. Binding inhibition assays indicated that Rev-QW11 bound to 7-6 with 2.1 times 
lower affinity than to 141, and this inefficient binding could have made the stabilizing effects 
of autologous β2m more important for the 7-6/Rev-QW11 complex. Based on the molecular 
modeling results, the 7-6/Rev-QW11 complex had the second lowest docking score overall, 
and had fewer salt bridges and more destabilizing repulsive-charged interactions than did the 
141/Rev-QW11 complex. In addition, and likely because of the reasons just listed, Rev-
QW11 bulged out from the 7-6 binding cleft more than it did from 141. This conformational 
change in bound Rev-QW11 could have negatively affected TCR recognition of the 7-6/Rev-
QW11 complex by Rev-QW11-specific CTL. Although crystal structures are needed, 
modeling provided plausible mechanisms for the inefficient binding of Rev-QW11 to 7-6, 
and for the inefficient Rev-QW11-specific CTL recognition of 7-6-expressing target cells. 
Given the efficient Rev-QW11-specific CTL recognition of 141-expressing target 
cells and the absence of Gag-GW12-specific CTL recognition of 141-expressing target cells, 
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the observation that Rev-QW11 bound 141 with half the affinity of Gag-GW12 was quite 
unexpected. Despite the lower MHC binding affinity, the 141-bound conformation of Rev-
QW11 must have been efficiently recognized by the TCR of Rev-QW11-specific CTL. In 
contrast, the TCR of Gag-GW12-specific CTL probably could not bind the sharply 
protruding and highly bulged conformation of Gag-GW12 in the 141/Gag-GW12 complex. 
The CTL epitopes (Env-RW12, Gag-GW12, and Rev-QW11) evaluated in this study 
were similar in that all three have a large aromatic tryptophan at the C terminus. Additionally, 
both the N-terminal and C-terminal residues are required for MHC binding and/or CTL 
recognition for all three epitopes (27, 51). For Env-RW12, the V2 residue is also a probable 
anchor residue based on 7-6 binding inhibition assays using peptides with amino acid 
substitutions (51). These observations are consistent with the molecular modeling results 
obtained in the present study. Analysis of the hydrophilic and hydrophobic amino acid 
residues for each of the three peptides indicate that Env-RW12 and Rev-QW11 differ from 
Gag-GW12 at positions 1, 2, 8, and 9. Both Env-RW12 and Rev-QW11 have hydrophilic 
residues at positions 1 and 8, whereas Gag-GW12 has hydrophobic residues at these 
positions. At positions 2 and 9, both Env-RW12 and Rev-QW11 have hydrophobic residues, 
whereas Gag-GW12 has hydrophilic residues at these positions. The differences in these 
residues, which included probable N-terminal anchor residues, likely contributed to the 
differences in MHC/peptide complex conformations that allowed CTL TCR recognition of 
all three peptides when presented by 7-6, but recognition of only Env-RW12 and Rev-QW11 
when presented by 141. 
Interestingly, all three peptides in this study were longer than the 8–10 aa generally 
considered optimal for MHC I binding. However, MHC I molecules can bind peptides as 
long as 14 aa in a bulged conformation and elicit dominant CTL responses (83). Importantly, 
the BZLF1 protein of EBV includes three completely overlapping CTL epitopes of 9, 11, and 
13 aa in length (84). Although all three peptides bind well to the HLA-B*3501 molecule, the 
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CTL response in individuals with this allele is directed exclusively toward the 11-mer 
epitope (84). Of particular interest, individuals with the B*3503 allele, which differs from 
B*3501 by a single amino acid in the F pocket of the peptide-binding cleft, do not mount 
CTL responses to these peptides because they do not bind B*3503. However, individuals 
with B*3508, which differs from B*3501 by a single amino acid in the D pocket of the 
peptide-binding cleft, develop CTL responses to the 13-mer epitope (84). The crystal 
structures indicate that the 13-mer binds both B*3508 and B*3501 in a centrally bulged 
conformation with the N and C termini anchored in the A and F pockets of the peptide-
binding cleft (73). The differential CTL response is due to a broader peptide-binding cleft in 
B*3508, since the narrower binding cleft of the B*3501-peptide complex interacts poorly 
with the dominant TCR (73). Crystal structures will be required to confirm that the peptides 
in the present study bind the 7-6 and 141 molecules in a bulged conformation, and whether or 
not similar mechanisms are involved in the differential recognition by Env-RW12-, Gag-
GW12-, and Rev-QW11-specific CTL. 
Although crystal structures of equine MHC I molecules are lacking, the sequences of 
the two equine class I alleles presented here are surprisingly similar to human and murine 
class I alleles, and many of the residues forming the binding pockets A–F (in human and 
murine class I molecules) are shared (85, 86, 87). This suggests that the structure of equine 
MHC I molecules is similar to that of the mouse and human. In the absence of 
crystallography, molecular modeling provided important insights into the differential 
recognition of 7-6- and 141-expressing targets by EIAV Gag-GW12- and Rev-QW11-
specific CTL. For example, the charged 152E to hydrophobic 152V substitution in the 141 
molecule likely affected stabilizing salt bridges for Gag-GW12 binding, as seen when the 13-
mer BZLF1 EBV peptide binds to B*3508 and B*3501, which differ only at residue position 
156 (charged 156R→hydrophobic 156L) (73). If the modeling is correct, the absence of these 
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stabilizing salt bridges contributed to the conformational change leading to loss of TCR 
recognition of the 141/Gag-GW12 complex. 
This study confirms that a single amino acid difference between naturally occurring 
MHC I molecules can result in the loss of Gag-specific CTL recognition and enhanced (or 
diminished) efficiency of Rev-specific CTL recognition. The CTL, peptide-binding, and 
molecular modeling observations in this study support and suggest molecular mechanisms 
for the observed differences in disease progression and CTL responses in HIV-1-infected 
individuals of the B*35-Px and B*35-PY MHC I genotypes, because these genotypes also 
only differ by as few as one amino acid in the peptide-binding domain (40, 41). The 
implications of the observed differences in CTL recognition of important EIAV epitopes due 
to a single amino acid difference between otherwise identical MHC I molecules are 
important for designing protective lentivirus-specific CTL-inducing vaccines and 
understanding differential lentivirus disease progression in individuals within a population. 
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CHAPTER 5. GENERAL CONCLUSIONS 
 
Characterization of macromolecular interactions is a basic step for understanding 
complex cellular events. Most essential cellular functions involve macromolecular 
interactions, such as protein-protein and protein-RNA interactions. Although most viruses do 
not encode all of their own components, they also require various macromolecular 
interactions for replication, with virally-encoded proteins often interacting with host cellular 
components. Lentiviruses, especially, as single stranded RNA viruses, evolve faster than 
their eukaryotes hosts because of a high mutation rate and frequent recombination events 
within the viral genome. It is important to understand how macromolecular interactions in the 
lentiviruses have been maintained in the presence of such strong evolutionary selective 
pressure. We have focused our studies on Equine Infectious Anemia Virus (EIAV), one of 
the most divergent known lentiviruses. It has a similar viral life cycle and overall genome 
structure to other lentiviruses, but it has a different disease course, with alternating periods of 
acute, chronic, and inapparent disease. EIAV is a valuable model system for studying virus-
host macromolecular interactions because it has a relatively small genome and a limited 
number of gene products, compared to other more complex lentiviruses like HIV-1. By 
studying the basic mechanisms involved in the EIAV replication, we can understand the 
essential conserved features of lentiviruses. 
 
IDENTIFICATION OF A BIPARTITE RNA BINDING DOMAIN IN 
EIAV REV 
 
The Rev protein of equine infectious anemia virus (EIAV) and other lentiviruses is an 
essential regulatory protein that facilitates export of incompletely spliced viral RNAs from 
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the nucleus to the cytoplasm (18). Discrete functional domains of Rev mediate protein-RNA 
and protein-protein interactions that are required for nuclear import, RNA binding, 
multimerization, and nuclear export. Rev binds a specific sequence in the lentiviral RNA, 
termed the Rev-responsive element (RRE). Previously it was shown that the nuclear export 
signal (NES) domain is conserved among the lentiviral Rev proteins, in terms of its leucine-
rich sequence composition. Moreover, the NES domain is interchangeable between lentiviral 
Revs, even though the spacing of the leucine residues within NES is atypical within EIAV 
(5). The C-terminal region of EIAV is important for nuclear localization and the central 
region is involved in RNA binding (2, 3, 8). To investigate interactions between EIAV Rev 
and the RRE in viral RNA, we characterized the RNA-binding activity of EIAV Rev and 
directly analyzed the roles of putative RNA-binding motifs for EIAV Rev binding for the 
first time, as described in Chapter 2 (12). Truncated Rev proteins were expressed as MBP-
fusion proteins and tested for RNA binding in vitro using a UV crosslinking assay. RNA-
binding activity was abrogated by deletions in either the central region or a region near the C-
terminus that overlaps the nuclear localization signal. Analysis of site-specific mutations 
identified two short arginine-rich motifs (ARMs) that are essential for RNA-protein 
interaction: an RRDRW motif in the central region (residues 76-80), and a KRRRK motif 
near the C-terminus (residues 159-163). Each motif was found to be necessary, but not 
sufficient, for RNA binding in vitro and nuclear export activity in vivo. These results 
strongly suggest that the two ARMs interact with the RRE in concert, and thus comprise a 
bipartite RNA-binding domain. Mapping the motifs on a three-dimensional structural model 
of EIAV Rev (9) indicated that the two motifs are located in close proximity within the 
predicted three-dimensional structure of the folded protein, where they could form a single 
RNA-binding domain (Fig 5.1).  
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Figure 5.1. Summary of functional domains and predicted model of EIAV Rev Exon 2. (A) The 
functional domains of EIAV Rev Exon 2 are represented as boxes on a line representing the primary sequence 
(amino acids 31-165) (B) The predicted structure of EIAV Rev Exon 2 is illustrated using cartoon rendering. 
The NES, nuclear export signal; ARM1, arginine-rich motif 1 (RRDRW motif);  NLS, nuclear localization 
signal (KRRRK motif); and L95, Leucine 95 and L109, Leucine 109, are shown in space-fill representation. 
 
PROBING RNA SECONDARY STRUCTURE OF REV-RRE 
INTERACTIONS IN EIAV 
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During lentiviral replication, Rev-RRE interaction is crucial for the regulated 
expression of differentially spliced mRNAs. The RRE in most lentiviruses, including HIV-1, 
is located near the junction between SU and TM genes (13). Previously, the RRE in EIAV 
had been mapped in two different regions within the Env gene (15). Based on an in vivo Rev 
export assay, a 555 nt fragment designated ERRE-1, located in 5′ end of the Env gene has 
more functional activity (60%) than the rest of the Env gene (20%) (1, 2). In Chapter 3, to 
better understand the interaction between EIAV Rev and the RRE, we performed chemical 
probing experiments to determine the ERRE-1 secondary structure and footprinting 
experiments to analyze complexes formed between EIAV Rev and ERRE-1. Interestingly, 
the secondary structures for ERRE-1 based on the combination of computational and 
experimental approaches, are relatively unstable compared with the secondary structure 
predicted using computational approaches alone. There are several distinct and relatively 
stable stem-loop structures. In particular, the two stem-loop structures near the 3′ splice site 
and 5′ splice site for exon 1 of Rev not only are stable secondary structural elements based 
on both computational and experimental studies, but also are very well conserved in 
sequences of EIAV variants. Previously, several studies have implicated stem-loop structures 
in regulated splicing events, including alternative splicing of HIV Tat exon (10). Therefore 
we hypothesized that these secondary structure elements near the Rev exon 1 splice sites can 
act as cis-regulatory elements for splicing and alternative splicing events by interacting with 
trans-acting proteins such as splicing factors of the host. Previously, EIAV Rev was shown to 
bind to an Exonic Splicing Enhancer (ESE), containing two purine-rich tracts in the ERRE-1 
(2, 3). We identified two high affinity RNA binding regions in the ERRE-1 by footprinting 
analysis and filter binding experiments. We call these regions RBR-1 (Rev binding region-1) 
and RBR-2. RBR-1 encompasses the ESE, identified as RNA binding in the previous studies 
mentioned above (2, 3, 7). Evidence from filter binding experiments suggested that the 
second region, RBR-2 actually has higher binding affinity for EIAV Rev than RBR-1. This is 
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particularly interesting because our comparative computational analyses identified an RNA 
structural motif in RBR-2, that is similar to one found in the HIV-1 high affinity Rev binding 
site (4, 19) and which is also found within or near RRE regions of four additional lentiviruses 
(HIV-2, SIV, FIV and OLV). This work thus provides the basis for future comparative 
analyses of lentiviral Rev-RRE interactions. 
 
COMPUTATIONAL MODELING OF EQUINE MHC CLASS I 
MOLECULES AND EPITOPES OF REV, ENV AND GAG IN EIAV 
 
The virus-specific Cytotoxic T Lymphocytes (CTL) response is the core immune 
response in virally-infected host. Viral infection induces the expression of MHC I complexes 
(MHC class I protein and processed viral peptides) on the surfaces of infected cell 
membranes. CTLs recognize the MHC I complexes and kill the infected cell. In EIAV 
infected horses, it has been shown that CTL epitopes in Rev, Env and Gag are crucial for 
immune control of lentiviruses (16, 17). Therefore, a detailed molecular understanding of the 
mechanism for recognition of CTL epitopes is important for the development of vaccines 
against lentiviruses. The key for differential recognition of different CTL epitopes by MHC 
class I proteins, is in polymorphisms that usually occur in the α-1/2 and β-1 domain of MHC 
class I molecules. In Chapter 4, two equine MHC I molecules that differ in only single amino 
acid within the α-2 domain, were identified and characterized to investigate how different 
MHC I molecules recognize Rev, Env and Gag epitopes during EIAV-specific CTL immune 
responses. Three different CTL peptides, Rev-QW11, Env-RW12 and Gag-GW12, were 
synthesized and tested to assess two different recognition processes: i) the recognition of 
MHC class I complexes by EIAV-specific CTL, and ii) the differential peptide binding 
affinities of MHC class I proteins. Briefly, the experiment results showed that a single 
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152E→V substitution in the α-2 domain of the 141 molecule did not affect the recognition of 
Env-RW12 by CTL, but did result in more efficient recognition of Rev-QW11 by CTL. Also, 
CTL recognition of the Gag-GW12/141 MHC class I complex was abrogated, despite Gag-
GW12 binding to 141 molecule. 
Because the 3D structures of equine MHC class I molecules are not available, we 
used molecular modeling techniques to predict the 3D structures of equine MHC class I 
proteins and the three EIAV epitope peptides. Docking was performed using the modeled 7-6 
and 141 MHC class I molecules with each of three epitope peptides to investigate the 
molecular basis for the differential experimentally determined binding affinities of MHC 
class I proteins for the peptides. Docking scores for each MHC class I molecule-peptide 
complex and detailed interaction statistics extracted from the proposed docking models 
supported the experimental observations. For example, the docking score difference between 
7-6/Rev-QW11 and 141/Rev-QW11, and the larger number of salt bridges in the 141/Rev-
QW11 complex docking model, can explain why the 141 molecule recognizes the Rev-
QW11 more efficiently than the 7-6 molecule. In conclusion, molecular modeling provided a  
mechanistic explanation for experimental results in which a single amino acid change in an 
equine MHC class I molecule affected the equine CTL immune response; a similar 
phenomenon has been observed in the human CTL immune response to HIV-1 infection (6, 
11).  
 
FUTURE STUDIES 
 
The combined results from the wet-lab experimental and computational approaches 
used in this study have brought us closer to understanding the macromolecular recognition 
mechanisms involved in protein-RNA and protein-peptide interactions during lentiviral 
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infection. In Chapter 2, we characterized the RNA binding domain of the EIAV Rev protein, 
and obtained important clues as to how the bipartite RNA binding domain in Rev specifically 
recognizes viral RNA. Our results suggest that EIAV Rev differs from HIV-1 Rev in terms of 
domain organization: two RNA binding domains separated in primary sequence are both 
required for high affinity binding to the EIAV RRE. Rev of EIAV is similar to that of HIV-1 
in that short arginine rich motifs are important for the RRE binding and appear to contact the 
RNA directly. An intriguing discovery is that the L95 residue (located in the protein core, 
based on the predicted Rev structure), is required for RNA binding, but we don’t yet 
understand why. 
There are at least two hypotheses regarding the structure and function of Rev that 
should be tested in future analyses: First is the suggestion that the "bipartite" RNA binding 
domain forms a single RNA binding domain in the context of the folded structure. Our 
current hypothesis is that, even though they are 79 amino acids apart in primary sequence, 
the RRDRW and KRRRK motifs are brought into close proximity within the three-
dimensional structure of folded protein (Fig 5.1). The best way to test this hypothesis would 
be to experimentally determine the 3D structure by NMR spectroscopy or X-ray 
crystallography. Another option would be to measure the distance between the two RNA 
binding domains using biophysical methods such as FRET. A second important hypothesis to 
test is related to the role of the leucine 95 in the RNA binding. We know that L95 is crucial 
for both ERev export function and RNA activity, based on a functional in vivo activity assay 
and an in vitro RNA binding assay. Our preferred hypothesis is that the L95 residue stabilizes 
EIAV Rev structure through hydrophobic interactions with other hydrophobic residues in 
neighboring alpha-helices in the protein core, based on our prediction of the secondary and 
tertiary structure of EIAV Rev. This is supported by our preliminary observation that the 
circular dichroism (CD) spectrum of L95D mutant Rev differs from that of wildtype. The 
best way to test this hypothesis is the same as for the first hypothesis: experimentally 
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determine the 3D structure of EIAV Rev. If it is not possible to obtain a complete structure, it 
may be possible to obtain important information regarding the distances between critical 
residues in Rev using NMR.  
In Chapter 3, we characterized the secondary structure of the EIAV RRE and its 
interactions with EIAV Rev. This study complements the characterization of the RNA 
binding domain in EIAV Rev, described in Chapter 2, by revealing sequence and structural 
feature of Rev binding site in RNA. Therefore, I want to propose more detailed analyses that 
can be built on the results in Chapter 2.  These should include:  i) more detailed mapping to 
identify correlations between specific nucleotides in EIAV RRE and Rev amino acids that 
contact them, and ii) more systematic comparative analyses of lentiviral Rev-RRE 
interactions, using both experimental and computational approaches. A tantalizing 
observation is that RRE is also recognized by the host splicing factor, SF2/ASF (2, 3, 7, 14). 
Previously, two models have been proposed to explain interactions among EIAV RRE, Rev, 
and the host SF2/ASF protein. The first model is an exclusive model, in which the two 
proteins, EIAV Rev and SF2/ASF, directly compete with each other for binding to the EIAV 
RRE sequence. The other alternate, non-exclusive model, is that EIAV Rev and SF2/ASF can 
bind to the EIAV RRE at the same time, but that the binding of one protein affects the 
activity of other protein. Several indirect lines of evidence have been presented previously, 
but direct and detailed analysis has not been performed to test either model so far. 
Comparison of the footprinting results obtained on Rev/ERRE-1 versus SF2/ERRE-1 
complexes, or direct binding competition assays between Rev and SF2 would give us a better 
understanding of the potentially competitive relationship between host proteins and EIAV 
proteins in regulating EIAV gene expression. In addition, this will be a good example for 
investigating how two different RNA-binding proteins may use the same (or different) 
recognition sites to interact with same RNA substrate.    
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Molecular modeling techniques are becoming increasing useful for analyzing and 
understanding experimental results regarding protein complexes for which high resolution 
structural data are lacking. In Chapter 4, we used homology modeling to analyze and 
rationalize how a single amino acid change in an equine MHC I molecule affects the 
recognition of three different viral epitope peptides, from Rev, Env and Gag proteins. The 
modeling processes used in this study provided rough models for equine MHC class I 
molecules and their cognate epitope peptides. I recommend more extensive searches for 
models be made by simulating dynamic features of MHC class I and peptide molecules using 
molecular dynamics approaches. Such results would be more reliable than the modeling 
procedures used here. Also, because only one docking method was applied in this study, it 
would be worthwhile to compare results obtained using different docking methods to model 
complexes of MHC class I molecules and epitope peptides. 
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ABSTRACT 
Telomerase is a ribonucleoprotein enzyme that adds telomeric DNA repeat sequences 
to the ends of linear chromosomes. The enzyme plays pivotal roles in cellular senescence and 
aging, and because it provides a telomere maintenance mechanism for ~90% of human 
cancers, it is a promising target for cancer therapy. Despite its importance, a high-resolution 
structure of the telomerase enzyme has been elusive, although a crystal structure of an N-
terminal domain (TEN) of the telomerase reverse transcriptase subunit (TERT) from 
Tetrahymena has been reported. In this study, we used a comparative strategy, in which 
sequence-based machine learning approaches were integrated with computational structural 
modeling, to explore the potential conservation of structural and functional features of TERT 
in phylogenetically diverse species. We generated structural models of the N-terminal 
domains from human and yeast TERT using a combination of threading and homology 
modeling with the Tetrahymena TEN structure as a template. Comparative analysis of 
predicted and experimentally verified DNA and RNA binding residues, in the context of 
these structures, revealed significant similarities in nucleic acid binding surfaces of 
 154
Tetrahymena and human TEN domains. In addition, the combined evidence from machine 
learning and structural modeling identified several specific amino acids that are likely to play 
a role in binding DNA or RNA, but for which no experimental evidence is currently available.   
 
INTRODUCTION 
In most eukaryotes, a remarkable ribonucleoprotein enzyme, telomerase, is 
responsible for the synthesis and maintenance of telomeres, the ends of linear chromosomes 
(2, 5, 9). Many exciting discoveries have been made in telomerase biology since 1984, when 
the enzyme was first identified in the ciliate, Tetrahymena thermophila, by Greider and 
Blackburn(13). Recently, pivotal roles for telomerase in signaling pathways that regulate 
cancer, stress response, apoptosis and aging have been demonstrated (4, 6, 10, 27).   
Two essential roles of telomeres are protecting or "capping" chromosome ends and 
facilitating their complete replication (reviewed in (2, 5, 9)). Typically, telomeres consist of 
arrays of simple DNA sequence repeats, ranging from ~50 copies of 5'-TTGGGG-3' in 
Tetrahymena, to ~1000 copies of 5'-TTAGGG-3' in humans and other vertebrates.  The 
sequence of telomeric repeats is specified by an RNA template (TER), which varies in length 
from ~160 nts in ciliates to ~1500 nts in vertebrates, and is an essential component of the 
catalytically active form of telomerase (4, 9). Human telomerase is composed of hTER and 
two bound proteins, the telomerase reverse transcriptase component (hTERT) and dyskerin 
(8). The regulation of telomerase activity involves interactions with a variety of other cellular 
proteins, many of which are essential for telomere homeostasis (10, 16). 
Telomerase is a promising target for cancer therapy because it is generally present in 
very low levels in normal somatic cells, but it is highly active in many human malignancies 
(12). Telomerase targeting strategies have included short interfering RNA (siRNA) 
knockdown of endogenous hTER and a combination of siRNA and expression of mutant 
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forms of the hTER RNA, which become incorporated into the enzyme and inhibit 
proliferation in variety of different human cancer cell lines (12). 
 
 
Figure A.1. TERT domain architecture. A) The telomerase reverse transcriptase (TERT) comprises 4 
functional domains: essential N-terminal (TEN) domain, RNA-binding domain (TRBD), reverse transcriptase 
(RT), and C-terminal extension (TEC). B) Cartoon illustrating TERT domain organization, and the RNA 
template (TER). The TEN domain is Tetrahymena structure (PDB ID: 2B2A), and RT domain is from HIV-RT 
(PDB ID: 3HVT). Figure modeled after Collins, 2006 (9). 
 
Despite its obvious clinical importance, currently there are no experimentally 
determined structures for the telomerase ribonucleoprotein complex or for telomerase 
complexes bound to telomeric DNA substrates, presumably because these are multisubunit 
structures.  The telomerase reverse transcriptase component, TERT, is generally thought to 
consist of four functional domains (see Figure A.1): the essential N-terminal (TEN) domain, 
an RNA-binding domain (TRBD), reverse transcriptase (RT), and a C-terminal extension 
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(TEC). Recently, a crystal structure of the essential N-terminal domain of TERT from 
Tetrahymena has been reported (18) and appears to represent a novel protein fold. Several 
conserved sequence motifs have been identified within the TEN domain on the basis of 
multiple sequence alignments and mutagenesis experiments (11, 35). In addition, 
experiments directed at mapping DNA and RNA binding sites within TERTs from several 
organisms have identified specific amino acids that appear to contact either the DNA 
template or the RNA component (reviewed in(2)). In human telomerase, the TEN domain 
binds both DNA, specifically interacting with telomeric DNA substrates, and RNA, 
apparently binding in a non-sequence specific manner (18). 
Although vertebrate TEN domain sequences share a high degree of sequence 
similarity, the TEN domains from more diverse species share very little sequence similarity 
(<30% identity), suggesting that a homology modeling approach to predicting the structure of 
the human TEN domain would be difficult.  However, an alignment of the N-terminal 
sequences of TERTs from organisms ranging from human to T. thermophila to S. cerevisiae, 
revealed several highly conserved residues distributed throughout the N-terminal domain, 
suggesting that TEN domains from diverse organisms may share similar architectures (18). 
Based on this suggestion, we set out to test the hypothesis that the N-terminal domains of 
TERTs in diverse organisms not only share a similar overall three-dimensional fold, but may 
also have phylogenetically conserved DNA and RNA binding surfaces. We used a strategy in 
which comparative protein structural modeling approaches were integrated with sequence-
based machine learning approaches for predicting DNA or RNA binding residues. 
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DATASETS, MATERIALS AND METHODS 
Datasets 
RNA-protein interface dataset 
A dataset of protein–RNA interfaces was extracted from structures of known protein–
RNA complexes in the Protein Data Bank (PDB) (3)solved by X-ray crystallography. 
Proteins with >30% sequence identity or structures with resolution worse than 3.5 Å were 
removed using PISCES(32). The resulting dataset, RB147 (31), contains 147 non-redundant 
polypeptide chains. RNA-binding residues were identified according to a distance-based 
cutoff definition: an RNA-binding residue is an amino acid containing at least one atom 
within 5 Å of any atom in the bound RNA. RB147 contains a total of 6157 RNA-binding 
residues and 26,167 non-binding residues. The RB147 dataset (31) is larger than the RB109 
dataset used in our previous studies (29, 30). 
 
DNA-protein interface dataset 
A dataset of protein-DNA interfaces was extracted from structures of known protein-
DNA complexes in the PDB(3). Proteins with >30% sequence identity or structures with 
resolution worse than 3.0 Å and R factor > 0.3 were removed using PISCES(32). The 
resulting dataset, DB208, contains 208 polypeptide chains, each at least 40 amino acids in 
length. DNA-binding residues were identified according to a definition based on reduction in 
solvent accessible surface area (ASA): an amino acid is a DNA-binding residue if its ASA 
computed in the protein-DNA complex using NACCESS (15) is less than its ASA in the 
unbound protein by at least 1 Å2 (19). DB208 contains a total of 5,721 interface residues and 
39,815 non-interface residues. The DB208 dataset is larger than the DB171 dataset used in 
our previous studies (36). 
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Algorithms for predicting interfacial residues 
We used sequenced-based Naïve Bayes classifiers (22, 33) for predicting protein-
RNA interfaces (29, 30) and protein-DNA interfaces (36).  Briefly, the input to the classifier 
is a contiguous window of 2n+1 amino acid residues consisting of the target residue and n 
sequence neighbors to the left and right of the target residue, obtained from the protein 
sequence using the “sliding window” approach. The output of the classifier is a probability 
that the target residue is an interface residue given the identity of the 2n+1 amino acids in the 
input to the classifier. With Naïve Bayes classifiers, it is possible to tradeoff the rate of true 
positive predictions against the rate of false positive predictions, by using a classification 
threshold, θ, on the output probability of the classifier. The target residue is predicted to be 
an interface residue if its probability returned by the classifier is greater than θ, and a non-
interface residue otherwise. The length of the window was set to 21 in the experiments 
described here. 
We used the implementation of the Naive Bayes classifier available in WEKA, an 
open source machine learning package (33) for training classifiers used to predict interface 
residues in this study. The performance of the protein-RNA interface predictor trained on 
RB147 dataset (RNABindR, http://bindr.gdcb.iastate.edu/RNABindR/), and estimated using 
leave-one-out sequence-based cross-validation, is documented in (31). The performance of 
protein-DNA interface predictor trained on the DB208 dataset (DNABindR, 
http://cild.iastate.edu/DNABindR) and estimated using 10-fold sequence-based cross-
validation, is comparable to that of the previously published protein-DNA interface predictor, 
which was trained on the DB171 dataset (36). The RNA interface predictions on TEN 
domains were obtained by using Naïve Bayes classifiers trained on the RB147 dataset (high 
specificity setting of RNAbindR). The DNA interface predictions were obtained by 
DNABindR (θ=0.168) trained on the DB208 dataset. 
 
 159
Structural modeling of telomerase TEN domains in human and yeast 
The N-terminal domains from human telomerase (GENBANK NP_937986) and yeast 
telomerase (GENBANK NP_013422) sequences, were threaded onto the T. thermophila 
telomerase N-terminal domain (TEN)  structure (PDB: 2b2a chain A) using FUGUE(28). 
The output alignments were used for generating 3D coordinates for the N-terminal domains 
of human and yeast telomerase by MODELLER (25). Among 15 generated models, the 
highest ranking model was chosen and refined using SCWRL (7) to reposition side-chains. 
Energy minimization was performed by 400 steps of steepest descent using the GROMOS96 
force field (26) with a 9Å non-bonded cutoff in the Deep View/Swiss PDB-viewer (14). One 
human TEN model was based on the Tetrahymena TEN structure in the PDB: 2b2aA, N-
terminal domain of tTERT. For a second model, several templates were selected using PSI-
BLAST (1) and the Swiss-Model HMM template library (20) to detect remote homologs of 
hTERT. The chosen templates were portions of the following PDB structures: 1imhC, 
Tonicity-responsive enhancer binding protein (TONEBP)-DNA complex; 1jfiB, Negative 
Cofactor 2-TATA box binding protein-DNA complex (NC2-TBP-DNA); 2dyrM, bovine 
heart cytochrome C oxidase; 1b1uA, bifunctional inhibitor of Trypsin and Alpha-amylase 
from Ragi seeds; 2b2aA, N-terminal domain of tTERT. The templates were aligned and 
models were generated using the procedure described above. All generated structures were 
evaluated using the ANOLEA server (21). 
 
Experimental identification of RNA and DNA binding residues 
Experimentally determined DNA and RNA binding sites in hTERT and tTERT were 
collected by mining relevant literature. Point mutations that affect RNA binding have not 
been reported, but Moriarty et al. showed that deletions at positions 30-39 and 110-119 in 
hTERT result in reduced RNA and DNA association, respectively (23, 24). Conserved 
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primer grip regions have been mapped in the TEN and RT domains of hTERT, between 
amino acids 137-141 and 930-934 (34). Alanine substitutions in the C-terminal region of 
TEN at positions Q168, F178, and W187 have been shown to substantially decrease tTERT 
association with DNA (18). 
 
RESULTS 
Rationale  
Computational and bioinformatic analyses can provide valuable insight into protein 
sequence-structure-function relationships, especially when the structure of a protein or 
complex is difficult to solve using experimental approaches. Surprisingly, despite the 
fascinating structural and regulatory complexity of telomerase, its pivotal role in cellular 
signal pathways, and its critical interactions with DNA, RNA and protein partners, very few 
studies have exploited bioinformatic or computational structural biology approaches to 
investigate the structure and function of telomerase. In this work, we use a combination of 
comparative structural modeling and sequence-based machine learning methods to test the 
hypothesis that the N-terminal domains of TERTs in diverse organisms share a similar 
overall architecture and conserved DNA and RNA binding surfaces. 
 
Sequence-based prediction of RNA and DNA binding sites in human and 
Tetrahymena TERT  
Conserved domains within the telomerase reverse transcriptase protein of human 
(hTERT) and Tetrahymena (tTERT) are illustrated in Figure A.2. In previous work, we used 
a sequence-based machine learning approach to predict RNA binding residues in TERT 
sequences and showed that our predictions compared favorably with available experimental 
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data(30). Results of these previously published predictions are included in Figure A.2 for 
comparison with DNA binding residues predicted in the current study (see Materials and 
Methods).  The predicted DNA and RNA binding regions in hTERT and tTERT are indicated 
by boxes under the middle sections of Figures A.2A and A.2B, respectively.  The lower 
portion of each figure shows specific examples, with boxed amino acids representing short 
deletions (in hTERT) or alanine-substitution mutations (in tTERT), that have been shown to 
compromise or abolish DNA binding. Note that for hTERT, the predictions either overlap or 
surround the amino acids implicated by deletion (Figure A.2A).  For tTERT, two of three 
experimentally-identified DNA binding residues lie within the predicted DNA binding region 
(Figure A.2B). 
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Figure A.2. Predicted interface residues and conserved domains for telomerase reverse transcriptase 
(TERT). Mapped functional domains and conserved motifs of TERT are shown above shaded boxes 
representing clusters of predicted RNA and DNA interface residues. Predicted interface residues are indicated 
by a + below the amino acid sequence. A) Human telomerase reverse transcriptase (hTERT).  In the sequence 
shown, boxed amino acids 110-119 and 137-141, correspond to the template anchor site and a putative primer 
grip, implicated in forming the hTERT-DNA active complex (23, 24, 34). B) Tetrahymena telomerase reverse 
transcriptase (tTERT). The amino acid sequence shown represents the C-terminal end of the TEN domain.  
Alanine mutations at positions Q168, F178 and W187 have been shown to significantly reduce hTERT-DNA 
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association. Predicted interactions spanning amino acids 181-190 are located in a highly flexible, disordered 
region(18). 
 
 
A. 
            i                                                    ii.                                                 iii.                                                  iv. 
 
hTEN model ii 
 (based on tTEN template) 
hTEN model iii 
(based on composite   
template) 
tTEN 
(PDB 2b2aA) 
sTEN model iv 
(based on tTEN template) 
 
 
B. 
                                     • 
T. thermophila      ----MQKINNINNNKQMLTRKEDLLTVLKQISALKYVSN--LYEFLLATEKIVQTSELDT 
H. sapiens          ----MPRAPRCRAVRSLLRSHYREVLPLATFVRRLGPQG---WRLVQRGDPAAFRALVAQ 
S. cerevisiae       --------------MKILFEFIQDKLDIDLQTNSTYKEN------LKCGHFNGLDEILTT 
                                                                               • 
T. thermophila      QFQEFLTTTII--ASEQNLVENYKQKYN-----QPNFSQLTIKQVID------DSIILLG 
H. sapiens          CLVCVPWD-----ARPPPAAPSFRQVSC-----LKELVARVLQRLCE---RGAKNVLAFG 
S. cerevisiae       CFALPNSR-------KIALPCLPGDLSH-----KAVIDHCIIYLLTG---ELYNNVLTFG 
                                                                •       • 
T. thermophila      NKQNY--VQQIGTTTIGFYVEYENINLSRQTLYSSNFRNLLNIFGEEDFKYFLIDFLVFT 
H. sapiens          FALLDGARGGPPEAFTTSVRSYLPNTVTDALRGSGAWGLLLRRVGDDVLVHLLARCALFV 
S. cerevisiae       YKIAR------NEDVNNSLFCHSAN-VNVTLLKGAAWKMFHSLVGTYAFVDLLINYTVIQ 
                            •  •        
T. thermophila      KVEQNGYLQVAGVCLNQYFSVQVKQKKWYKNN---- 
H. sapiens          LVAPSCAYQVCGPPLYQLGAATQARPPPHASGPRRR 
S. cerevisiae       FNG-QFFTQIVGNRCNEPHLPPKWVQRSSSSSAT-- 
 
Figure A.3. Comparison of TEN domain structures and sequences and in Tetrahymena, human and 
yeast, S. cerevisiae.  A) Comparison of Tetrahymena TEN domain structure determined by X-ray 
crystallography with modeled structures of TEN domains from other species. i) T. thermophila, experimentally-
determined structure, PDB ID: 2b2aA (18);  ii) human structural model, based on threading using the T. 
thermophila 2b2aA structure as template;  iii) human structural model, based on threading using a composite of 
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several different structures as template; iv) yeast, S. cerevisiae, structural model, based on threading using the T. 
thermophila 2b2aA structure as template.  B) Multiple sequence alignment of telomerase TEN domains from T. 
thermophila, H. sapiens, and S. cerevisiae(18). Amino acids conserved in all 3 species in the multiple sequence 
alignment are highlighted.    
 
Structural modeling of N-terminal domain of TERT from human and yeast 
Our initial attempts to generate structural models of the human and yeast TEN 
domains by submitting their sequences to several web-based homology modeling servers 
were unsuccessful, due to failure of the servers to identify appropriate homology modeling 
templates (the pairwise sequence identity between TEN domains of hTERT and tTERT is < 
20%).  However, the results of multiple sequence alignment (Figure A.3B) and predicted 
secondary structure similarities (data not shown), led us to try threading, using the FUGUE 
server (see Materials and Methods). The Tetrahymena TEN domain structure (PDB ID 
2b2aA) was identified as the highest scoring structural template for both the human and yeast 
TEN domain sequences (hTERT: certain, with 99% confidence; sTERT: likely, with 95% 
confidence). Based on the alignments generated by FUGUE, we generated all-atom models 
and performed energy minimization to generate the final models illustrated in Figure A.3A 
(see Materials and Methods for details). Two different models for the human TEN domain, 
model ii, based on the Tetrahymena TEN template, and model iii, based on a composite 
template from several different structures, were very similar to one another as well as to 
model iv, for the yeast TEN domain, despite their highly divergent amino acid sequences. 
Table A.1 shows the root mean square deviation (RMSD) values calculated for comparison 
of the Tetrahymena TEN domain structure (determined by X-ray crystallography(18)) with 
the hTEN and sTEN modeled structures, using TOPOFIT (17) for structural alignment. 
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Aligned RMSD (
tTEN vs 1.11 
Structures Å) 
 hTEN 
 
 
tTEN vs 1.41 
sTEN vs 1.39 
 sTEN 
 hTEN 
 
 
Table A.1. RMSD computed from structural alignments of TEN domain structures: tTEN,  
Tetrahymena, PDB structure, 2b2aA (Fig.3A, structure i); hTEN, human, modeled structure (Fig. 3A, model ii); 
sTEN, yeast, modeled structure (Fig. 3A, model iv). Alignments were performed using TOPOFIT (17) 
 
Analysis of RNA and DNA binding surfaces in human and Tetrahymena TEN 
domains 
To compare RNA and DNA binding surfaces in human and Tetrahymena TEN 
domains, we examined both our predicted nucleic acid binding sites and available 
experimental data in the context of the experimentally determined structure of Tetrahymena 
TEN domain (18) and modeled structure of the human TEN domain (model ii, Figure A.3A).  
Examples of these analyses are illustrated in Figures A.4 and A.5.  The predicted RNA 
binding residues in hTEN overlap with several RNA binding sites implicated by deletion 
experiments (Figure A.4A, compare left and right models). Furthermore, additional putative 
RNA binding residues on the "back" side of the hTEN model (Figure A.4B, left, in oval) co-
localize with an experimentally defined RNA binding site mapped onto the  tTEN crystal 
structure (Figure A.4B, right, in oval). 
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A. 
 
 
 
 
 
 
 
hTEN Experimental RNA binding 
(mapped on model, view 1) 
hTEN Predicted RNA binding 
(mapped on model, view 1) 
 
 
B. 
hTEN Predicted RNA binding 
(mapped on model, view 2) 
tTEN Experimental RNA binding 
(mapped on crystal structure) 
 
 
 
 
 
 
 
 
Figure A.4. Comparison of predicted and experimentally determined RNA binding surfaces in TEN 
domains.  A) Sequence-based RNA binding site predictions mapped onto the hTERT TEN domain model ii 
(left) overlap with experimentally determined RNA binding residues (right); Black residues are predicted (left) 
or actual (right) RNA binding residues.  B) Another patch of predicted RNA binding residues in the hTEN 
model (left, in oval) co-localizes with an experimentally verified RNA binding region in tTEN (right). Figures 
A.4 and A.5 were generated using PyMol (http://pymol.sourceforge.net/). 
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B. tTEN Experimental  
DNA binding 
 (mapped on crystal structure) 
C. hTEN Experimental  
DNA binding 
(mapped on model, view 2)
A. tTEN Predicted DNA binding 
(mapped on crystal structure) 
Figure A.5. Comparison of predicted and experimentally determined DNA binding surfaces in TEN 
domains. A) Residues predicted to interact with DNA (black), mapped onto tTEN, PDB 2b2aA. Predicted 
binding sites encompass residues shown in B) which illustrates the only 3 experimentally defined DNA binding 
residues in tTEN (see Fig. 2B). Note that additional predicted DNA binding residues in A (in oval) are 
consistent with C), which shows experimentally validated DNA binding residues in the human protein mapped 
onto our modeled structure of hTEN. 
 
Only three DNA binding residues in the TEN domain of tTERT have been 
experimentally identified: Q168, F178, and W187 (Figure A.5B). Several additional putative 
DNA binding residues are predicted by our machine learning classifiers (Figure A.5A). Some 
of these predicted residues in tTEN (in oval) co-localize with experimentally defined DNA 
binding residues in the human protein, when viewed in the context of our modeled structure 
of the hTEN domain (Figure A.5C).  
Taken together, these results support our hypothesis that TEN domains in diverse 
organisms have similar three dimensional structures and conserved nucleic acid binding 
surfaces. Further, they identify additional putative interface residues that could be targeted in 
experiment studies. 
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SUMMARY AND DISCUSSION 
Telomerase is one of several clinically important regulatory proteins for which it has 
been difficult to obtain high resolution structural information.  The recent experimental 
determination of the structure of the N-terminal domain of tTERT, the telomerase reverse 
transcriptase component from Tetrahymena, suggests that at least partial structural 
information for human telomerase may soon become available. It seems unlikely, however, 
that experimental elucidation of the structure of the multisubunit RNP complex 
corresponding to the catalytically active form of telomerase will occur in the near future.  
Thus, the integrative strategy proposed here, in which structural information gleaned from 
comparative modeling is combined with machine learning predictions of functional residues, 
can be expected to provide valuable insights into the sequence and structural correlates of 
function for telomerase and other "recalcitrant" proteins. We are currently pursuing several 
avenues for improving the reliability of machine learning predictions, including the use of 
different sequence representations and additional sources of input information (e.g., structure 
and phylogenetic information, when available) and more sophisticated machine learning 
algorithms. We are also pursuing additional approaches for protein structure prediction, 
including ab initio and fold recognition methods capable of incorporating predicted protein-
protein contacts as constraints.  Given the large number of proteins with which telomerase 
interacts and the essential roles of telomerase in cellular signaling, aging, cancer, and other 
human diseases, this should continue to be rich and challenging area of research. 
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 APPENDIX B. CHARACTERIZATION OF ISOMERIZING 
PROLINES USING SEQUENCE AND STRUCTURE 
INFORMATION 
 
Preliminary data and results described 
 
ABSTRACT 
In polypeptide chains, there are two potential configurations (cis and trans), for the 
peptide bond that connects neighboring amino acids, cis and trans. For thermodynamic 
reasons, the cis configuration is almost never observed for amino acids in stably folded 
proteins, with the notable exception of peptidyl-prolyl bonds, which are observed in the cis 
configuration for ~5% of prolines that have been characterized. The structure of proline, 
which lacks an amide hydrogen atom, lowers the thermodynamic barrier between cis and 
trans peptide bond configurations. Peptidyl-prolyl cis/trans isomerization has considerable 
biological significance in the regulation of protein folding and in protein structure 
stabilization. In some cases, however, proline residues have been shown to undergo cis/trans 
isomerization within stably folded proteins, a change that has been shown to alter the 
recognition properties of several proteins. Consequently, it has been suggested that proline 
cis/trans isomerization could represent a novel post-translational regulatory mechanism.  
Here we present a systematic characterization of the amino acid sequence correlates of 
peptidyl-prolyl cis/trans isomerization. In addition, we use machine learning approaches to 
generate classifiers for predicting whether a specific prolyl peptide bond is likely to be in the 
trans, cis or isomerizing (isom) configuration, using only the amino acid sequence of a query 
protein as input. The configuration of every peptidyl-prolyl bond for all proline residues (>1 
million)  in the PDB database of protein structures was determined and comprehensive 
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datasets for training and testing algorithms to perform cis versus trans and cis or trans versus 
isom classification were generated. Two machine leaning algorithms, Naïve Bayes and 
Support Vector Machine (SVM), were used for constructing classifiers and 4 different 
features were used as input for classifiers. Analysis of the secondary structure environment 
and the propensity for certain amino acid residues to be located at specific positions relative 
to the target proline residue showed that proline residues that undergo cis/trans isomerization 
have a distinguishable secondary structure environment and a different neighboring amino 
acid propensity distribution from cis and trans cases. In classification tasks, the cis/trans 
classifier outperformed either isom/trans or isom/cis classifiers. Generally, SVM classifiers 
and using a combination of different physicochemical features as input gave the best 
classification results. 
INTRODUCTION 
Post-translational modifications of proteins, such as phosphorylation and 
glycosylation, represent an important mechanism for regulating the cellular functions of 
proteins. Recently, a new potential regulatory "switch" has been proposed: a conformational 
change mediated by cis/trans isomerization of proline residues (1, 2). Proline is unique 
among amino acids in its capacity to accommodate the thermodynamic change between cis 
and trans peptide bond configurations because it lacks the amide hydrogen atom (8). 
Although most proline residues are observed in either the trans (95%) or the cis (5%) 
conformation, conversion of the planar peptide bond of a proline residue between the trans 
and cis form is thermodynamically feasible, and this phenomenon is referred to as cis/trans 
isomerization (Fig. B.1). The ability to monitor protein dynamics using NMR spectroscopy 
led to the discovery of a "proline switch" in the Itk tyrosine kinase, in which proline cis/trans 
isomerization determines the specificity of Itk protein-protein interactions by regulating the 
transition between two alternative binding surfaces (14). Generally, proline isomerization 
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plays a important role in many biological functions such as protein folding (19, 30) and cell 
signaling (16, 20, 32).  
 
Figure B.1.  Cis and trans configurations of a proline residue. (A) There are two configurations of the 
C-N bond in polypeptides. (B)  Based on the omega (ω) angle, proline residues can have either configuration: 
cis or trans.  
 
Several computational approaches have been used to analyze cis/trans conformations 
of prolyl peptide bonds in protein structures. Peptide bond conformation at proline residues 
can be investigated using 3D structures of proteins that have been solved using high-
resolution experimental structure determination methods (e.g., from the PDB database (4). In 
addition, several studies have reported the analysis of the prolyl peptide bonds using other 
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biochemical or biophysical methods. The first data-driven computational analysis of 
sequence determinants of proline isomerization was reported by Frommel, et al. (9). They 
analyzed the distribution of amino acids in the neighborhood of prolyl residues, using a 
dataset extracted from the PDB, and calculated the propensity for certain amino acid residues 
to be located in the neighborhood of cis-prolyl residues. Based on these amino acid 
propensities, they tried to predict the conformation of prolyl peptide bonds on the basis of 
sequence, but their dataset was too small to generate reliable predictions. Recently, the same 
group updated the study and showed that cis-prolyl bonds in proteins are well-conserved 
during evolution, compared with trans-prolyl residues (13). Pahlke, et al. (17) analyzed cis 
and trans conformations of proline residues using Chou-Fasman parameterization, an 
occurrence matrix for amino acids, and secondary structures. Recently, Wang et al. (29), used 
a Support Vector Machine (SVM) algorithm to construct classifiers for predicting the 
cis/trans conformation of proline residues. Enhanced predictions on cis/trans conformation 
have done by Song, et al. (23). In their study, different machine leaning algorithms and 
various data features for cis and trans prolyl residues were systematically tested. No studies 
to date have attempted to systematically identify proline residues that can undergo cis/trans 
isomerization within stably folded proteins, or to distinguish such proline residues from those 
that are thought to exist in only the cis or only the trans conformation.  
At the time we initiated this study, cis/trans isomerization had been observed in only 
a handful of proteins. This is at least partly due to the technical difficulty of detecting the 
phenomenon:  protein crystallization would be expected to "freeze" potentially isomerizing 
prolines in a single configuration. Proline isomerization would be detected only if two 
different structures produced by X-ray crystallography happen to "capture" a proline in two 
different configurations. Only with NMR spectroscopy is it possible to directly measure 
cis/trans isomerization and evaluate it dynamically. Therefore, we set out to explore whether 
proline-mediated isomerization might actually occur at a significant frequency in folded 
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proteins by performing a systematic examination of the structural environment of every 
proline residue in all known protein structures. Machine learning approaches were used to 
differentiate three (rather than just two) different configuration of prolyl peptide bonds; cis, 
trans and isomerization (isom) cases, using either sequence or a combination of sequence and 
structural information extracted from the PDB. The ultimate goal of this study is to develop a 
computational model that can be used to identify additional “proline-switch” candidates, 
which can then be experimentally evaluated, using NMR spectroscopy.  
 
MATERIALS AND METHODS 
Exploring and analyzing proline configurations in PDB 
To generate data for our analyses of the sequence correlates of each of the three 
different proline conformations, cis, trans and isom, we extracted datasets from the PDB 
(April 20th, 2007). At that time, there were 42,861 PDB entries, including 92,210 protein 
chains that are greater than 20 amino acids in length. Every proline residue in all chains was 
analyzed to calculate the omega angle of the peptide bond. Each proline entity in our 
database of extracted peptidyl proline bonds contains the PDB chain ID, the absolute omega 
angle value, the amino acid identities of  residues in a 21 amino acid window containing the 
target proline residue (including 10 residues before and after the proline), the corresponding 
secondary structure information for residues in the 21 amino acid window, and the calculated 
configuration of the prolyl peptide bond (if the absolute omega angle value of the prolyl 
peptide bond is < 30°, the bond is classified as in cis configuration; if it is >150°, the bond is 
classified as in trans configuration). A total 1,019,085 proline residues were extracted and 
analyzed.  Based on the omega angle, 948,081 (93%) of these proline residues are in the 
trans configuration and 45,353 (4.5%) are in cis configuration. The omega angle for 25,651 
prolyl peptide bonds could not be classified as cis or trans. To generate a dataset for the 
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isomerization cases (i.e., proteins in which a specific proline has been observed in both the 
cis and trans configurations) it was necessary to collect “redundant” structures. Therefore, to 
compare different protein structures that have the same or almost the same sequences, 
datasets of clustered protein sequences, available from the PDB were used. These are 
generated by an algorithm that clusters all protein sequences in PDB, based on sequence 
similarities (to reduce redundancy of the PDB database for certain applications). Clusters of 
proteins with ≤95%, ≤90%, ≤70%, and ≤50% sequence homology are generated. For 
generating our primary dataset, the 90% sequence homology cluster dataset and a 2.5 A° 
resolution cutoff for structures determined by X-ray crystallography were used. In the PDB 
cluster data, there are 15,271 different clusters and within each cluster, protein chains that 
have more than 90% sequence homology are listed. Initially, all 21 amino acid windows from 
all protein chains in one cluster were extracted and the 21 amino acid windows were 
compared using pair-wise sequence alignment. If two identical 21 amino acid windows from 
the same cluster have different configurations of target proline (i.e., one trans and one cis), 
we assigned the proline centered in this 21 amino acid window the isom case label.  Using 
this procedure, 460 unique isomerization cases were collected and used for further structural 
and sequence analysis. 
 
Generation of datasets for classification tasks 
To avoid redundancy problems in the classification tasks, the entire dataset of 21 
amino acid windows generated to evaluate the relative frequency of different proline 
configurations was not used. Instead, protein chains from PISCES server (28) (less than 30% 
sequence identity and structures with resolution greater than 2.5A°) were collected and used 
for identifying 21 amino acid windows (hereafter referred to as "windows") for further 
analysis. This resulted in total 46,472 windows containing 44,148 trans cases, 2,140 cis cases 
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and 184 isom cases. Four different features associated with each instance were used for 
construction of dataset. The sequence information, i.e., amino acid identity, was the primary 
data feature and always used for the construction of dataset and derivation of other features 
that were explored for providing better performance. Secondary structure information was 
obtained using DSSP software (12) to analyze each PDB structure and the output was pre-
processed and presented simply as an assignment of one of three basic secondary structure 
classes; helix (H), sheet (E) and coil (C). The other two data features, extracted from the 
HSSP database (21), were sequence entropy information and profiles for each amino acid 
residue. The HSSP database is a database that combines three dimensional structure and 
primary sequence information for proteins. Each entity in HSSP database has a multiple 
sequence alignment from sequence homologs and a value representing the sequence 
variability at each position, calculated based on the alignment. Because the HSSP database 
entity originally came from PDB structures, the information from HSSP database contains 
evolutionary information based not only on sequence information but also on the structural 
conservation of the protein. The entropy for each amino acid position represents how well-
conserved an amino acid is in the multiple sequence alignment. The HSSP profile has more 
information about the conservation of the amino acid position than the entropy, because the 
profile for each amino acid position includes 20 different vectors that encode the frequency 
of occurrence of each of the 20 amino acid in a multiple sequence alignment.   
Five different combinations of data features were evaluated in the classification tasks: 
i) sequence alone (seq); ii) sequence + secondary structure (seq+ss);  3) sequence + HSSP 
entropy (seq+hssp_ent);  iv) sequence + HSSP profile (seq+hssp_pro); v) sequence + 
secondary structure + HSSP profile (seq+ss+hssp_pro).  To examine the effect of window 
length (for local amino acid features near the target proline) for constructing classifiers, nine 
different window lengths (3, 5, 7, 9, 11, 13, 15, 17, 19, 21 aa), with the target proline always 
in the middle of the window, were generated and evaluated. 
 180
 
Naïve Bayes method 
Naïve Bayes learning is based on Bayes theorem (15). Bayesian learning infers the 
optimal hypothesis by weighing the evidence supporting alternative hypothesis. The 
probability of a hypothesis given a set of data D, P(h|D), can be calculated based on its prior 
probability P(h), the probability of observing the data given the hypothesis P(D|h) and the 
probability of the data P(D) using Bayes theorem. 
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for all hi ∈H. 
Sometimes this assumption may not be true in real situations, but various Naïve 
Bayes applications have shown good performance in many practical examples and have good 
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computational efficiencies. Recently, bioinformatic applications based on Naïve Bayes 
method showed good performance for prediction of interface residues in protein-protein, 
protein-DNA and protein-RNA interactions (e.g., 24-26, 33, 34). 
 
Support Vector Machine (SVM) method  
Support Vector Machine, which is based on the perceptron algorithm, tries to find the 
best hyperplane boundary between classes in a high dimensional space (27). If the class 
patterns are not be separable in the original n-dimensional pattern space, a non-linear kernel 
function can be used to implicitly map the patterns in the n-dimensional input space into a 
higher dimensional feature space in which the patterns become separable. (Fig B.2A).  Also 
in the SVM, the overfitting problem for the training dataset is resolved by selecting the 
hyperplane that maximizes the margin of separation between two classes from among all 
separating hyperplanes (Fig B.2B).  
 
Figure B.2. The role of kernel function in SVM and maximization of the margin. (A) The kernel 
function can map linearly non-separable class patterns onto a high dimensional space in which the classes can 
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be separated. (B) A maximal margin hyperplane with its support vector highlighted in the 2-dimensional feature 
space (φ1, φ2). 
 
Recently, several biological classification problems such as protein function 
classification (7), protein secondary structure prediction (10), sub-cellular localization 
prediction (11), and protein-protein interaction sites prediction (33) were analyzed using 
different machine learning classification algorithms. 
 
Evaluating machine learning classification performance  
Previous studies (3, 33) mentioned various measures for evaluating the performance 
of classifiers. Generally, the measurements include: 1) sensitivity for a class: the probability 
of correctly predicting an example of that class, 2) specificity for a class: the probability that 
a positive prediction for that class is correct, 3) accuracy: the overall probability that a 
prediction is correct, and 4) Matthew’s correlation coefficient: a measure of how predictions 
correlate with the actual data. 
FNTP
TPySensitivit
FPTP
TPySpecificit
FNTNFPTNFPTPFNTP
FNFPTNTPtCoefficiennCorrelatio
FNTNFPTP
TNTPAccuracy
POS
POS
+=
+=
++++
×−×=
+++
+=
))()()((
)()(
 
In our performance measures, we define, 
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- TP (true positives): the number of proline residues predicted to be members of the 
positive classes (cis or isom cases) that actually are members of positive classes (cis or isom 
cases). 
- TN (true negatives): the number of proline residues predicted to be members of 
negative class (trans cases) that actually are members of the negative class (trans cases) 
 
- FP (false positive): the number of proline residues predicted to be positive (cis or 
isom) cases that actually are negative (trans) cases. 
 
- FN (false negative): the number of proline residues predicted to be negative (trans) 
cases that actually are positive classes (cis or isom) cases. 
 
The correlation coefficient has values ranging from -1 to 1, and the more accurate the 
predictions are, the closer correlation coefficient is to 1. On the other hand, a correlation 
coefficient of -1 means the opposite prediction is always obtained, and a correlation 
coefficient of 0 means the predictions are random. Because any single measure is not 
sufficient to adequately evaluate a classifier, all of the above measurements are used. 
 
Analysis of the distribution of amino acid types and secondary structure near 
proline residues 
The datasets for classification were first used to analyze the distribution of amino acid 
types and secondary structural features in the neighborhood of proline residues. There are 
three different classes (trans, cis and isom) of 21 amino acid windows (containing the target 
proline residue in the middle). The frequency of occurrence of each of the 20 amino acids or 
of each of the 3 secondary structural assignments (helix, sheet and coil) at each residue 
 184
position in the windows for each class (trans, cis and isom), was determined and normalized, 
based on the natural distribution of amino acids. The natural distribution of 20 amino acids 
was calculated based on the entire PISCES non-redundant dataset. The calculated 
distributions are presented as a 20 X 20 matrix for each class (Table B.1) and if the value in a 
cell is > 1, it means the amino acid at that position is over-represented relative to other amino 
acids. 
 
RESULTS 
Distribution of amino acids and secondary structures near proline residues 
Table B.1 shows the normalized propensities calculated for 10 residues preceding and 
10 residues following the central proline residue in datasets of 21 aa windows. The columns 
for amino acids are arranged on the table column on the basis their hydrophobicity; 
Phenylalanine (F) is the most hydrophobic amino acid and the arginine (R) is the most 
hydrophilic residue (5). The over-represented amino acids (values >1) are colored red and 
under-represented amino acids (values <1) are colored blue. The amino acid propensities for 
each of the 3 proline configurations has a different distribution trend. In trans cases, 
hydrophobic residues (FLIYWV) are overrepresented within window and hydrophilic 
residues (except arginine) are underrepresented. The overall trend of propensities for cis 
cases is similar to that of trans, but two hydrophobic residues, leucine (L) and isoleucine (I) 
and two hydrophilic residues, asparagine (N) and histidine (H), have the opposite 
propensities, relative to the trans cases. In the isom cases, there is no general tendency based 
on the hydrophobicity of amino acids, but a definite "signal" exists in the propensity 
distribution, with specific favorable and unfavorable amino acids readily detectable.  
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F L I Y W V M P C A G T S K Q N H E D R
-10 1.0267 1.0319 1.0577 1.0466 1.1458 1.0587 1.0827 1.0362 1.0377 1.0001 1.0015 1.0422
1.081 1.0778 1.0198 1.0888 1.2084 1.0868 1.0699 1.0006 1.0284 1.0039 1.0216
1.0804 1.0896 1.0924 1.1495 1.2002 1.0868 1.0699 1.0009 1.0167 1.0229
1.0945 1.0862 1.0533 1.0677 1.1491 1.1047 1.017 1.0093 1.0037 1.0204 1.0119
1.1064 1.0638 1.0113 1.1152 1.182 1.077 1.0111 1.2057 1.0123 1.0015 1.009 1.0474
1.1652 1.0876 1.1049 1.1218 1.2414 1.0695 1.07 1.1121
1.0866 1.0852 1.019 1.0842 1.1177 1.0361 1.1102 1.1378 1.0108 1.0163
1.1194 1.1079 1.1359 1.0146 1.1298 1.0057 1.1274 1.061 1.0057
1.1612 1.08 1.073 1.1323 1.1392 1.0276 1.0621 1.0314 1.1926 1.0475 1.1325
1.0188 1.1547 1.1884 1.0248 1.0822 1.2185 1.2215 1.3194 1.2316 1.2005
1.0274 1.0716 1.0988 1.1134 1.0053 1.0692 1.0347 1.2852 1.1773
1.1211 1.0444 1.0089 1.1099 1.1128 1.0538 1.0253 1.106 1.0602 1.0109
1.0855 1.0714 1.1337 1.1721 1.1982 1.1092 1.0788 1.0155
1.0663 1.0202 1.0373 1.2084 1.0881 1.1083 1.047 1.0094 1.0157 1.0465
1.0634 1.0707 1.0682 1.0756 1.1787 1.1243 1.0744 1.0167 1.032 1.0263 1.0255
1.129 1.107 1.0694 1.1198 1.215 1.108 1.0112 1.0367 1.0378
1.0589 1.0506 1.0779 1.0492 1.1491 1.093 1.0062 1.0809 1.0406 1.0413
1.0493 1.0057 1.0908 1.1309 1.0374 1.0883 1.0531 1.0098 1.0052 1.0091 1.0427 1.0606
1.0193 1.0395 1.0363 1.1026 1.0765 1.0035 1.1341 1.0451 1.0417 1.0077 1.0395
1.0578 1.0705 1.0677 1.1342 1.0521 1.1011 1.0689 1.0031 1.0343
0.8506 0.9935 0.9149 0.9088 0.96 0.8726 0.9522 0.9776
-9 0.8525 0.9797 0.907 0.9072 0.9671 0.9804 0.8624 0.9201 0.98
-8 0.7902 0.9787 0.9861 0.9384 0.8935 0.9598 0.9622 0.8718 0.8968 0.9354
-7 0.8058 0.9848 0.8913 0.942 0.9254 0.9552 0.8402 0.9577 0.971
-6 0.8175 0.9246 0.9115 0.9532 0.9085 0.9128 0.9171 0.9644
-5 0.7844 0.9743 0.9944 0.9632 0.9317 0.8697 0.9115 0.988 0.9222 0.8903 0.9765 0.9712
-4 0.7815 0.9515 0.998 0.9735 0.9397 0.8903 0.9917 0.9427 0.9053 0.9819
-3 0.9911 0.9662 0.6997 0.967 0.9675 0.9701 0.9772 0.9085 0.9528 0.9272 0.9213
-2 0.7678 0.8393 0.9795 0.8775 0.9103 0.8957 0.8124 0.9877 0.9007
-1 0.7765 0.8506 0.8438 0.8268 0.7622 0.9915 0.9115 0.9302 0.7095 0.9156
1 0.9764 0.9833 0.8432 0.6919 0.8443 0.8405 0.9476 0.9848 0.8587 0.8837 0.8534
2 0.8457 0.9745 0.9951 0.8063 0.949 0.9514 0.976 0.9512 0.9986 0.8503
3 0.9961 0.8087 0.8772 0.9937 0.8856 0.9915 0.9483 0.8891 0.8213 0.9387 0.9218 0.9804
4 0.9796 0.7377 0.9414 0.9415 0.9988 0.9358 0.9839 0.9063 0.8786 0.9714
5 0.8321 0.927 0.9388 0.8834 0.9562 0.8859 0.876 0.962 0.9408
6 0.8934 0.9851 0.9233 0.9358 0.8712 0.9465 0.8988 0.9171 0.9034 0.9462 0.9957
7 0.8486 0.9592 0.9768 0.9309 0.8912 0.981 0.9358 0.894 0.9571 0.985
8 0.9884 0.8078 0.9576 0.9774 0.9156 0.9225 0.989 0.8872
9 0.835 0.965 0.9541 0.9045 0.9574 0.9638 0.882 0.9761 0.9924
10 0.9928 0.8243 0.9984 0.9886 0.9287 0.9479 0.9544 0.9525 0.8718 0.9833 0.9199
Table B.1A. Amino acid propensity near proline residue in trans case. Propensities >1 are shown in 
red, otherwise values are shown in blue (see text for additional details).  
F L I Y W V M P C A G T S K Q N H E D R
-10 1.1547 1.1571 1.1563 1.0425 1.0979 1.0195 1.0844 1.0918 1.0573 1.02 1.0796
1.1244 1.1896 1.1299 1.0203 1.0715 1.0728 1.0267 1.0393
1.0497 1.2388 1.2584 1.1052 1.0627 1.4387 1.0425 1.0525 1.1704 1.0085 1.005
1.0497 1.0029 1.1646 1.1979 1.2584 1.186 1.0728 1.5144 1.0045 1.138 1.035
1.2596 1.0788 1.4702 1.5305 1.3141 1.3251 1.0653 1.1194
1.0147 1.0079 1.0482 1.7005 1.2399 1.3562 1.3629 1.0716 1.1879 1.0418
1.2363 1.0399 1.266 1.5645 1.186 1.3967 1.1736 1.0334 1.0569 1.1025 1.0861 1.0756 1.0122
1.2013 1.0333 1.173 1.0346 1.1904 1.1119 1.3866 1.2115 1.0525 1.1093 1.0562 1.0529 1.1108
1.2363 1.1027 1.0883 1.0445 1.4777 1.4387 1.1673 1.1268 1.0871 1.0225 1.1637 1.1108
1.4463 2.4095 2.1766 1.1943 1.5501 1.0562 1.035 1.2856
1.8078 2.0147 1.1223 1.0984 1.174 1.0601 1.094 1.0331 1.2302 1.4811
1.1663 1.0315 1.2796 1.1563 2.1254 1.0979 1.1099 1.2753 1.2967 1.0579 1.1116
1.0282 1.0648 1.1979 1.1223 1.3006 1.5789 1.0601 1.153 1.1108 1.0303
1.283 1.2728 1.3613 1.3604 1.1793 1.255 1.1268 1.1526 1.1813
1.0964 1.2116 1.3944 1.1591 1.255 1.0979 1.0079 1.0307 1.1256 1.0579 1.3275
1.1663 1.2146 1.6325 1.0243 1.174 1.2115 1.0972 1.0132 1.1596
1.1663 1.0482 1.4624 1.1456 1.0601 1.0716 1.118 1.0973 1.0227 1.1888
1.108 1.1223 1.1523 1.1133 1.0222 1.0539 1.078 1.2229 1.199 1.0538
1.1313 1.1571 1.2244 1.1119 1.7415 1.1169 1.1992 1.0474 1.0716 1.0122
1.0497 1.1397 1.1299 1.4964 1.0176 1.0711 1.153 1.1415 1.0935
0.9826 0.9068 0.9569 0.6023 0.9098 0.9477 0.8312 0.8816 0.958
-9 0.9564 0.9035 0.9843 0.9737 0.9441 0.9521 0.8635 0.9685 0.8355 0.8866 0.8816 0.9676
-8 0.9978 0.7737 0.8031 0.9869 0.8555 0.7482 0.9254 0.9916 0.9128
-7 0.7629 0.9795 0.9441 0.9637 0.7426 0.8816 0.7836 0.9516 0.8314
-6 0.9567 0.7629 0.9514 0.8764 0.9346 0.8327 0.9685 0.8729 0.8816 0.743 0.9836 0.723
-5 0.9816 0.9436 0.9394 0.9483 0.7586 0.8729 0.8816 0.7363 0.7997 0.9037
-4 0.9623 0.7629 0.8534 0.7909 0.7482 0.7565 0.6478
-3 0.8834 0.9222 0.7506 0.8853 0.8173 0.6238 0.8314
-2 0.861 0.782 0.9035 0.7332 0.8797 0.7633 0.9037 0.967
-1 0.7344 0.5574 0.5324 0.5622 0.9465 0.9222 0.8822 0.8716 0.8816 0.9187 0.7117 0.8043
1 0.9978 0.6905 0.5019 0.9823 0.9084 0.6053 0.9352 0.5404 0.7357 0.8314
2 0.8205 0.9906 0.7428 0.6472 0.902 0.7264 0.5861 0.689 0.8857
3 0.9331 0.8232 0.7446 0.8675 0.9175 0.8151 0.7482 0.942 0.8849 0.9516
4 0.8256 0.6023 0.795 0.8993 0.9823 0.8712 0.7829 0.8853 0.8376 0.9596 0.7953
5 0.9472 0.9151 0.8232 0.8305 0.7829 0.9851 0.9642 0.7701 0.7501
6 0.9421 0.9938 0.8834 0.9451 0.9175 0.7748 0.7856 0.942 0.9345 0.9187 0.8405
7 0.9472 0.9068 0.8633 0.9008 0.8878 0.9252 0.8878 0.8645 0.8397 0.976
8 0.856 0.9151 0.9121 0.783 0.8481 0.8636 0.9976 0.9642 0.9516 0.8947
9 0.932 0.9234 0.8432 0.8704 0.7599 0.8018 0.8878 0.931 0.8111 0.9727
10 0.932 0.9235 0.8299 0.9843 0.976 0.7864 0.8958 0.8729 0.9169 0.9795 0.9676
Table B.1B. Amino acid propensity near proline residue in cis case.  The color scheme is same with 
the Table B.1A. 
F L I Y W V M P C A G T S K Q N H E D R
-10 1.2343 1.2716 1.347 1.1251 1.2325 1.2692 1.1728 1.2224 1.2752
1.0971 1.3698 1.2716 1.1997 1.1885 1.4379 1.0439 1.8659 1.0325 1.5045
1.072 1.2716 1.2805 2.3994 1.347 1.1803 1.7806 1.0776 1.0501 1.1297 1.1388 1.0425
1.1315 1.1738 1.3091 1.0102 1.746 1.2692 1.2337 1.3196 1.0425 1.1284
1.3714 1.0124 1.076 1.2805 1.347 1.071 1.3355 1.2001 1.5184 1.3502
1.7828 1.1738 1.5996 1.347 1.071 3.5613 1.3598 1.0439 1.0425
1.6457 1.5471 2.6709 1.0501 1.3352 1.4505 1.1388 1.2752
1.0971 1.072 1.4406 1.6661 2.6709 1.2001 1.3598 1.0439 1.0263 1.1689
1.1738 1.1205 1.1997 1.7851 1.2751 1.027 1.2692 1.4235 1.0325 1.4105
1.1205 1.5996 1.071 1.1449 2.2501 1.1785 1.3286 1.8244 1.0366 1.3502
2.3314 1.1315 2.0809 1.1885 1.0501 1.1297 1.8659
1.0971 1.6007 1.0301 1.6661 1.1251 1.027 1.3286 1.1729 1.2708
1.1315 1.1738 1.071 2.2258 1.0501 1.3352 1.1388 1.8659 1.2708 1.5045
1.5085 1.1738 1.19 1.1449 1.3352 1.0263 1.1728 1.0366 1.1689
1.5651 1.1885 1.3091 1.3355 1.2325 1.9944 1.0439 1.3196 1.0325 1.3164
1.6457 1.2507 1.6629 1.1093 1.4164 1.2337 1.1729 1.3164
1.3714 1.1911 1.6007 1.9995 1.347 1.3355 1.8487 1.0878 1.0425 1.2752
1.3714 1.1315 1.076 1.0301 1.2123 1.2325 1.1388 1.0263
1.0971 1.1315 1.7607 1.1997 1.3355 1.2796 1.0501 1.027 1.1785 1.0439 1.0366 1.2224
1.2343 1.1315 1.4406 1.4164 1.0102 1.0501 1.027 1.1785 1.6941 1.2708 1.0626
0.9529 0.8003 0.3999 0.7082 0.595 0.8903 0.7408 0.7592 0.7331 0.622 0.7148
-9 0.9604 0.2361 0.952 0.4452 0.7408 0.525 0.272 0.8797 0.9122 0.7438
-8 0.8228 0.595 0.7252 0.8797 0.2073 0.7942 0.7522 0.6376
-7 0.6857 0.9604 0.7998 0.9508 0.4721 0.4452 0.6 0.4146 0.7942 0.4251
-6 0.7998 0.7082 0.7408 0.7189 0.6346 0.5865 0.6516 0.8293 0.5642 0.9564
-5 0.7742 0.9604 0.4721 0.6735 0.9 0.9243 0.8797 0.622 0.7942 0.7522 0.6376
-4 0.7147 0.5869 0.8003 0.7998 0.7924 0.7082 0.8755 0.5865 0.7819 0.8293 0.7942 0.8463
-3 0.7825 0.7998 0.8716 0.4721 0.7408 0.7189 0.9122 0.8293 0.9531 0.2821
-2 0.6857 0.8338 0.8716 0.9443 0.8903 0.202 0.8797 0.6516 0.4146 0.9564
-1 0.6857 0.2978 0.5869 0.2377 0.2361 0 0.9243 0.8797 0.7522 0.9564
1 0.5869 0.3999 0.2361 0.952 0.4452 0.8082 0.9972 0.5694 0.8797 0.7819 0.9531 0.9403 0.4251
2 0.7742 0.6847 0.7998 0.9443 0.8903 0.5388 0.7252 0.9122 0.8293 0.9403 0.9564
3 0.6857 0.8003 0.3999 0.6339 0.9443 0.4041 0.9972 0.7331 0.3909 0.9564
4 0.9529 0.4802 0.7998 0.8716 0.9443 0.4452 0.9 0.9065 0.8541 0.8737 0.7522
5 0.6857 0.3573 0.8003 0.3999 0.9443 0.6061 0.75 0.6516 0.4146 0.9564
6 0.9604 0.7998 0.238 0.8903 0.8082 0.825 0.7189 0.7252 0.9122 0.622 0.7942 0.7438
7 0.9782 0.9443 0.714 0.8082 0.525 0.1898 0.8797 0.8293 0.7942 0.5642
8 0.9604 0 0.9443 0.952 0.8903 0.825 0.9972 0.9122 0.622 0.8737 0.8463 0.8501
9 0.8803 0.5547 0.9443 0.952 0.5865 0.9122 0.556 0.7438
10 0.7825 0.3999 0.8716 0.833 0.8903 0.2847 0.5865 0.4146 0.9403
Table B.1C. Amino acid propensity near proline residue in isom case.  The color scheme is same with 
the Table B.1A. 
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To facilitate comparison the propensities in cis, trans and isom cases, propensity 
differences were calculated directly by subtracting the propensities in the isom cases from 
those of either the trans or cis cases (Table B.2). Values in blue indicate that the propensity 
difference between two cases is <1 at a position, which means the residue at the position is 
disfavored in the isom cases. Conversely, values in red are used to indicate residues favored 
in the isom cases. The favored and disfavored residues common to both comparisons (trans 
vs isom and cis vs isom) were obtained by comparing values in Table B.2A and B.2B, using 
boxes to highlight common values. Favored residues (for isom) identified in both 
comparisons are:  i) cysteine residues at positions -5, -4, -3 and 3; and ii) tryptophan residue 
at position -8. There is only one common disfavored residue (for isom), tryptophan residue at 
position 8. Interestingly, a previous study on proline isomerization using short synthetic 
peptides found that the rate of the isomerization was enhanced in the disulfide bridge 
containing peptides, Ac-Cys-Pro-Xaa-Cys-NH2 or Ac-Cys-Gly-Pro-Cys-NH2 (22). Also, in 
studies on oxidative folding pathways of cysteine-rich peptides derived from minicollagen-1, 
two different proline isomers were detected, depending on the sequence environment (6). Our 
analysis reported here, however, provides the first evidence based on a comprehensive 
analysis of prolyl-peptide bonds, that cysteine is favored near the isomerizing proline 
residues in native protein structures. 
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F L I Y W V M P C A G T S K Q N H E D R
-10 0.208 -0.079 0.214 -0.246 -0.746 0.288 -0.142 -0.398 -0.192 -0.295 0.087 0.232 0.354 -0.15 -0.268 0.213 -0.251 -0.237 0.245 0.233
-9 0.016 0.292 0.252 -0.128 -0.009 0.102 -0.616 -0.028 -0.625 -0.26 -0.503 0.434 -0.635 0.137 -0.087 -0.068 1.004
1.199
2.449
1.533
1.665
1.488
1.355 1.053
1.349 1.045
1.056
0.112 0.525 -0.278
-8 -0.258 -0.018 0.179 0.131 0.26 0.39 -0.384 0.711 0.077 0.033 0.144 -0.213 0.245 -0.08 0.08 -0.664 -0.103 -0.183 -0.385
-7 -0.409 0.045 0.121 -0.107 -0.349 -0.154 -0.334 0.292 -0.564 0.025 -0.404 0.726 0.378 0.292 0.394 0.087 -0.426 -0.163 0.157 -0.587
-6 0.265 -0.051 0.065 0.165 -0.382 0.27 -0.109 0.06 0.13 -0.271 0.199 -0.29 -0.29 0.607 -0.367 -0.257 -0.084 0.433 -0.4 -0.091
-5 0.618 -0.313 0.069 -0.161 0.358 0.278 -0.312 0.001 -0.301 -0.094 -0.039 0.428 0.174 -0.032 0.055 -0.3 -0.096 -0.224 -0.334
-4 0.559 -0.371 -0.432 -0.284 -0.318 -0.244 -0.073 0.437 -0.076 0.039 0.337 0.477 0.199 -0.304 -0.21 -0.113 -0.111 -0.136 0.259
-3 -0.022 0.081 -0.184 0.333 -0.336 -0.143 -0.228 0.536 -0.226 0.073 -0.342 0.354 0.076 0.056 -0.065 -0.079 3E-04 -0.645 0.248
-2 -0.476 -0.246 0.101 -0.012 0.061 -0.156 0.176 0.723 -0.141 -0.637 0.082 -0.02 0.29 0.546 -0.031 -0.481 -0.481 0.22 0.423 0.056
-1 -0.333 -0.857 -0.601 0.096 0.823 -0.844 -0.615 0.227 -1.219 0.318 -0.297 0.187 0.417 -0.051 0.505 -0.195 0.641 -0.448 0.041
1 0.148 -0.256 -0.672 0.09 -0.456 0.108 -0.395 -0.139 -0.063 0.145 -0.008 -0.289 -0.19 -0.253 0.982 -0.332 -0.237 -0.428
2 -0.024 -0.27 -0.324 0.491 -0.313 -0.024 0.099 0.641 -0.084 -0.456 0.019 -0.033 -0.286 0.522 0.224 -0.039 -0.147 0.32 -0.058 0.106
3 -0.4 0.135 0.102 -0.333 -0.772 -0.564 0.136 -0.038 -0.59 0.164 0.256 0.006 0.19 -0.282 -0.498 0.332 0.583 -0.024
4 0.442 -0.027 0.154 -0.557 -0.409 -0.216 0.207 0.082 -0.496 0.098 -0.041 0.336 -0.029 -0.13 0.017 0.267 0.158 -0.142 -0.219 0.122
5 -0.378 -0.713 0.497 -0.275 -0.779 0.064 0.112 0.235 0.319 -0.426 -0.177 0.206 0.161 0.363 -0.234 -0.461 0.071 0.376 -0.069
6 0.517 0.144 0.593 -0.159 -0.415 0.001 0.523 -0.747 -0.121 -0.229 -0.098 -0.319 -0.211 0.362 0.226 0.013 -0.295 -0.109 0.37 -0.252
7 0.312 0.141 -0.1 0.551 0.85 0.254 0.096 -0.292 0.255 -0.232 -0.434 0.872 0.157 -0.701 -0.101 0.107 -0.065 -0.163 -0.421 0.234
8 0.322 0.143 0.07 -0.13 -1.131 -0.007 0.137 -0.006 -0.198 0.159 -0.152 0.223 0.082 0.216 0.021 -0.077 -0.265 -0.135 -0.196 -0.21
9 0.078 0.092 -0.156 0.658 0.123 -0.449 0.109 -0.013 0.201 0.235 0.008 0.019 0.224 0.139 -0.371 -0.052 0.155 -0.42 0.23 -0.296
10 0.176 0.061 -0.21 0.373 -0.734 -0.181 0.592 -0.165 -0.211 -0.059 0.047 0.038 0.25 -0.663 -0.368 0.742 -0.457 0.288 0.02 0.028
 
Table B.2A. Amino acid propensity difference between isom and trans cases 
 
F L I Y W V M P C A G T S K Q N H E D R
-10 0.08 -0.03 0.365 -0.357 -0.756 0.39 0.106 -0.447 -0.208 -0.279 0.041 0.141 0.359 -0.298 -0.215 0.342 -0.26 -0.305 0.143 0.317
-9 0.141 0.245 0.082 -0.169 0.179 0.117 -0.667 -0.121 -0.539 -0.233 -0.419 0.486 -0.592 0.075 0.044 0.026 0.984 0.006 0.537 -0.295
-8 -0.227 0.074 0.498 0.042 1.141
2.198
1.497
1.459
1.166
0.242 0.377 -0.468 0.342 0.035 -0.002 -0.041 -0.262 0.283 0.132 0.034 -0.798 -0.131 -0.239 -0.275
-7 -0.364 0.129 0.009 -0.238 -0.459 -0.235 -0.291 0.236 -1.069 0.031 -0.344 0.741 0.305 0.096 0.285 0.3 -0.467 0.011 0.177 -0.406
-6 0.112 -0.066 0.119 -0.19 -0.731 0.033 -0.055 0.12 0.01 -0.136 0.135 -0.216 -0.198 0.55 -0.286 -0.468 -0.052 0.607 -0.419 0.233
-5 0.768 -0.234 0.192 -0.088 -0.101 0.107 -0.471 -0.285 -0.266 -0.172 -0.264 0.411 0.285 0.007 7E-04 -0.26 0.058 -0.047 -0.266
-4 0.409 -0.248 -0.453 -0.466 -0.765 -0.394 -0.055 0.15 0.022 0.017 0.278 0.348 0.348 -0.162 -0.304 -0.246 0.038 0.199 0.263
-3 -0.104 0.039 -0.39 0.406 -0.391 -0.24 -0.411 0.279 -0.181 0.148 -0.39 0.304 0.293 0.141 -0.141 -0.282 0.136 -0.342 0.337
-2 -0.551 -0.027 0.392 0.018 0.111 -0.173 0.041 0.307 -0.548 -0.531 0.108 -0.1 0.182 0.544 -0.143 -0.512 -0.696 0.269 0.507 -0.011
-1 -0.761 -0.437 0.03 -1.289 -0.577 -0.295 -0.326 -0.123 -0.946 0.223 0.7 0.042 0.122 0.457 -0.155 0.539 0.155 0.432 0.041 0.152
1 0.524 0.134 -0.104 0.066 -0.722 0.09 -0.266 -0.222 -0.615 -0.286 0.068 0.221 -0.036 -0.036 -0.055 -0.448 0.385 0.413 0.205 -0.406
2 -0.069 -0.046 -0.347 0.321 -0.357 0.039 0.201 -0.459 -0.208 -0.108 0.015 -0.248 -0.177 0.602 0.587 -0.384 -0.229 0.582 -0.171 0.071
3 -0.247 0.103 0.109 -0.398 -0.722 -0.667 0.121 -0.508 -0.341 0.183 0.182 0.08 0.324 -0.015 -0.551 0.755 0.386 0.553 -0.074
4 0.226 0.127 -0.099 -0.881 -0.561 -0.308 0.342 -0.065 -0.35 0.246 -0.082 0.208 0.035 0.071 0.141 0.02 -0.145 0.036 -0.207 0.374
5 -0.411 -0.59 0.65 -0.411 -0.995 0.029 0.121 0.054 0.238 -0.224 -0.258 0.202 0.869 0.261 0.334 -0.313 -0.643 0.262 -0.011 0.206
6 0.479 0.309 0.448 -0.033 -0.833 0.085 0.533 -0.936 -0.321 -0.137 -0.272 -0.294 -0.192 0.459 0.387 -0.03 -0.313 -0.124 0.157 -0.097
7 0.205 0.244 0.071 0.552 0.537 0.201 0.081 -0.187 0.275 -0.08 -0.547 0.731 0.163 -0.698 -0.218 0.178 -0.193 -0.395 -0.275 0.299
8 0.263 0.276 0.161 0.048 -1.122 -0.122 0.161 -0.161 -0.132 0.158 -0.253 0.01 0.149 0.275 0.029 -0.052 -0.577 -0.18 -0.105 -0.045
9 -0.034 0.2 -0.043 0.604 -0.025 -0.557 0.101 0.082 -0.406 0.163 -0.149 0.267 0.377 0.156 -0.461 -0.019 0.226 -0.417 0.151 -0.268
10 0.185 0.2 -0.357 0.311 -1.097 -0.146 0.493 0.003 -0.094 -0.061 0.074 -0.126 0.392 -0.611 -0.286 0.553 -0.502 0.291 -0.027 -0.031
 
Table B.2B. Amino acid propensity difference between isom and cis cases 
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Table B.3 summarizes secondary structure tendencies, calculated for each case and 
represented as described above for the amino acid propensity comparisons. 
Helix Sheet Coli Helix Sheet Coli Helix Sheet Coli
-10 0.95486 1.08426 1.26258 1.06935 1.43669 1.02556
1.13045 1.30331 1.07771 1.58035
1.16609 1.41328 1.03111 1.67613
1.18642 1.01469 1.54565 1.03709 1.50852 1.02556
1.21377 1.03948 1.61081 1.06098 1.62824 1.03961
1.18998 1.09108 1.60674 1.11953 1.36485 1.23629
1.16964 1.18768 1.45808 1.27366 1.05357 1.48917
1.0958 1.41529 1.28091 1.50903 1.71395
1.60549 1.00396 1.81132 2.10731
1.93532 2.14706 2.2197
1.68032 2.41708 2.304
1.4205 1.82446 1.82634
1.21067 1.24629 1.50306 1.17329 1.39083
1.00765 1.09403 1.40513 1.18763 1.24513 1.20819
1.14121 1.49474 1.05979 1.29302 1.0958
1.16224 1.41531 1.01558 1.41274
1.13174 1.28091 1.00363 1.01366 1.34091
1.01832 1.0886 1.29517 1.36485
1.0342 1.04763 1.25647 1.04262 1.17329
1.03485 1.00469 1.25036 1.02962
1.03999 1.13429 1.0571
0.99436 -10 0.76972 -10 0.70956
-9 0.93032 0.99106 -9 0.73647 -9 0.72404 0.92722
-8 0.90113 0.99847 -8 0.71799 -8 0.75301 0.84293
-7 0.87212 -7 0.63179 -7 0.66612
-6 0.83003 -6 0.56775 -6 0.57924
-5 0.79123 -5 0.50986 -5 0.53579
-4 0.70395 -4 0.4409 -4 0.46339
-3 0.51399 -3 0.30542 -3 0.36202 0.83807
-2 0.382 0.98989 -2 0.16133 -2 0.13033 0.55073
-1 0.26297 0.62455 -1 0.03818 0.63536 -1 0.08689 0.43101
0 0.60056 0.50096 0 0.03695 0.17717 0 0.14481 0.19156
1 0.77368 0.65752 1 0.21798 0.88788 1 0.33306 0.6944
2 0.872 0.85258 2 0.33252 2 0.49235
3 0.89845 3 0.56159 3 0.63716
4 0.92155 0.99326 4 0.63918 4 0.72404
5 0.95856 0.94501 5 0.73277 5 0.88333 0.87102
6 0.98966 0.93274 6 0.82637 6 0.78673
7 0.93025 7 0.86701 0.95584 7 0.9847 0.80078
8 0.93888 8 0.91504 0.93194 8 0.85697
9 0.96343 9 0.93475 0.91641 9 0.99918 0.98341
10 0.95909 0.98521 10 0.96184 0.95823 10 0.9099 0.99746
               trans                                       cis                                          isom 
 
Table B.3. Secondary structure propensities near proline residues. 
 
The distribution of secondary structure tendencies for residues near proline in the three cases 
is distinguishable, suggesting that secondary structure information could be useful in 
developing classifiers to accurately identify isomerizing cases.  
 
Classifying Prolyl Peptide Bonds as Cis, Trans or Isomerizing  
As described in the Materials and Methods section, we compared 5 different 
combinations of 4 different input features (seq, seq+ss, seq+hssp_ent, seq+hssp_pro and 
seq+ss+hssp_pro) and 2 different machine learning algorithms (Naïve Bayes and SVM, from 
the WEKA software package (31)). For building classifiers to distinguish the three different 
prolyl peptide ond classes (trans, cis and isom), three binary classifiers; cis/trans, isom/cis 
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and isom/trans were constructed and evaluated for classification performance. Also 5-fold 
cross-validation was used for all evaluations. 
In Figure B.3, a comparison of several different classifiers, using different feature 
combinations for the cis/trans classification task, is presented using Receiver Operating 
Characteristics (ROC) curves. Except for the classifier that used only sequence information, 
the classifiers evaluated in the ROC curve were constructed using the SVM method, which 
gave us better performance than Naïve Bayes on this task. Based on the area under curve 
(AUC) in the ROC, the classifier that uses sequence, secondary structure and hssp profile 
information as input, has the best performance. Interestingly, the classifier that uses 
secondary structure information outperformed classifiers using either HSSP entropy or HSSP 
profile information. This suggests that secondary structure is an important data feature for the 
cis/trans classification problem. 
 For overall comparisons among the three classification tasks (cis/trans, isom/cis and 
isom/trans), the classifier that showed the best performance for each classification task was 
chosen and presented in the ROC curve in shown in Figure B.4. As expected, we obtained 
the best performance in the cis/trans classification task. Unfortunately, we did not obtain 
comparable performance in the isom/trans and isom/cis classification tasks, although the 
isom/trans classification performance was better than that of the isom/cis classification.  In 
Table B.4, the classifier performance is summarized using measures described in Materials 
Methods. It is important to note that in Table B.4, the classifier for each classification task 
was optimized based on the correlation coefficient (not, for example, based on specificity for 
the positive class). Therefore, a meaningful comparison of the overall performance of 
classifiers on each classification task has to be carefully considered, using both ROC curves 
in Figure B.2 and the measures in Table B.4. 
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Figure B.3. Receiver Operating Characteristics (ROC) curves for classifiers using 5 different 
combinations of 4 different data features. Combinations of data features used are shown in the box. 
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Figure B.4. ROC curves for the best classifiers for each of three different classification tasks.  Blue 
line, cis/trans classification; green line, isom/trans classification; pink line, isom/cis classification task. 
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classification task data features methods window size ACC CC AUC SP SN
cis/trans seq+ss+hssp_pro SVM 11 0.80 0.21 0.79 0.13 0.59
isom/cis seq+hssp_ent Naïve Bayes 11 0.92 0.10 0.54 0.57 0.02
isom/trans seq+hssp_ent Naïve Bayes 21 1.00 0.05 0.55 0.50 0.01
 
Table B.4. Overall performance measures (based on optimization of correlation coefficient).  ACC: 
accuracy, CC: correlation coefficient, AUC: area under ROC curve, SP: specificity for positive class (cis or 
isom), SN: sensitivity for positive class (cis or isom). Definitions of performance measures are provided in the 
Materials and Methods. 
 
FUTURE STUDIES 
Two important preliminary studies on the characterization of the proline cis/trans 
isomerization are presented in this report:  i) Analysis of the amino acid and secondary 
structure propensities of residues near proline residues in each of three different 
configuration classes (cis, trans and isomerizing), and ii) Application of machine learning 
algorithms to attempt to classify of prolyl peptide bonds into one of three classes (cis, trans 
and isom) was attempted for the first time. The results have not been fully discussed and 
presented in this Appendix (which is a very preliminary draft of a future manuscript), but I 
would like to propose several suggestions for the future study based on the current stage of 
this analysis. Further discussion of the current results and additional computational 
experiments suggested below would solidify and enhance the quality of this study.   
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Systematic analysis of data on amino acid and secondary structure propensities 
near proline residues 
We have already analyzed the amino acid sequence and secondary structure 
propensities for the different three classes of prolyl peptide bond configurations. The results 
in this study show significant differences among cis, trans and isom cases near the proline 
residues, in terms of amino acid distribution and secondary structure tendencies.  Previous 
studies have shown that there is a statistically significant difference between the cis and trans 
cases, based on neighboring sequence information (9, 13, 17) and one study showed a 
structural differences in a protein with has two prolyl bond configurations (18). I propose a 
systematic characterization and comparison of three classes presented in study. Analysis can 
be based on both sequence information and structural information near the proline residues. 
Detailed analysis of the available data for the three different configurations of prolyl peptide 
bonds is important not only for understanding the nature of the proline isomerization but also 
for use of the distinguishing data features in classification tasks.  The results from this 
analysis would give us opportunities to construct sequence and/or structural motifs defining 
each proline configuration and to identify additional “proline switch” candidates. 
 
More sophisticated machine learning methods for classification tasks 
The ultimate goal in this study is to find more candidates for the “proline switch” in 
order to investigate its possible role as a cellular mechanism for post-translation regulation of 
protein function. To achieve this goal, we tried to construct and evaluate classifiers for 
predicting the cis, trans and isom classes. Although the method used in this study did not 
achieve good classification performance in isom/cis and isom/trans classification tasks, we 
can differentiate and classify the cis and trans classes as has been shown in previous studies 
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described above. Difficulties in classifying isom/trans and isom/cis may be inherent to this 
biological phenomenon and reflect the low thermodynamic barrier that separates the 
isomerizing configuration from more "stably" cis and trans configurations in a living 
biological system. Still, the preliminary analyses suggest there is room to achieve better 
performance in identifying isomerizing prolines. I propose two potential strategies. First, data 
features correlated with isomerizing proline residues should be explored extensively. The 
above section already mentioned the data analysis, but feature extraction is a very important 
step in building machine learning classifiers. Therefore, if more distinctive features in the 
isomerization cases, such as structural features of the isomerizing proline or correlated amino 
acids near the isomerizing proline residues, could be used in the classification task, better 
performance might be achieved. A second opportunity for improving performance would be 
to use machine learning algorithms designed especially for multi-class classification 
problems and unbalanced datasets. In this study, only binary classifiers were used as a first 
attempt on these classification problems. We know that the isomerizing cases could have 
both trans and cis proline configurations. Therefore, algorithms that explicitly take into 
account the intrinsic features of isomerizing cases would be the best way to achieve better 
performance. Algorithms that are able to handle extremely unbalanced datasets would also be 
helpful for achieving our goal of finding more candidates for the “proline switch”. 
 
Structural analysis for isomerizing cases 
Preliminarily, we found total 460 cases in which the same prolyl peptide bond can 
have two different configurations in a folded protein. Of these 460 cases, we used only a non-
redundant subset of 184 cases for the classification datasets. If the "proline switch" is the 
general mechanism for regulating cellular function, it may be possible to find common 
structural features or motifs in different proteins. The 184 cases would be a good starting 
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point to investigate characteristic structural features of the isomerizing cases. The analyses 
could be performed using structural alignment methods or more extensive computational 
approaches such as molecular dynamics. 
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